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Summary
Increasing data has led to tremendous success in discovering molecular biomarkers
based on high throughput data. However, the translation of these so-called genomic
signatures into clinical practice has been limited. The complexity and volume of
genomic profiling requires heightened attention to robust design, methodological
details, and avoidance of bias. During this thesis, novel strategies aimed at closing
the gap from initially promising pilot studies to the clinical application of novel
biomarkers are evaluated.
First, a conventional process for genomic biomarker development comprising feature
selection, algorithm and parameter optimization, and performance assessment was
established. Using this approach, a RNA-stabilized whole blood diagnostic classifier
for non-small cell lung cancer was built in a training set that can be used as a
biomarker to discriminate between patients and control samples. Subsequently,
this optimized classifier was successfully applied to two independent and blinded
validation sets. Extensive permutation analysis using random feature lists supports
the specificity of the established transcriptional classifier.
Next, it was demonstrated that a combined approach of clinical trial simulation and
adaptive learning strategies can be used to speed up biomarker development. As a
model, genome-wide expression data derived from over 4,700 individuals in 37 studies
addressing four clinical endpoints were used to assess over 1,800,000 classifiers. In
addition to current approaches determining optimal classifiers within a defined study
setting, randomized clinical trial simulation unequivocally uncovered the overall
variance in the prediction performance of potential disease classifiers to predict the
outcome of a large biomarker validation study from a pilot trial. Furthermore, most
informative features were identified by feature ranking according to an individual
classification performance score.
Applying an adaptive learning strategy based on data extrapolation led to a data-
driven prediction of the study size required for larger validation studies based on
small pilot trials and an estimate of the expected statistical performance during
validation. With these significant improvements, exceedingly robust and clinically
applicable gene signatures for the diagnosis and detection of acute myeloid leukemia,
active tuberculosis, HIV infection, and non-small cell lung cancer are established
which could demonstrate disease-related enrichment of the obtained signatures and
phenotype-related feature ranking.
In further research, platform requirements for blood-based biomarker development
were exemplarily examined for micro RNA expression profiling. The performance
as well as the technical sample handling to provide reliable strategies for platform
implementation in clinical applications were investigated.
Overall, all introduced methods improve and accelerate the development of biomarker
signatures for molecular diagnostics and can easily be extended to other high through-
put data and other disease settings.
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1. Introduction
The introduction of genome-wide gene expression profiling by microarrays in the
mid-1990s (Schena et al., 1995) enabled multidimensional measurement of biologi-
cal processes in parallel. Researchers investigated in the enormous potential of this
technology for both gaining insights into molecular biology as well as its use in clini-
cally motivated applications. Golub et al. were the first to successfully demonstrate
microarray-based transcriptional classification to distinct acute myeloid and acute
lymphocytic leukemia (Golub et al., 1999). Further landmark studies in cancer re-
search have highlighted the power of this technology to classify types of tumors
(Alizadeh et al., 2000; Bittner et al., 2000; Sorlie et al., 2001; Khan et al., 2001;
Yeoh et al., 2002) and to predict the outcome (Beer et al., 2002; van de Vijver et al.,
2002; van ’t Veer et al., 2002; Pomeroy et al., 2002; Shipp et al., 2002; Bullinger
et al., 2004; Valk et al., 2004) and even the response to chemotherapy (Kihara et al.,
2001; Rosenwald et al., 2002). A major challenge with high-throughput technologies
is the analysis of a complex data output. Different approaches and mathematical
algorithms were utilized to classify patients on the basis of expression profiles (Yeang
et al., 2001; Ramaswamy et al., 2001; Dudoit et al., 2002a; Simon, 2003).
Nevertheless, despite a growing number of studies on transcriptional-based biomark-
ers, only a handful of gene signatures have entered into clinical practice to date.
One prominent example is the prognostic breast cancer signature MammaPrint®.
In 2002, scientists established a 70-gene signature for the identification of lymph
node negative breast cancer patients at high risk for disease progression (van ’t Veer
et al., 2002) and further validated this test to assess prognosis of distant metasta-
sis in a series of independent studies (van de Vijver et al., 2002; Glas et al., 2006;
Bueno-de Mesquita et al., 2007). In 2007, the US Food and Drug Administration
(FDA) proved the MammaPrint and further large multi-institutional clinical trials
are assessing this test (Cardoso et al., 2008). Still, in comparison to thousands of
studies reporting microarray-based classifiers, the resulting number of clinical test
is deficient.
Furthermore, the initial enthusiasm was tempered by serious concerns on the ro-
bustness and reproduciblity of the methodology (Ioannidis, 2005; Liu and Karu-
turi, 2004; Michiels et al., 2005). Microarray technology is particularly susceptible,
because measurement errors can occure from sampling, preprocessing, processing,
calibration and data analysis. Focussing on technical aspects, little overlap was
reported among interplatform and cross-laboratory comparison studies (Ramalho-
Santos et al., 2002; Tan et al., 2003; Miller et al., 2004). Already in 2001, re-
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searchers need to present accurate information on crucial aspects of measurements
let to the use of highly standardized protocols documented in the minimum informa-
tion about a microarray experiment (MIAME) guidelines for reporting, annotation,
and data analysis of microarray data (Brazma et al., 2001). As an important result
of concerns about the reliability of the technology, the MicroArray Quality Control
(MAQC)-I project systematically addressed the impact of different microarray plat-
forms and lab-to-lab variability in reproducibility and comparability of microarray
results. With the aim to provide quality control tools to the microarray community
to avoid procedural failures the study successfully demostrated that the technology
itself is reliable and reproducible (Shi et al., 2006; Guo et al., 2006; Kuo et al., 2006;
Canales et al., 2006; Shippy et al., 2006).
Despite the clear demonstration of microarray robustness performed under strin-
gent conditions, further doubts have been raised by non-overlapping gene signatures
derived by several studies adressing the same clinical outcome (Dupuy and Simon,
2007; Sotiriou and Piccart, 2007) questioning their biological significance and clin-
ical implications. However, for example in breast cancer profiling most classifiers
although having only few genes in common show a significant concordance in out-
come prediction (Fan et al., 2006; Ein-Dor et al., 2005). Another major drawback
of microarray studies are small sample sizes in the original studies and a lack of
independent validation sets leading to overoptimistic claims that can arise from
uncommon, fragmented and incomplete validation (Simon et al., 2003; Ntzani and
Ioannidis, 2003). Michiels et al. employed a multiple random validation strategy
on published studies to show that because of inadequate validation, originally re-
ported assessments are overoptimistic and prognostic values should be considered
with caution (Michiels et al., 2005).
Recently, these concerns about biased results could be eased by improving the an-
alytical processes used within these pilot studies (Fan et al., 2010a). In addition,
the second phase of the MAQC project (MAQC-II) set the framework for mak-
ing clinically useful predictions from large-scale gene expression data (Shi et al.,
2010; Oberthuer et al., 2010; Luo et al., 2010; Parry et al., 2010; Huang et al.,
2010; Fan et al., 2010b). Several important issues are solved by this large con-
sortium effort sought to evaluate various data analysis methods in developing and
validating microarray-based predictive models. Most important, model prediction
performance was found to depend heavily on the endpoint, probably the most crit-
ical finding supporting further development of gene signature technology. Further,
internal validation performance from well-implemented, unbiased cross-validation
shows a high degree of concordance with blinded external validation performance.
Nevertheless, external validation is a critical feature for signature development. For-
merly questioned by others, the analysis also clearly established that many classifiers
with similar performance can be developed from a given data set. Not surprising,
proficiency of investigators and good modeling practice are leading to improved re-
sults. Overall by collecting and analyzing more than 18,000 predictive models, the
MAQC-II highlighted that rigorous standards for reporting the analytical steps are
2
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neccessary and systematically gave evidence that predictive models can be reliable
enough to justify clinical applications.
These comprehensive findings strongly suggest to bring transcriptional-based models
into clinical practice. Since a key challenge in cancer medicine is to detect a disease as
early as possible to improve treatment and reduce the mortality, the establishement
of simple, fast and robust clinical diagnostic biomarkers are highly desirable. For
many disease states, the primary affected tissues are not readily available or can only
be obtained by invasive intervention. Alternativly, the use of the surrogate tissue
peripheral blood for transcriptional profiling may be feasible for the development
of new diagnostic markers since it is the most accessible and practical source of
messenger RNA (mRNA) in patients and is in contact with almost every organ
and tissue in the body (Baird, 2006; Burczynski and Dorner , 2006). Based on
the assumption that circulating blood might reflect pathological changes occuring
in different tissues of the body (Liew et al., 2006), an increasing number of clinical
studies monitored blood-based biomarkers by gene expression profiling (Twine et al.,
2003; Burczynski et al., 2005; Sharma et al., 2005; Osman et al., 2006; Critchley-
Thorne et al., 2007; Showe et al., 2009; Staratschek-Jox et al., 2009; Chaussabel
et al., 2010).
Within this thesis, methods are established to improve and accelerate the devel-
opment of transcriptional blood-based diagnostic biomarkers from explorative pilot
studies to their clinical routine use. The complexity and volume of transcriptional
profiling requires heightened attention to robust design, methodological details and
avoidance of bias. It is structured as follows:
In chapter 2, I will present all background knowledge that is needed to understand
and follow this thesis. The fundamentals of molecular biology will be explained as
well as genome-wide transcriptional profiling using microarrays followed by sketching
basic microarray data analysis methods. This section mainly focusses on microarray
classification analysis including study design, major classification algorithms and
performance measurements.
Chapter 3 briefly introduces the most important Material and Methods used for
this thesis covering data sets used and bioinformatic methods applied. Further
information on the experimental setups can be found in (Zander et al., 2011; Gaarz
et al., 2010) and in Appendix C.
In chapter 4, a conventional microarray classification workflow is established for
the identification of non-small cell lung cancer (NSCLC) in comparison to control
samples. This workflow comprises (i) comparison of feature selection cut-offs and
classification algorithms in a training set, (ii) building an optimized classifier in the
training set using the choosen features and algorithm and (iii) application of this
classifier to two independent validation cohorts and assessment of classifier perfor-
mance. This approach is further applied to one of the MAQC-II gene expression
datasets.
3
Introduction
Chapter 5 introduces methods to enhance molecular diagnostics including novel
strategies to predict the outcome of a large biomarker study from a small pilot
study and to estimate the sample size of future pivotal validation cohorts. These
concepts are developed on a large acute myeloid leukemia (AML) data set and then
applied to molecular diagnosis using peripheral blood of NSCLC, active tuberculosis
(ATB) and human immunodeficiency virus (HIV).
In chapter 6, I would like to focus on the challenges when a novel high-throughput
technology is applied to the development of blood-based diagnostic biomarkers. Rea-
sonable concerns would arise from the reproducibility of expression profiles and the
impact of RNA isolation methods. The following study interrogates the latter con-
cern using a recently introduced bead-array based microRNA (miRNA) expression
technology.
The last chapter of the thesis gives a summary of all previous discussions and aligns
these into a broader context. Here future research directions are pointed out and
possible study limitations are discussed.
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2. Background
All background knowledge that is needed to understand and follow this thesis as
well as biological, technical and bioinformatics terms will be explained in this chap-
ter. Starting with the fundamentals of molecular biology, the definition of the three
macromolecules Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA) and proteins
will be clarified. Next, genome-wide transcriptional profiling using microarray tech-
nology is introduced followed by sketching basic microarray data analysis methods.
The following section focuses on microarray classification analysis including study
design, major classification algorithms and performance measurements. Finally, all
diseases addressed in this thesis will be briefly introduced.
2.1. Molecular biology
The discovery of the DNA’s double helix structure by Watson and Crick in 1953 in-
troduced a new view on biology as it raised the question about how biological infor-
mation is encoded in DNA (Watson and Crick, 1953). Remarkable, DNA structure
can store complex information in a digital code. Its information covers two features
that are essential for all known forms of life: The genes that encode proteins which
are involved in regulatory processes of cells and the gene networks that regulate the
function of genes (Hood and Galas, 2003).
DNA is a nucleic acid containing the genetic information used in the development
and functioning of all known living organisms and some viruses. The DNA molecule
is composed of so called nucleotides, whereas each nucleotide consists of a desoxyri-
bose, one phosphoric acid and one out of the four organic bases adenine (A), guanine
(G), cytosine (C) and thymine (T). The nucleotides are arranged in two long polymer
strings which run in opposite directions to each other and are therefore anti-parallel.
The double stranded DNA forms a helical structure (Watson and Crick, 1953). The
four bases of the DNA molecules carry genetic information whereas their sugar and
phosphate groups perform a structural role. Almost any sequence of bases and
hence, any digital information can be accommodated by the DNA molecule.
In a process called transcription, the DNA is copied into a template for protein
synthesis, the RNA molecule. Each gene encodes a complementary RNA transcript
called messenger RNA (mRNA) (Brenner, Jacob, and Meselson, 1961). Like DNA,
RNA consists of nucleotides but the sugar unit in RNA is ribose and the base
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thymine is replaced by the derivate uracil (U). Additionally, RNA usually is single-
stranded, except for some viruses. Additionally to the coding mRNA which serves
as a template for protein synthesis, different types of non-coding RNA exist. The
most prominent representatives of non-coding RNAs are transfer RNAs (tRNA) and
ribosomal RNAs (rRNA). Other non-coding RNAs include antisense RNA (aRNA),
microRNA (miRNA) and small interfering RNA (siRNA) which all function as gene
regulation molecules.
In the next step in protein synthesis, the translation, a mRNA produced by tran-
scription encodes for the production of a specific amino acid chain by the ribosome
that is fold into an active protein (Fig. 2.1.1). Sequences of the four bases A, C,
G and T/U of genes are used to decode proteins. Each triplet of nucleotides in a
nucleic acid sequence, so called codons, are mapped to one of the 20 amino acids
of the protein alphabet (Crick et al., 1961), this information definition is called the
genetic code (Nirenberg and Matthaei, 1961).
Figure 2.1.1.: From DNA to RNA to Proteins:
Process of information transfer. The graphic was modified from Chisholm et al.
(2007).
Proteins are essentially for all biological processes, most known is the role of pro-
teins as enzymes to catalyze biochemical reactions (Gutteridge and Thornton, 2005).
Furthermore they transfer cell signals and are involved in signal transduction, they
serve as antibodies in the immune system and transport other molecules. Struc-
turally, proteins are build from amino acid chains that are fold together to unique
structures by the linkage of peptide bonds.
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2.2. Microarray technology
Microarrays are the major technology to assess genome-wide transcriptional pro-
files of cells, tissues or even whole organs that allow to probe of the expression of
thousands of genes simultaneously (Quackenbush, 2006b; Schena et al., 1995). A
microarray is an orderly arrangement of probes in a ’micro’ format in which many
objects share a relatively small area. In this thesis, the term ’probe’ is used to
describe the sequence of nucleotides that are immobilized on the array. The term
’sample’ is used to define the mRNA extracted from the biological samples analyzed
in a microarray experiment.
The basic principle works as follows (Fig. 2.2.1): A large number of probes con-
taining short nucleic sequences representing thousands of individual genes or other
DNA elements are immobilized on a solid surface. RNA is extracted from samples
of interest and labeled with a fluorescent or radioactive marker. The pool of labeled
mRNA-representing nucleotides, refered to as targets, is hybridized to the probes.
Hybridization is the process where complementary strands of nucleotides, in this
case those of probe and target, bind to each other by building hydrogen bridges be-
tween the complement base pairs (Watson-Crick base pairs). After the hybridization
process, probe-target hybridization is detected by measuring the fluorphore-labeled
target intensity which determines the relative abundance of nucleic acid sequences
in the target and later on is quantified into numerical values. Higher hybridiza-
tion degrees result in increased signal intensity implying a higher relative level of
expression of the particular gene.
Figure 2.2.1.: Principle of the microarray technology.
RNA is extracted from a sample of interest, labeled with a marker dye and hy-
bridized to complementary gene-specific probes on the array. Relative levels of
gene expression is estimated by measuring the fluorescence intensity for each probe
and summarized in a expression data matrix. The figure was modified fromQuack-
enbush (2006b).
Among the most widely used technologies is the GeneChip distributed by Affymetrix
(Lockhart et al., 1996). The Affymetrix GeneChips are a constructed using a combi-
nation of two techniques, photolithography and solid-phase DNA synthesis. Probes
on these arrays are synthesized using a light mask technology to sequentially build
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nucleotide sequences. An Affymetrix chip comprise of a number of probesets, each
probeset consist of 25mer probe pairs (25 bases) selected from the target sequence:
one perfect match and one mismatch for each chosen target position. The mismatch
probe contains the same 25 base long sequence as the perfect match probe, except
the middle base is substituted for its complement base. Other array types such as
those from Illumina are based on randomly assembled arrays of microscopic beads,
each with a specific address sequence, which do not interfere with the fluorescent
dyes used on the target sequence (Kuhn et al., 2004). Further distributors of DNA
microarrays include GE Healthcare, Applied Biosystems, Beckman Coulter, Eppen-
dorf Biochip Systems and Agilent.
2.3. Basic microarray data analysis methods
2.3.1. Quality control
After collection, the data is usually controlled for quality. Quality control (QC) is
an important step before further downstream data analysis as it quantifies the mea-
surement quality for any particular sample and hence, identifies outlier samples and
detects poor quality or uninformative data. Several methods have been proposed,
some of which are depicted here:
Most methods are based on visual inspection of the data, where either the distribu-
tion of all samples in the experiment is shown (density or box plots, Fig. 2.3.1A) or
pairwise comparisons such as scatterplots (Fig. 2.3.1B) or MA plots (introduced by
Dudoit et al. (2002b), Fig. 2.3.1C) are performed.
Figure 2.3.1.: Diagnostic plots for microarray quality control
Depicted here are (A) a boxplot, (B) a pairwise scatter plot and (C) a MA plot
of log-intensity values.
Box plots (also known as box-and-whisker diagram) present the distribution of sig-
nal intensities across all samples of a given data set by summarizing key descriptive
statistics. The plot consists of boxes with a central line and two tails. Each box
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represents the inter-quartile range (IQR) of that sample where the middle 50% of
the ranked data are found, whereas the central line state the median of the data.
The upper (75% percentile) quartile Q1 and the lower (25% percentile) quartile Q3
are the bottom and top edges of the box, respectively. The tails of the whiskers can
represent several values, including minimum and maximum values or 5th and 95th
percentiles.
Similarily, the spatial distribution can be visualized by density plots to access
the homogeneity between the samples of an experiment. Density estimation is the
estimation of an underlying probability density function based on observed data
(Silverman, 1986). Specifying this density function f allows probabilities associated
with a random quantity X to be found from the equation
P (a < X < b) =
bˆ
a
f(d)dx for all a < b (2.3.1)
Density estimations provide an easy explanation and illustration of data. The total
area under the density function integrates to 1.
For pairwise comparisons, for example when comparing biological replicates, a scat-
terplot is one of the simplest methods to visualize expression levels. Each tran-
script’s intensity from one sample is plotted against the intensity value of the other
sample and transcripts with similar expression levels in two experiments will ap-
pear around the first diagonal of the coordinate system. The correlation coefficiant
between both samples can be calculated as well.
A MA plot is a rotation of the scatterplot by 45° with a subsequent re-scaling of
the data. Both sets of signals are not treated separately. Hence, a transcripts’s
M-value as the log-ratio of the two intensities is plotted against the A-value as the
mean of their logarithms. As most transcripts are expected to have equal expression
in both experiments, the majority of points will be grouped around the horizontal
line.
Another way to examine the quality of microarrays is checking background hy-
bridization levels by determining the absent and present status of probes (absent/
present calls). This is performed by calculating a detection p-value which statis-
tically compares the expression signal to a background control usually present on
the microarray. A probe is called present if the expression signal significantly differs
from the negative signal, otherwise absent. As a quality control measure, the per-
centages of present genes indicating the sensitivity of arrays within an experiment
should be similar for each array within an experiment.
If any of the quality measurements (different diagnostic plots or percentages of
present probes) indicates an obvious strong technical outlier in the data set, the
affected sample is usually removed from further analysis.
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2.3.2. Normalization
Normalization is an essential procedure that is directed at resolving the systematic
errors and bias, introduced by the experimental process in the microarray technology.
Different sources of systematic variation such as unequal quantities of starting ma-
terial, efficiency of RNA extraction, reverse transcription, labeling, photodetection
etc. can affect the measured gene expression. Therefore data should be corrected for
those effects in order to detect biological differences between RNA samples. Normal-
ization comprises the steps background correction, data transformation (usually on
logarithmic scale to deliver approximately normal symmetric distribution allowing
the use of a powerful group of statistical tests) and estimation of a “rescaling” factor
(using internal controls).
Generally there are two groups of normalization methods to account for systematic
errors: The within array normalization to handle error effects on one array individ-
ually and the between array normalization to achieve consistency between arrays
(Smyth and Speed, 2003; Yang et al., 2002a).
The within array normalization method works by subtracting the fitted values on a
linear or non-linear regression in one or two dimensions. We obtain the normalized
expression value log2(pik) by
log2(pik) = log2(p˜ik)− f (log2 (p˜ik)) (2.3.2)
where p˜ik is the original expression value of gene i on array k and f is a regression
function.
The between array normalization methods are mainly performed by scaling and
centering of the data. Most methods are based on the assumption that between two
conditions the majority of genes are not supposed to be differentially expressed and
only a small group is supposed to be differentially expressed.
Most common methods are
• Scale normalization: Here the scale of the data is simply adjusted to have the
same median-absolute-deviation across arrays, e.g. by setting the median of
differences to zero (Yang et al., 2002b).
• Quantile: Each of the array-specific distributions of intensities are transformed
so that all have the same values at specified quantiles in order to ensure that
the intensities have the same empirical distribution across arrays and across
channels (Bolstad et al., 2002).
• Variance stabilizing transformation (VSN): The VSN method builds upon the
fact that the variance of microarray data depends on the expression intensity
and transforms the data to have equal variance for all intensities. It is similar
to the natural log transformation at the upper end of the intensity scale but
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tries to adjust high-variance effects at the lower end, e.g. from background
correction (Huber et al., 2002).
• MAS5: For Affymetrix arrays, additional normalization is necessary using the
perfect and mismatch probe sets on the array. MAS5 normalizes each array
independently and sequentially by using the mismatch probes to calculate a
"robust average", based on subtracting the mismatch probe value from the
match probe value (Hubbell et al., 2002).
• Robust multichip average (RMA): The RMA method calculates probe level
summaries with empirically motivated statistical models and does not use the
mismatch probes due to the fact that their intensities are sometimes higher
than the match probes, making them unreliable as indicators of non-specific
binding (Irizarry et al., 2003).
2.4. Classification of high-dimensional microarray
data
Genomic biomarkers are developed by classification analysis of high-throughput ex-
pression patterns. This classification analysis is a supervised learning process in
which class memberships are predefined. A predictive model based on a set of la-
beled observations (the training set) with a set of features is used to build a classifier.
The resulting mathematical rules from this classifier can be applied to predict the
classes of new observations (Hastie et al., 2001). The process of biomarker develop-
ment involves three steps:
• identification of informative features
• selection of classification algorithms and model building
• performance assessment.
A general overview of the process to build a predictive model for sample classification
is shown in Fig. 2.4.1.
2.4.1. Feature selection
Microarray data simultaneously measures the expression levels of several thousands
of transcripts on a small number of samples. Settings in which the number of
features p are much larger than the number of observations, in this case samples N
(pN) can lead to high variance and overfitting problems as the misclassification
rate in the training set decrease, but the misclassification rate of new samples might
begin to increase (Hastie et al., 2001). Additionally, expression levels can be highly
correlated.
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Figure 2.4.1.: An overview of the process for building a prediction model to classify
samples
The partition into training and test data is ideally chosen at random across the
entire set of samples. Many prediction methods require tuning some parameter
such as the number of genes or the number of nearest-neighbors to consider. This
choice is often evaluated by cross-validation. The final model is then tested on
entirely new data not used in the model generation process. The model itself, as
well as the prediction results and the influential genes, may yield new biological
insights. Figure is taken from Slonim (2002) with permission from the journal.
One common approach to overcome this problem involves the application of feature
selection. When eliminating for example transcripts with minimal variance across
sample collection the complexity of the dataset is reduced. Hence only informative
features are kept showing significantly different signal intensities between two or
more groups, often referred to as differentially expressed genes. The most simple
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method is to calculate the fold-change (FC) between two groups:
FC = m1
m2
(2.4.1)
where m1 and m2 are the mean expression levels of the two experimental groups.
Features with a FC greater then a predefined threshold (e.g. features with at least
a 2-fold change) are selected.
However, the FC measure alone is not considered as an adequate test statistic be-
cause it does not provide a significance estimate for the observed changes, the thresh-
olds for the FC are arbitrary and it does not incorporate variance (Allison et al.,
2006). This problem can be overcome when restating the biological question of
differential expression to a problem in statistical hypothesis testing. The intent
of statistical hypothesis testing is to determine whether observations made are at-
tributed to chance or provide enough evidence to reject a proposition. The usual
process consists of three steps (Fisher , 1935; Lehmann and Romano, 2005):
1. A conjecture or hypothesis associated with the process, referred to as the null
hypothesis H0 (often, that the observations are obtained by chance) and an
alternative hypothesis H1 are formulated. Importantly, H0 and H1 refer-
ence population values and not observed statistics. In this case the null hy-
pothesis can be claimed as no differential expression between the experimental
groups.
2. A test statistic that measures deviations from the H0 is identified to test
the hypothesis. The statistical testing method must be chosen depending on
the underlying data, for instance, Welch t-statistics, Wilcoxon statistics, F-
statistics or paired t-statistics can be used for testing. The test statistic from
experimental observations is compared to its know sampling distributions.
3. The corresponding p-value, the associated probability of obtaining a test
statistic at least as extreme as the one that was actually observed, assuming
H0 is true is determined. The p-value is then compared to an acceptable
significance value α and H0 is rejected if the p-value is equal or less than α
(p-value≤ α), otherwise H0 is retained.
The Welch t-test is the most commonly applied test in micoarray testing and defined
as follows:
H0 : µX = µY
H1 : µX 6= µY
with samples X and Y exhibiting unequal variance (σX 6= σY ) and normal distribu-
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tion (X ∼ N(µX , σ2X);Y ∼ N(µY , σ2Y ). The test statistic is defined as
T (X, Y ) = |X − Y |√
s2X
n1
+ s
2
Y
n2
(2.4.2)
with X andY as the means of X and Y, s2X and s2Y as the estimated variances of X
and Y and n1 and n2 as the sample sizes of X and Y , respectively. The degrees of
freedom ν can be calculated as
ν =
(
s2X
n1
+ s
2
Y
n2
)2
/
(
(s2X/n1)2
n1 − 1 +
(s2Y /n2)2
n2 − 1
)
(2.4.3)
The decision to reject H0 is done on a significance level α if |T | ≥ tv;1−α2 .
All hypothesis tests implicate the risk for making the wrong conclusion. In any
testing situation, independent from the test statistic used, two types of errors can
be committed (see Tab. 2.1).
truth
H0 is true H0 is wrong
decision H0 accepted ! type II error
H0 rejected type I error !
Table 2.1.: Types of errors in hypothesis testing
Two types of errors can be committed in a testing situation: A type I error, which
is the wrong decision that is made when a test rejects a true null hypothesis H0
and a type II error, which is the wrong decision that is made when a test fails to
reject a false null hypothesis H0.
A type I error, is defined as the rejection of a true null hypothesis H0. Its rate α
is the probability of a type I error and is also called the significance level of a test.
Typical choices for α are 0.05 or 0.01. A type II error, is defined as the failure
of rejecting a false null hypothesis and its probability is denoted by the symbol β.
Statistical tests can be compared by their power (1 − β) to detect true positives.
For the analysis of differentially expression, α is committed by declaring a feature
to be differentially expressed when it is not, and β is committed when the test fails
to identify a truly differentially expressed feature (Allison et al., 2006).
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2.4.2. Multiple testing corrections
All the different statistical approaches to find the differentially expressed features
suffer from the problem of multiple testing since thousands of genes are analyzed
simultaneously and the number of features is much larger than number of samples
(pN) (Quackenbush, 2006a), for example if 10,000 features are tested at a sig-
nificance level α = 0.05, a total of 5% or 500 features might be called significant
by chance alone. This leads to hundreds of false positives by chance when tens of
thousands of features are tested. To compensate the error of multiple testing, a
correction must be done. Most frequently used methods are listed in Tab. 2.2.
Method Type of error control Stringency
Bonferroni FWER more false negatives
Holm-Bonferroni FWER lWestfall and Young Permutation FWER
Benjamini and Hochberg FDR
None none more false positives
Table 2.2.: Methods for multiple testing correction
The methods are listed in order of their stringency, with the Bonferroni correction
being the most stringent, and the Benjamini and Hochberg FDR being the least
stringent. The more stringent a multiple testing correction, the less false positive
features are identified. The trade-off of a stringent multiple testing correction is
that the rate of false negatives is very high.
All methods control either the family-wise error rate (FWER) or the false discovery
rate (FDR). The FWER is defined as the probability that at least one false pos-
itive error will be committed (Dudoit et al., 2002b) and the FDR is the expected
proportion of Type I errors among the rejected hypotheses.
In the Bonferroni correction (Bonferroni, 1936) the p-value is multiplied with
the number of tests performed (p˜ = min[p∗nfeat, 1]; nfeat number of features). If the
adjusted p-value p˜ is still below the error rate, the feature will be called significant.
This method is very conservative and leads to a high number of false positives.
A less stringent method is the Holm-Bonferroni Step-down correction (Holm,
1979). The p-value of all features are ranked with p1 ≤ ... ≤ pk ≤ ... ≤ pnfeatand then
is p˜j = max
k=1,...,nfeat
{min[pk ∗ (nfeat − k + 1), 1]}. Both methods are called single-step
procedures, where each p-value is corrected independently.
In contrast to this, theWestfall and Young permutation method (Westfall and
Young, 1993) takes advantage of the dependence structure between features and is
based on a resampling procedure to compute p-values. The proportion of resampled
data sets where the minimum resampling p-value is less than the original p-value is
the adjusted p-value. More information can be obtained in (Ge et al., 2003).
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Rather than controlling the probability under the null hypothesis, the Benjamini-
Hochberg method (Benjamini and Hochberg, 1995) to control the false discovery
rate (FDR) can be applied. This method is the least stringent of all the four methods,
and therefore leads to less false negatives at the cost of more false positives. It is
defined by the following: Let S be the total number of features called significant, a
sensible balance between the number of false positives F and the number of correctly
rejected null hypotheses T can be achieved by considering
number of false positive features
number of significant features
= F
F+T =
F
S
.
The FDR is defined to be the expected value of this quantity FDR = E(F
S
). To
control for multiple testing, let p1 ≤ ... ≤ pk ≤ ... ≤ pnfeatbe the ranked p-values
with respective null hypotheses H0,1, ..., H0,k, ..., H0,nfeat . As long as pk ≤ knfeatα the
null hypotheses H0,1 to H0,k can be rejected.
For completion, various algorithms exist for the analysis of differential expression
incorporating multiple testing correction. Among the most widely used methods are
the significance analysis of microarrays (SAM) which estimates the false discovery
rate (Tusher et al., 2001), linear models for microarray analysis (LIMMA) which uses
adjusted p-values to control the FWER (Smyth, 2004), empirical Bayes analysis of
microarrays (EBAM) which uses a simple nonparametric empirical Bayes model and
where the empirical Bayes inferences are closely related to the FDR criterion (Efron
and Tibshirani, 2002) and the method of rank products (RankProd) which provides
a non-parametric approach to determine the significance level for each gene and
which allows the control of the FDR and FWER (Breitling et al., 2004).
2.4.3. Classification methods
In general, there are two different classification methods which can be distinguished,
unsupervised and supervised classification. Unsupervised classification disregards
prior knowledge and can be applied for the identification of sample subgroups such
that objects within each subgroup are more closely related to one another than
objects assigned to different subgroups (Quackenbush, 2006a). Different methods
include hierarchical cluster analysis and principal component analysis (PCA). As
the focus of this thesis is on supervised classification, further information on unsu-
pervised classification can be found elsewhere (Quackenbush, 2006b; Allison et al.,
2006). In supervised classification, also known as class prediction, sample classes
in a training set are known a priori and a reusable predictive model can be build
from this training set to classify future samples into the predefined output classes.
Many algorithms have been applied to high-throughput expression data. Among
the most prominent methods are k-Nearest neighbor classifier, decision trees, neural
networks, quadratic and linear discriminant analysis, shrunken nearest centroids,
random forest and support vector machines. All formulas used in this section are
taken from (Tarca et al., 2007; Hastie et al., 2001) if not stated otherwise.
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2.4.3.1. Terminology
In this section, vector and matrix notation (x denotes an ordered p-tuple of numbers
for some integer p, X denotes a rectangular array of numbers with xij being the value
in the i-th row and j-th column of X) is employed.
In supervised learning, a set of input variables is used to predict the values of one
or more outputs. In contrast to regression analysis where the output is quantitative,
qualitative outputs are predicted in classification analysis.
Generally, a collection of input variables i = 1, ..., n is classified into K predefined
classes derived from a finite set. For a binary classification task, K is derived
from [0, 1] representing the two distinct classes case and control. An available set of
measurements can then be organized in a n×pmatrixX = (xij), where xij represents
the observed values of the variable (e.g. feature intensity) j in the independent
object (e.g. RNA sample) i. To every row of the matrix X, which is a vector
xi with p features, a response (class label) yi, y = 1, ..., c, ..., K is associated. A
prediction rule (model) C(x) based on the information from the input samples can be
constructed. This classifier can be viewed as a collection of K discriminant functions
gc(x) that partition the feature space X into K disjoint subsets A1, ..., AK such that
for an object xi with measurements xi = (xi1, ..., xip)AK the predicted class is k.
Classifiers are build from a known learning or training set L = {(x1, y1) , ..., (xn, yn)}
and may be applied to a test set T = {(x1, y1) , ..., (xnT , ynT )} where each future
unlabelled observation x0 can be predicted by this rule C(x0|X) = y0.
2.4.3.2. Quadratic and linear discriminant analysis
This standard classification approach assumes that for each class c, x follows a
multivariate normal distribution N(mc,Σc) with mean mc and covariance matrix
Σcwhere the element i, j of this matrix is the covariance between the variables i and
j. Then the discriminant function for each class can be written as
gc(x) = −(x−mc)
∑ˆ−1
c
(x−mc)T − log(|
∑ˆ
c
|) (2.4.4)
with mc = 1nc
∑nc
i=1 xi and Σˆc = 1nc
∑nc
i=1(xi −mc)T (xi −mc).
The discriminant functions yield higher values for larger densities p(x | y = c)
and differences are only based on estimates of the mean and covariance matrix.
The class of a new object x0 will be defined on its largest discriminant value. As
class boundaries here are nonlinear (quadratic), this method is called quadratic
discrimant rule.
Alternatively, linear discriminant analysis (LDA) is based on the assumption
that all the classes have the same covariance matrices Σc = Σ ∀k. Then a single
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pooled covariance matrix is used. Another assumption is that the data must be linear
separable which suggests that the groups can be separated by a linear combination
of features that describe the objects
These classifiers work optimally when their underlying assumptions are fulfilled
which is not the case in many applications.
2.4.3.3. k-Nearest neighbor classification
The k-NN classification is not based on prior data distribution assumptions and
requires no model fitting to the data which makes it an easy method. For each new
object x0, the k nearest vectors from the training set xi, i = 1, ..., n are found based
on distance measures. A popular distance metrix is the Euclidean distance
deuc(x, z)) =
√√√√ p∑
j=1
(xj − zj)2 (2.4.5)
Then the classification is done by majority voting among the k neighbors and put
simply, x0 is assigned to the class most highly represented in its k nearest neighbors.
When nc denotes the number of objects among the k ones which belong to the
class c, then the k-NN method classifies x0 in the class that maximizes nc, hence
gc(x) = nc.
2.4.3.4. Nearest shrunken centroid classification
Nearest shrunken centroid (NSC) classification, also known as prediction analysis of
microarrays (PAM), is an enhancement of the nearest centroid classification method
(Tibshirani et al., 2002). Briefly, the square distance from a test sample x0 to
each of the class centroids is computed and the class whose centroid is the closest
is the predicted class. NSC classification modifies the standard nearest centroid
classification. The idea is to shrink each class centroid toward the overall centroid
for all classes by an fixed amount (Fig. 2.4.2) .
In details, the method works as follows:
Let xij be the measurement for feature i = 1, ..., p and sample j = 1, ..., n and Ck
be the indices of the nk samples in class k. Then the i-th component of the centroid
for class k is defined as the mean expression in class k for feature i :
x¯ik =
∑
j∈Ck
xij
nk ij
(2.4.6)
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Figure 2.4.2.: Nearest shrunken centroids classification
NSC represents each class by its centroid and classifies new instances by assigning
them the class of the closest centroid. NSC shrinks the class centroids in the
direction of the overall data centroid. The figure was modified from Struyf et al.
(2008).
and the i-th component of the overall centroid is
x¯i =
n∑
j=1
xij
n
(2.4.7)
The class centroids are shrunken toward the overall centroids after standardizing by
the within-class standard deviation for each feature. This normalization is defined
by a t statistic comparing class k to the overall centroid
dik =
(x¯ik − x¯i)
si
(2.4.8)
where si is the pooled within-class standard deviation for feature i :
s2i =
1
n−K
∑
k
∑
i∈Ck
(xij − x¯ik)2 (2.4.9)
Then each dik is shrunken towards zero, giving d′ik. Here, soft thresholding is used
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as shrinkage which is defined by
d′ik = sign(dik)(| dik | −∆)+ (2.4.10)
where + means the positive part (t+ = t if t > 0 and zero otherwise) meaning each
dik is reduced by an amount ∆ in absolute value, and is set to zero if its absolute
value is less than zero. The parameter ∆ is selected by cross-validation which is
described in section sec. 2.4.4. If the shrinkage parameter ∆ is large enough, many
features are eliminated as far as class prediction is concerned. By standardization,
higher weights are given to features with stable patterns within the same class.
This procedure yields the new shrunken centroids or prototypes
x¯′ik = x¯i + sid′ik (2.4.11)
After shrinking the centroids, the new sample x∗ is classified by the usual nearest
centroid rule, but using the shrunken class centroids. This classification rule is
C(x∗) = l if δl(x∗) = minkδk(x∗) (2.4.12)
where δk are the discriminant scores, similar to those used in LDA, for class k
δk(x∗) =
p∑
i=1
(x∗i − x′ik)2
s2i
− 2logpik (2.4.13)
2.4.3.5. Support vector machines
A support vector machine (SVM) discriminates one class form the other by a sepa-
rating hyperplane with maximum margin (Furey et al., 2000; Vapnik, 1998). Since
there are many possibilities for a decision boundary that is capable of separating
a binary linearly classification problem correctly (Fig. 2.4.3A), SVMs find the one
that achieves the greatest margin between the two classes (Fig. 2.4.3B), especially
to objects close to the margin. Those are called support vectors.
Let L = (x1, y1) , ..., (xNT , yNT ) be the labeled training set with xi ∈ <p, yi ∈
{−1; +1} . The hyperplane is defined by
{x : f(x) = wxT + b = 0} (2.4.14)
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Figure 2.4.3.: Support vector machines class boundaries
A: A binary classification problem (two classes marked with circles and squares)
with different linear decision boundaries. B: The maximum-margin decision
boundary implemented by the SVMs together with the separating hyperplane.
Samples along the dashed lines marked in grey are called SVs. The figure was
adapted from Tarca et al. (2007).
where w is the p-dimensional vector perpendicular to the hyperplane with ‖w‖ = 1
and b is the bias. SVMs find the optimal w and b such that the hyperplane separates
the data and maximizes the margin 1/ ‖w‖2 (Fig. 2.4.3B). The linear SVM problem
can be formulated by introducing non-negative slack variables ξi, a penalty function
measuring classification errors and a penalty parameter C set by the user as follows:
minw(
1
2 ‖x‖
2 + C
NT∑
i=1
ξi) (2.4.15)
subject to constraints
yi(wxTi + b)− 1 + ξi ≥ 0,∀i (2.4.16)
The classification function can be defined by
f(x) = sign(wxT + b) = sign(
∑
i
αiyi(xixT ) + b). (2.4.17)
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The solution to this dual problem and the computation of the coefficients αi can be
found using quadratic programming.
It is not always possible for a single linear function to completely separate two given
sets of points (Fig. 2.4.4A). In case where more sophisticated decision boundaries
are needed, SVMs use the so-called kernel trick to still fit a hyperplane to the data.
Therefore, the data points are projected by the use of kernel transformations into a
higher-dimensional feature space where the data points effectively become linearly
separable in the transformed space (Fig. 2.4.4B). The decision boundaries are linear
in the projected feature space whereas the constructed hyperplane is nonlinear in
the original input space (Fig. 2.4.4C).
Figure 2.4.4.: The support vector machine kernel trick
When objects are not linearly separable (A), the SVM approach uses the kernel
trick to transform the vector space into a higher dimensional feature space in which
a linear hyperplane can be fit to the data points (B). The construced hyperplane
could be nonlinear in the original input space (C). The figure was adapted from
Van Looy et al. (2007).
The kernel transformation is performed by replacing every matrix product
(
xix
T
)
with a nonlinear kernel function K (xix) . Common choices for K are
• linear: K(x, z) = xT z
• polynomial: K(x, z) = (xT z + 1)d
• radial: K(x, z) = e(−γ‖x−z‖2)
• sigmoidal: K(x, z) = tanh
(
γxT z + c0
)
where d, γ and c0 are parameters to be tuned to get better performance, e.g. using
cross-validation.
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2.4.4. Resampling designs
The best approach for model assessment would be to divide the data set into three
parts: a training, validation and test set. The training set is used to build the
models; the validation set is used to estimate the model performance and to choose
the best one; the test set should only be used to assess the performance of the final
chosen model. Independent validation means that there is no overlap between the
training and testing data sets. In the absence of a large, independent and blinded test
set (external validation), which is often due to the paucity of microarray data,
numerous techniques exist for assessing the prediction accuracy by implementing
some form of partitioning or resampling of the original observed data (internal
validation). Each of these techniques involves dividing the data into a learning
or training set L and a test set T to assess the predictive ability of the trained
model. If the same data is used in both L and T , referred to as resubstitution, the
performance will be optimistically biased (Hastie et al., 2001). Sample splitting,
cross-validation and the bootstrap are fundamental tools for efficient sample re-use
and work as follows:
• k-fold Cross-validation (CV): This method randomly systematically splits
the data into k approximately equal-size subsets. Each partition is used as a
test set for the model build on its complement, the remaining k−1 subsets. The
average of the k prediction estimates forms the k-fold CV estimates (Golub
et al., 1979; Speed, 2003). A common choice for k is 10 (10-fold CV). An
extreme form of CV is the so called leave-one-out CV (LOO-CV). Here, a
data set of size n leads to n model fits, each using n − 1 records (k = n).
LOO-CV is almost unbiased at the cost of high variance.
• Sample splitting: Data splitting also known as the holdout method (McLach-
lan, 1992) entails a single division of the data into a training and test set based
on a predetermined p using the test set to assess predictive ability of the trained
model. For example, p = 13 would lead to a ratio 2:1 for training and test set.
• Bootstrap: The bootstrap is a general tool for assessing statistical accuracy
introduced by (Efron and Tibshirani, 1993). Basically, data sets are randomly
drawn with replacement from the training data, each bootstrap sample the
same size as the original training set. This is done B times, producing B
bootstrap data sets. The model is fit to each of the bootstrap sets and exam-
ined over the B replications. Due to the overlap between training and test set,
predictions can be overestimated. The “.632+ estimator” can be used to take
into account the amount of overfitting (Efron and Tibshirani, 1997).
Using multiple resampling, e.g. with 100 repetitions of each method, one can obtain
a mean, as well as a standard deviation, for the classifier performance.
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2.4.5. Performance measurements
A number of different measures are commonly used to evaluate the performance
of predictive algorithms. These measures differ according to whether the output is
derived from a predefined set of responses or the classifier result is a quantitative
score. A binary classification task is to distinguish between positive and negative
samples and its performance can be assessed by the following metrics (Shapiro,
1999).
When the diagnostic test results in classification into positive and negative samples,
the counts of correct and incorrect predictions can be summarized in a 2 × 2 con-
tingency table or confusion matrix (see Tab. 2.3) of predictions against actual class
labels. Most commonly, the terms sensitivity and specificity are used to characterize
a classification rule and can be calculated from the entries of this contingency table.
Predicted positive Predicted negative
Actual positive TP FP PPV
Acutal negative FN TN NPV
PP PN
Table 2.3.: Contingency table or confusion matrix
TP: true positives (predicted positive, actual positive); TN: true negatives (pre-
dicted negative, actual negative); FP: false positives (predicted positive, actual
negative); FN: false negatives (predicted negative, actual positive); PPV: pos-
itive predictive value; NPV: negative predictive value; PP: predicted positives
(sensitivity); PN: predicted negatives (specificity).
Sensitivity (sens) or true positives (TP) measures the probability of predicting pos-
itives given true positive status, for example the probability that a positive sample
is predicted to be truly positive. It is calculated by
Sensitivity = TP
TP + FN (2.4.18)
Specificity (spec) or true negatives (TN) relates the test’s ability to identify neg-
ative results as the proportion of controls that will test negative for it. It can be
written as
Specificity = TN
TN + FP (2.4.19)
The total accuracay (proportion of correct prediction) from the contingency table
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can be calculated by
Accuracy = TP + TN
TP + FP + FN + TN (2.4.20)
As accuracy is sensitive to the prior class probabilities and does not fully describe
the actual difficulty of the decision problem for highly unbalanced distributions, the
Matthews correlation coefficient (MCC) can be used as a balanced performance
measurement. It can be interpreted as a correlation coefficient between observed
and predicted binary classifications and as for the Pearson correlation, a value of 1
corresponds to a perfect correlation, meaning a perfect performance. The MCC is
defined as
MCC = TP × TN − FP × FN√
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
(2.4.21)
Some classification models result in a continuous output (e.g., an estimate of an in-
stance’s class membership probability or another quantitative score) that represents
the degree to which an object is a member of the specific class. When assessing the
distribution of test results X for positive and negative groups, the degree of overlap
determines a tests discriminatory ability and by introducing a threshold or decision
limit c, the samples can be separated into predicted negatives (X > c) and predicted
positives (X > c). (see Fig. 2.4.5).
Different discrimination thresholds of c can then be applied to predict membership
into the two classes and yields a different 2×2 contingency table where true positive
rate (TPR) and false positive rate (FPR) can be estimated. When c increases, sensi-
tivity increases as well at the cost of reduced specificity and vice versa, a decreasing
c leads to higher specificity with decreasing sensitivity.
The receiver operating characteristic (ROC) curve is a useful graphical plot to
visualize classifier performance for such a varying threshold c (Swets, 1988). The
ROC curve is constructed by using different values of the threshold c to plot the
Sensitivity (sens(c)) on the y-axis against 1-specificity (1−spec(c)) on the x-axis (see
Fig. 2.4.6). The point (0, 1) represents perfect classification with 100% sensitivity
and 100% specificity whereas a random model guessing class labels would lead to a
ROC curve at the diagonal line.
The information in the ROC curve can be reduced to one single scalar summary met-
ric of predictive performance, the area under the ROC curve (AUC) (Bradley,
1997). An AUC value close to 1 indicates excellent classification whereas a value of
0.5 indicates useless prediction performance. The AUC is a robust measure of perfor-
mance and compared to the MCC, it is independent of the choice of the threshold c.
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Figure 2.4.5.: Hypothetical distributions of diagnostic test results X for negative
and positive samples. The vertical line at the threshold X = c indicates the
decision limit for a positive test. The shaded area to the right of c is the false
positive rate (FPR); the shaded area to the left of c is the false negative rate
(FNR). The figure was modified from Shapiro (1999).
The AUC is equal to the value of the Wilcoxon-Mann-Whitney test statistic and also
the probability that the classifier will rank a randomly drawn positive sample higher
than a randomly drawn negative sample (AUC = Prob(positive > negative)). Fur-
thermore, the AUC represents the average sensitivity over all values of FPR.
ROC curves and the AUC can be estimated under parametric or non-parametric
assumptions as described in (Faraggi and Reiser , 2002; Shapiro, 1999). The non-
parametric approaches include the use of the Mann–Whitney statistic and the fit
a smooth ROC curve using kernel smoothing followed by estimation of the AUC
by integration. The parametric approaches cover the assumption that the marker
values for negative and positive samples are normally distributed where the AUC
can be estimated by parametric methods as well as the application of a Box–Cox
type power transformation together with the use of normal theory.
Additional to the AUC, the Youden Index (Youden, 1950) is frequently used in
practice. This index is defined as
J = maxc {sens(c) + spec(c)− 1} (2.4.22)
and ranges between 0 and 1. The Youden Index (YI) has an attractive feature
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Figure 2.4.6.: Examples of ROC curves
Shown is the true positive rate on the y-axis against the false positive rate on the x-
axis for three different ROC curve examples (AUC=0.9813 excellent, AUC=0.8169
good and AUC=0.5647 worthless classification)
not present in the AUC: it enables the choice of an optimal threshold value c∗, the
threshold value for which sens(c) + spec(c) − 1 is maximized. The YI is easy to
apply and does not require further information such as prevalence rates.
2.5. Epidemiology and clinical characteristics of
analyzed diseases
2.5.1. Cancer
Cancer is a generic term for a class of diseases characterized by unregulated cell
growth. Abnormal cells grow beyond their usual boundaries and can invade ad-
joining parts of the body. Uncontrolled dividing cells form a lump or masses of
tissue called tumor. Not all tumors are concerous, benign tumors can be removed
and do not spread to other parts of the body. In contrast to this, malignant tumors
spread throughout the blood or lymph system to to other organs, a process known as
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metastasis (National Cancer Institute, 2012; American Cancer Society, 2012; Cancer
Research UK , 2012). There are over 100 different types of cancer and each subtype
is classified by the type of cell or organ that resembles the tumor (National Cancer
Institute, 2012). Broader categories of cancer include:
• Carcinoma: Malignant tumors derived from skin or in tissues that line or
cover internal organs. This group represents the most common type of cancer,
including the common forms of breast, prostate, lung and colon cancer.
• Sarcoma: This rare cancer type arises from bone, cartilage, fat, muscle, blood
vessels, or other connective or supportive tissues.
• Leukemia: Type of cancer of the blood or bone marrow. It is characterized by
the production of large numbers of abnormal blood cells that enter the blood
and do not form tumors.
• Lymphoma and myeloma: Malignancies derived from the cells of the immune
system.
• Central nervous system cancer: Type of cancer that begin in the tissues of the
brain and central spinal cord.
Cancer is a leading cause of death worldwide. In 2008, the World Health Organiza-
tion (WHO) estimated about 12.7 million cancer cases and 7.6 million cancer deaths
(13% of all deaths) to have occurred (Jemal et al., 2011; World Health Organization,
2012).
2.5.1.1. Lung cancer
Lung cancer is a disease of uncontrolled cell growth that forms in tissues of the lung.
This growth may lead to metastasis and impede the function of the lung. Symptoms
of lung cancer include shortness of breath, unexplained weight loss, chronic fatigue,
and coughing (National Cancer Institute, 2012).
Lung cancer is still the leading cause of cancer related death worldwide. It is the
most common cause of cancer-related death in men and the second most common in
woman with a total of 1.37 million deaths (18% of all deaths) in 2008. Tabacco use
is the most important risk factor for lung cancer causing 71% of global lung cancer
deaths, other risk factors include genetic factors, asbestos, radon, and air pollution
(Jemal et al., 2011; World Health Organization, 2012).
The two main types are small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC), both categories refer to the size and appearance of the malignant cells
seen by a histopathologist under a microscope. SCLC accounts for about 13% of
all lung cancers and is an aggressive and fast-growing cancer that spreads quickly.
The cancer cells look small and oval-shaped when looked at under a microscope.
NSCLC is the most common kind of lung cancer (about 87%) and spreads more
slowly than SCLC (National Cancer Institute, 2012). Lung cancers are described in
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different stages, starting from an occult stage 0 where the cancer has not invaded
nearby tissues to stage IV where malignant growths of cells may be found in more
than one area of the other lung, the fluid surrounding the lung, or distant parts of
the body.
Usually, diagnosis is performed by chest radiography and computed tomography
(CT) imaging to gain more information about the type and extend of the disease.
In a biopsy, a pathologist examines lung tissue samples under a microscope to make
a definite diagnosis (National Cancer Institute, 2012). The type of lung cancer and
the stage of the disease determine what type of treatment is needed. Prognosis
has remained poor with a disastrous 5-year survival rate of only about 15.9% due
to diagnosis of the disease in late, i.e. incurable stages in the majority of patients
(Jemal et al., 2008; National Cancer Institute, 2012). The 5-year survival rate for
cases detected with a early, localized stage of disease is 52%, however only 15% of
lung cancers are diagnosed at this early stage. NSCLC has a higher 5-year relative
survival rate (17%) in comparison to SCLC (6%) (American Cancer Society, 2012).
2.5.1.2. Multiple myeloma
Multiple myeloma (MM) is a cancer of plasma cells, a type of white blood cells,
characterised by clonal proliferation of malignant plasma cells in the bone marrow
microenvironment (Palumbo and Anderson, 2011). These abnormal plasma cells ac-
cumulate in the bone marrow and may damage the solid part of the bone (National
Cancer Institute, 2012). MM has many varying symptoms including bone pain,
frequent infections, and weight loss. MM is diagnosed with blood tests and bone
morrow examination. Additional studies include standard cytogenetic analysis as
any chromosomal abnormality is associated with a worse outcome in comparison to
a normal karyotype (Palumbo and Anderson, 2011). MM characterizes a heteroge-
neous picture in terms of symptoms, biologic characteristics, response to treatment,
and clinical outcome and several studies focus on translating the wide molecular
heterogeneity into classification and prognosis models that could be used for patient
management (Zhan et al., 2006; Avet-Loiseau et al., 2009; Broyl et al., 2010; Munshi
and Avet-Loiseau, 2011).
MM is the second most common hematological malignancy and accounts for ap-
proximately 1% of neoplastic diseases and 13% of hematologic cancers (Palumbo
and Anderson, 2011) and most people are diagnosed after the age of 65 (National
Cancer Institute, 2012). The 5-year relative survival rate for MM is around 40%
(American Cancer Society, 2012) and survival is lower in elderly people. Patients
under 60 years have a 30% 10-year relative survival rate (Brenner et al., 2008).
2.5.1.3. Leukemia
Leukemia is a malignant disease of the myeloid white blood cell line characterized
by a increased growth of abnormal white blood cells. Malignant cells interfere with
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normal blood cell production and initially accumulate in bone marrow and peripheral
blood with further suppression of its normal counterparts and later infiltrate solid
organs and tissues (National Cancer Institute, 2012). To understand the different
types of leukemia, a basic overview of the blood and lymph system is given below:
Figure 2.5.1.: All cells of the immune system arise from hematopoietic stem cells
in the bone marrow
The pluripotent HSCs divide to produce several types of progenitor cells, the
lymphoid stem cell and the myeloid stem cell. The lymphoid progenitor cell gives
rise to lymphocytes, including T lymphocytes, B lymphocytes, and natural killer
cells. The myeloid progenitor cell gives rise to, for example, erythrocytes (red
blood cells), platelets, and granulocytes. The figure is adapted from (National
Cancer Institute, 2012).
Most blood cells are developed from cells in the bone marrow called hematopoietic
stem cells (HSCs). Pluripotent HSCs mature into different kinds of blood cell types
from the myeloid and lympoid lineages (Fig. 2.5.1). Myeloid stem cells develop into
red blood cells (erythrocytes), platelets and granulocytes (white blood cells). Red
blood cells mainly carry oxygen to other tissues of the body, platelets help prevent
bleeding and granulocytes fight infections and diseases. This system responds early
and nonspecifically to infection. The lympoid stem cells develop into a lymphoblast
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cell and then differentiates into one of the three types of lymphocytes (white blood
cells): B lymphocytes (B cells), T lymphocytes (T cells), and natural killer cells.
Upon immune activation, B cells differentiate into plasma cells that produce and re-
lease thousands of specific antibodies into the bloodstream. The T cells differentiate
into cells that can kill infected cells or activate other cells of the immune system,
thereby coordinating the entire immune response. Natural killer cells attack cancer
cells and viruses (National Cancer Institute, 2012). White blood cells, red blood
cells, and platelets are produced on demand and older or damaged cells die.
Leukemia is subdivided into a chronic and an acute form. Chronic leukemia is
characterized by slow cancer progression and in early stages of disease, abnormal
blood cells still retain parts of their function and people may not have any cancer
symptoms. Most of the abnormal cancer cells are partly mature but not completely
and look more like normal white blood cells. In acute leukemia, the number of
abnormal blood cells increases rapidly and the disease progresses quickly. Acute
leukemia develops from immature blood cells that cannot carry out their normal
function. Leukemia can arise in lympoid or myeloid cells and taken together, these
two classifications provide four main types: Acute myeloid leukemia (AML), chronic
myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lympho-
cytic leukemia (CLL).
The production of normal platelets, red and white blood cells often is stopped from
the bone marrow. Deficiency of white blood cells impairs a patient’s ability to fight
infections and therefore, recurrent minor infections or poor healing of minor cuts
because of inadequate white blood cell counts may occur. A shortage of red blood
cells results in a condition called anemia, whose symptoms include paleness and
easy fatigue. The lack of platelets can lead to easy bleeding and bruising (American
Cancer Society, 2011). People who have chronic leukemia may not have major
symptoms; they may be diagnosed as a result of a routine physical examination.
Leukemia strikes males and females of all ages and its cause of most leukemia cases
is unknown (American Cancer Society, 2012), however, leukemia risk factors include
exposure to high levels of radiation and exposure to high levels of benzene.
Leukemia accounts for 350,000 cancer cases worldwide in 2008 (Cancer Research
UK , 2012). From estimated 274,930 leukemia cases in the United States in 2008,
ALL accounted for approximately 58,854 cases, CLL for 105,119 cases, AML for
30,993 cases and CML for 26,359 cases (American Cancer Society, 2011). The most
common leukemia types in adults are AML and CLL, whereas ALL accounted for
76 percent of new leukemia cases in children and adolescents ages 0 to 19 years.
Furthermore, leukemia is the most common cancer in children and adolescents less
than 20 years old. Approximately 21,780 people died from leukemia in the United
States in 2011.
From 2001 to 2007, the overall leukemia 5-year relative survival rate in the United
States was 57%. In detail, the 5-year survival rates were 55% for CML, 81% for
CLL, 24% overall and 64% for children and adolescents younger than 15 years in
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AML, and 67% overall and 91% for children and adolescents younger than 15 years
in ALL (American Cancer Society, 2011).
The diagnosis of leukemia requires specific blood tests and bone marrow examination
to determine the type of cells and the number of mature cells and blasts (National
Cancer Institute, 2012). Importantly, current diagnostic strategies involve bone mar-
row examination by an experienced hematologist, flow cytometry, polymerase chain
reaction (PCR) as well as cytogenetic analysis (Cheson et al., 2003). This rather
time-consuming procedure does not allow for designing novel induction therapies
according to risk factors.
2.5.2. Human immunodeficiency virus
The Human Immunodeficiency Virus (HIV) is a retrovirus that infects cells of the
immune system and therefore, destroys of impairs a person’s surveillance and defense
system against infections. Infected persons become immunodeficient, resulting in
increased susceptibility to a wide range of infections and diseases that a healthy
immune system normally can fight off. The most advanced stage of HIV infection
is Acquired Immunodeficiency Syndrome (AIDS). It can take 10-15 years for an
HIV-infected person to develop AIDS (World Health Organization, 2012).
HIV symptoms depend on the stage infection, starting with flu-like illnesses and
then with progressing infection and a weaker immune system, symptoms may in-
clude weight loss, fever, and cough. Without treatment, severe illnesses such as
tuberculosis, meningitis and cancers, can develop. HIV is transmitted through un-
protected contact with a variety of body fluids of infected individuals. Diagnosis
of HIV infection can be done by blood tests detecting presence or absence of anti-
bodies and antigens in the blood (World Health Organization, 2012). HIV can be
suppressed by combination antiretroviral therapy (ART). The HIV infection is not
cured by ART, but the viral replication is controlled and people can live healthy
with HIV.
The WHO reported that HIV caused more than 30 million deaths over the past
three decades. In 2011, approximately 34.2 million people were living with HIV,
over 60% of infected people live in Africa. A total of 2.7 million people were newly
infected with HIV in 2010 and 1.8 million died from AIDS in 2010 (World Health
Organization, 2012).
After HIV infection, the individual genetic background plays a central role for the
variable disease progression towards AIDS. Long-term non progressors (LTNPs) are
rare represented individuals in the HIV infected patient population (1− 2%) having
AIDS-free survival without ART for more than 10-15 years (Sheppard et al., 1993).
It is estimated that 1 in 500 people with HIV maintain this favorable course of
infection (National Institute of Allergy and Infectious Diseases, 2012). LTNPs are
of interest because they serve as an ideal model for HIV vaccine development due
to their natural control of HIV infection (Poropatich and Sullivan, 2011).
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2.5.3. Tuberculosis
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis
strains. TB bacteria usually attack the lungs. Most infections remain asymptomatic,
termed latent TB, and about 5− 10% progress to active disease, which can be fetal
if left untreated (Lawn and Zumla, 2011). Importantly, latent TB can turn into
active TB at any time of the infected person’s lifetime. People with compromised
immune systems such as people with HIV have a higher risk of falling ill, 30% of TB
patients coinfected with HIV develop active TB (World Health Organization, 2012).
Active TB may have mild symptoms such as cough, fever, and weight loss in the
first months. Later on, symptoms of active TB are cough with sputum and blood,
chest pains, weakness, fever and high sweats. TB is transmitted through the air by
minute aerosol droplets (McNerney et al., 2012).
TB diagnosis is made by finding M. tuberculosis bacteria in a clinical sample and
accurate TB infection and disease status is difficult (Barry et al., 2009). Given lim-
ited laboratory capacity, often light microscopic examination of sputum specimens
is the only TB test available (McNerney et al., 2012). This test performs poorly
in young and immunocompromised people and fails to detect active disease cases.
Hence optimal detection of active and latent TB infection, especially among HIV
infected people, remains a major challenge in resource-limited settings (McNerney
et al., 2012).
One third of the world’s population, approximately 2 billion people, is estimated to
be infected with TB. The WHO indicated a total of 8.8 million incident cases of
TB worldwide and 1.4 million associated deaths. After HIV/AIDS it is causes most
deaths to a single infectious agent worldwide. About half a million children under
14 years have TB and approximately 64,999 children died from the disease in 2010
(World Health Organization, 2012). Most cases occur in Asia and Africa. About
13% of all TB cases occurred among people infected with HIV (McNerney et al.,
2012).
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3. Material and Methods
3.1. Sample and data collection
For the analyses performed in this thesis, new data was generated in our laboratory
and also previously published datasets were used. A detailed description of data
sets is provided in the supplemental material (Appendix C). As to our knowledge
all studies were performed following guidelines of the respective local Ethics Com-
mittees. For our own data, we followed the approval by the Ethics Committee of
the University of Cologne.
3.1.1. Non-small cell lung cancer data set
NSCLC cases and hospital based controls were recruited at the University Hospital
Cologne and the Lung Clinic Merheim, Cologne, Germany. Healthy blood donors
were recruited at the Institute for Transfusion Medicine, University of Cologne.
From all individuals blood samples stabilized using PAXgeneTM. Blood DNA tubes
were taken for blood-based gene expression profiling. For all NSCLC cases blood
was taken prior chemotherapy. In total, patients with NSCLC (n=95) of stage I-IV,
hospital based controls (n=68) and healthy blood donors without prior history of
lung cancer (n=70) were included. The hospital based controls enclosed individuals
suffering from advanced chronic obstructive pulmonary disease (COPD) (n=13), hy-
pertension (n=28) or other malignancies (n=27). Detailed information on cases and
controls are summarized in Tab. 4.1. All gene expression profiling (GEX) samples
(in total n=233) were generated using the Illumina Human WG6-V2 BeadChip mi-
croarray and were used to establish a whole blood derived GEX signature to detect
patients with NSCLC. Data is provided in the NCBI GEO database (Edgar et al.,
2002) with the accession number GSE12771.
3.1.2. MAQC-II multiple myeloma data set
The multiple myeloma dataset provided by the MAQC-II study (n=554, GSE24080)
was used for initial setup of the analytical approach described within this the-
sis. These samples were all derived from highly purified bone marrow plasma
cells. Plasma cells were enriched by anti-CD138 immunomagnetic bead selection of
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mononuclear cell fractions of bone marrow aspirates in a central laboratory. All sam-
ples applied to the microarray contained more than 85% plasma cells. Dichotomized
overall survival (OS) and event-free survival (EFS) were determined based on a two-
year milestone cutoff. For these GEX samples the Affymetrix microarray Human
Genome model HG-U133A microarray format was used.
3.1.3. Data set for the development of a primary diagnostic test
for AML
GEX experiments performed on the Affymetrix microarray HG-U133A in the NCBI
GEO database (Edgar et al., 2002) and from other sources including our own un-
published data characterizing human disease conditions based on peripheral blood
or bone marrow samples were collected and annotated. Our resulting data set in-
corporated both acute and chronic leukemia and other unrelated disease samples
as well as healthy controls across 17 data sets comprising 2013 individual samples.
Patients with AML (n=717), acute lymphoblastic leukemia (ALL, n=230), chronic
myeloid and lymphoblastic leukemia (n=98), infectious diseases (n=262), coronary
artery disease (n=101), Parkinsons disease (n=85), Colitis ulcerosa and Crohns dis-
ease (n=85), Huntingtons disease (n=17), post-infectious chronic fatigue syndrome
(n=8), and 410 healthy controls from these studies were included (see Tab. 5.1 and
Tab.A.1 for detailed information of studies).
A second AML data set was derived from GEX samples (n=2088, see Tab. 5.3)
performed on the Affymetrix HG-U133 2.0 microarray collected from 15 individ-
ual studies and comprised patients with AML (n=1093), myelodysplastic syndrome
(n=302), healthy controls (n=155) as well as other diseases (n=538). The unrelated
disease cohort comprises patients with liver transplant (n=9), Alzheimer/ dementia
(n=6), samples from the malaria vaccine trial (n=39), multiple sclerosis (n=240), ju-
venile idiopathic arthritis (n=180), Steven-Johnson syndrome (n=5) and peritonitis
(n=59).
3.1.4. Data set established to detect patients with active
tuberculosis
The tuberculosis (TB) data set comprised all samples (n=147) from a recent study
using whole blood derived GEX signatures to detect patients with ATB (GSE19491).
This study includes patients with ATB (n=54), latent TB (LTB, n=69) and control
samples (n=24). Detailed information can be found in Tab.A.3. Patients with
ATB were confirmed by laboratory isolation of M. tuberculosis on mycobacterial
culture of a respiratory specimen. Latent TB patients were defined by a positive M.
tuberculosis antigen-specific IFN-γ release assay (IGRA) result. In this study the
Illumina platform utilizing Illumina Human HT12-V3 BeadChip arrays was applied.
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3.1.5. Data set established to detect patients with HIV infection
We generated a data set of GEX samples (n=257), to identify a HIV infection co-
hort irrespective of viral load including both HIV+ and long-term non progressor
(LTNP) patients in comparison to control samples (see Tab.A.2 for detailed infor-
mation). Patients were recruited into this study at the HIV outpatient clinics at
the University hospital Cologne. Patients were included based on virological and
serological diagnosis to be HIV+ and have documented HIV infection since ≥1 year.
LTNP patients (n=27) were defined as 1st never treated with anti-retroviral drugs,
2nd CD4+ T-cells ≥ 500/µL, 3rd HIV-RNA in plasma ≤ 2000 copies/mL and 4th
CDC stage A. Patients progressing to AIDS (n=79) were defined as 1st documented
CD4+ T-cell decline ≤ 300/µL and 2nd CDC stage C. Control samples from HIV-
donors were collected in our local blood bank. Healthy controls (n=88) and sam-
ples of patients with the other inflammatory diseases sepsis (n=34) and scleroderma
(n=29) were included. From all individuals PAXgene stabilized blood samples were
taken for blood-based GEX. All samples were processed using the Illumina Human
HT12-V2 BeadChips.
3.2. Statistical and bioinformatic analysis
All statistical and bioinformatical analysis were performed using R software (Ihaka
and Gentlemen, 1996) and packages from the bioconductor project (Gentleman
et al., 2004). Following recommendations made by the MAQC-II consortium, all
methods are provided in accompanying R scripts (Appendix D).
3.2.1. Data preparatory steps
Samples were subjected to an extended quality check prior use and all GEX data
presented in this thesis were of high quality. First, a visual inspection of pairwise
array’s spatial distribution of feature intensities was performed using scatter plots
from all arrays of a data set. Overall, the correlation was required to be above 0.7.
Next, the present call rate had to reach a threshold determined above 0.2. Third,
homogeneity between the arrays and the overall sample distribution was visually
analyzed by box and density plots.
When Affymetrix microarrays were used, all samples of a data set provided by cel-
files were normalized using the MAS5 method, a method summarizing background
correction, signal intensity and scaling calculations, from the affy package. For
Illumina microarrays, expression values were quantile normalized using the limma
package as advised by Dunning et al. (2008). Illumina microarray data was provided
in text-files comprising transcript intensity together with a corresponding detection
p-value. Transcripts with mean signal intensity below a calculated background sig-
nal were removed from the final data set. The background signal intensity was
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calculated by linear regression modelling between normalized expression values and
corresponding detection p-values. The estimated signal intensity at a detection p-
value of 0.05 was used as the background threshold. Background signal intensities
were 6.8093 for TB, 65.8358 for HIV and 57.9289 for NSCLC data, respectively.
In total, the Affymetrix data sets contain 22,283 transcripts, whereas the TB data
profiled 19,080, the HIV data 13,386 and the NSCLC data 13,264 transcripts.
Due to our overall strategy including simulation and adaptive learning methods and
to be able to better mimic expected clinical routine of subsequent data generation,
which is naturally prone to batch-effects, we voted against batch-effect removal when
collecting samples from one platform. When comparing HG-U133A and HG-U133
2.0 data, we filtered transcripts present on both arrays and normalized those together
using quantile normalization.
3.2.2. Standard classification
Generally, a mathematical model for classifier development has two steps. First,
genes that are differentially expressed (DE) between the experimental groups are
selected and second, a classifier is constructed using those identified DE genes. As
the preferred feature selection approach, we used a combination of FC and p-values
based on t-tests (2-sided, unequal variance = Welch test, unpaired) between the
two experimental groups. The p-values were adjusted for multiple testing using
Benjamini-Hochberg correction as implemented in the R stats and multtest pack-
ages. The gene filtering was performed in the training set (TS) of samples to avoid
overfitting. Usually, a FC of 2 and a p-value of 0.05 were used for DE calculation. For
supervised classification the packages e1071 (SVM), pamr (PAM) and class (LDA)
were used. We utilized a linear SVM kernel if not stated otherwise and default,
untuned parameters. For performance assessment, AUC, MCC, sens and spec were
used. AUC values were calculated using prediction probabilities as implemented in
the ROCR package (Sing et al., 2005) applying the non-parametric AUC estimation.
MCC, sens and spec were calculated at the maximum Youden Index.
For standard classification, the classifier was built and optimized based on the TS
using 10 times repeated 10-fold CV. In the internal CV, feature selection cut-offs
and classification algorithms are determined according to the maximum mean AUC
values reached. A classifier was then build using the respective cut-off and selected
algorithm in the TS and then validated in the independent validation set (VS).
3.2.3. Random sample-split design
A sample-split resampling design was used for clinical trial simulation (TSA, see
sec. 5.2.2). We employ a multiple random validation setup, where the data are re-
peatedly randomly divided into a TS and two independent VSs without replacement.
We perform nss = 10, 000 and nss = 1000 random samplings, each with a ratio of
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1:1:1 for the size of training to the two validation sample sizes if not stated other-
wise. Class proportions remained balanced. The classifier was built in the TS based
on DE genes selected by statistical testing between the two experimental groups in
the TS. This model was then applied to the two independent VSs and prediction
performance was assessed by calculating AUC, MCC, sens and spec respectively. For
completion, prediction performance was compared between our sample split design
(without replacement) to classical bootstrap (with replacement).
3.2.4. Resampling feature selection
The resampling design described above can furthermore be used to select informative
features and to train a good classifier. All different B subsamplings of the original
data lead to B different signatures obtained by feature selection from the TS in the
TSA. A consensus feature signature can be build from the various signatures by
different aggregation methods of ranking the features from most important to least
important. Each feature will obtain a rank and the mean rank can be computed as
r¯j =
1
B
B∑
b=1
rj,b. (3.2.1)
This means, assign a rank rj,b to feature j in each sample split b. Then we can
compute the mean rank of each feature j and use only the best features or the best
ranking features. Most important features can then be used to train the classifier
on the whole data set. Different ways of obtaining the rank are as follows:
1. Each feature can be ranked according to the number of times it is identified as
differentially expressed in each TSA. By using subsets of the original data set,
stable markers would be expected to appear more often than uninformative
features in the signatures.
rj,b =
1 if the feature j is DE in b0 otherwise (3.2.2)
2. The procedure in (1) would lead to a stable biomarker signature, yet still
stability alone is not a good quality measure as it needs to be assessed together
with classification performance. In linear SVM classification, the absolute
values of the weights of each feature wj,b can be regarded as the contribution
of each feature:
rj,b =
wj,b if j DE0 otherwise (3.2.3)
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3. All features can be ranked according to both the calculated p-value and FC in
the subset, hence rj,b = pVj,b or rj,b = FCj,b.
3.2.5. Negative controls
Two different negative control procedures were implemented as well. First, class
labels were randomly assigned to each single data set. TSA (1000 iterations) was
repeated using this non-predictable data set.
Second to test the final classifier specificity, the whole analysis of classifier building
and application was repeated 1000 times by using random feature sets of equal size.
3.2.6. Heuristic approach for artificial sample generation
In biomarker studies, the number of features is typically larger than the sample
size due to the paucity of high-throughput genomic data. The generation of more
samples often is not possible or expensive and time-consuming. With this practical
limitation in mind, an alternative might be the inclusion of artificial samples. The
idea is to simulate new samples according to the distribution of given samples. Here,
metric relationships from two randomly chosen samples were used to calculate new
samples in a rather simple feature-by-feature approach by the following heuristics:
Randomly draw two samples y, z from the same experimental group. When y < z,
generate ten new sample values for each feature by calculating
(y + z)/2
y + 12(z − y)
y − 110(z − y)
y − 15(z − y)
y − 12(z − y)
y − (z − y)
z − 12(z − y)
z + 110(z − y)
z + 15(z − y)
z + 12(z − y)
Those parameters were chosen to increase the variance within the data set and to
decrease homogeneity in the simulated dataset.
3.2.7. Adaptive learning approach
Central to the adaptive learning approach is the integration of each new sample or
case into the classifier to stepwise optimize the diagnostic assessment. In contrast
to static initial best biomarkers, continuous incremental improvement is evaluated
as follows (see Figure Fig. 5.2.13A):
The complete AML data set (n=2013) is divided into a set for adaptive learning
(ALS) and two external validation sets (ExVS1, ExVS2), each of size 671 samples.
In the adaptive learning process, an initial TS of size 50 is drawn from the ALS.
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Internal classifier validation is performed by TSA (100 iterations), summarized in
a mean AUC performance assessment and then a classifier based on the entire TS
is applied to ExVS1 and ExVS2. Next stepwise, additional sample sets of size 20
are subsequentially drawn from the ALS and for each new sample set added to the
initial TS, internal and external validation is performed based on the enlarged set
(of size 70, 90, 110 etc.). To ensure adaptive learning is not depending on sample
draw ordering, this procedure is repeated 100 times, leading to summarized mean
of mean of 100x100 AUCs.
The adaptive learning approach is furthermore developed to determine minimal
sample size required for validation cohorts based on a small pilot trial data. Based
on the summarized mean of mean AUCs, a cubic smooth spline curve is fitted to
these values (Hastie and Tibshirani, 1990). This spline function requires the AUCs
xi stated as x0 < x1 < ... < xn as the predictor value and the sample sizes yi as
the responses, i = 1, ..., n. The relation Yi = f(xi) models these observations. The
smoothing spline estimate fˆ of the function f is defined to minimize
n∑
i=1
(Yi − fˆ(xi))2 + λ
ˆ xn
x1
fˆ”(x)2dx (3.2.4)
where fˆ is a twice-differentiable function on [x1, xn] and λ is the smoothing pa-
rameter indicating the roughness of the resulting spline function. Cubic splines
for given x1 < t1 < t2 < ... < tn < xn are cubic polynomials on each interval
[x1, t1] , [t1, t2] , ..., [tn, xn] and the polynomial pieces fit together at points ti, mean-
ing fˆ itself and its first and second derivatives are continuous at each ti, and hence
on the whole [x1, xn] . The cubic splines are specified as
fˆ(t) = di(t− ti)3 + ci(t− ti)2 + bi(t− ti) + ai (3.2.5)
for ti ≤ t ≤ ti+1.
As this method intends to estimate sample sizes, a maximum value xmax of this
function is predicted at 2 ∗ xn and then the fitted values fˆ(0.9 ∗ xmax) as well as
fˆ(0.95 ∗ xmax) are calculated. The R package stats is used to fits a cubic smoothing
spline to the supplied data and to predict the smoothing spline fit at new points.
3.2.8. Functional analysis of signatures
For biological interpretation of gene signatures, we performed an enrichment analy-
sis of gene ontology (GO) terms (Ashburner et al., 2000) using GOrilla (Eden et al.,
2009) as well as a cancer-related disease gene enrichment analysis using FunDO (Du
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et al., 2009). GOrilla discovers enriched GO terms in a target set versus a back-
ground set (e.g. all transcripts present on the microarray). FunDO uses the Disease
Ontology annotation (Osborne et al., 2009) to provide analysis of disease terms as-
sociated with genes in a gene list. Both tools evaluate significance of associations
by a Fisher’s exact test based on hypergeometric distribution.
3.2.9. Implementation of a web-based AML diagnosis tool
A tool for AML classification was implemented using RWui (Newton et al., 2011).
This tool performs AML diagnosis based on the entire AML HG-U133A data set.
A SVM classifier is established on 200 best performing features and can be applied
to a new HG-U 133A sample uploaded by the user.
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approach for biomarker
development
In this chapter a conventional microarray classification workflow is established for
the identification of non-small cell lung cancer (NSCLC) in comparison to control
samples. This workflow comprises
• Comparison of feature selection cut-offs and classification algorithms in a train-
ing cohort by CV
• Building an optimized classifier in the TS using the chosen features and algo-
rithm
• Application of this classifier to two independent validation cohorts and assess-
ment of classifier performance
This approach is further applied to one of the gene expression datasets, a multiple
myeloma dataset, provided by the MAQC consortium (Shi et al., 2010).
4.1. Motivation
Lung cancer is still the leading cause of cancer related death worldwide. Prognosis
has remained poor with a disastrous five year survival rate of only about 15% due
to diagnosis of the disease in late, i.e. incurable stages in the majority of patients
(Jemal et al., 2008) and still disappointing therapeutic regimens in advanced disease
(Sandler et al., 2006). Thus, there is an urgent need to establish reliable tools for
the identification of NSCLC patients at early stages of the disease e.g. prior to the
development of clinical symptoms. Today, the only way to detect non-small cell
lung cancer is by means of imaging technologies detecting morphological changes in
the lung in combination with biopsy specimens taken for histological examination.
However, these screening approaches are not easily applied to secondary prevention
of non-small cell lung cancer in an asymptomatic population (Henschke et al., 2006).
The use of surrogate tissue-based, e.g. blood-based, biomarkers for non-small cell
lung cancer might therefore circumvent the known pitfalls of imaging technologies
and invasive diagnostics (Henschke et al., 2006; Bach et al., 2007). Such biomark-
ers might be utilized to direct imaging based and invasive screening approaches
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to only those individuals identified as potential non-small cell lung cancer patients
by biomarker screening. Array-based assessment of disease-specific gene expres-
sion patterns in peripheral blood mononuclear cells (PBMC) have been reported
for non-malignant (Staratschek-Jox et al., 2009) and malignant diseases including
renal cell carcinoma, melanoma, bladder, breast and lung cancer (Burczynski et al.,
2005; Twine et al., 2003; Sharma et al., 2005; Osman et al., 2006; Critchley-Thorne
et al., 2007; Showe et al., 2009). In some cases gene expression profiles derived from
PBMC were even suggested as promising tools for early detection (Showe et al., 2009;
Sharma et al., 2005) or prediction of prognosis (Burczynski et al., 2005), albeit these
findings have not yet been validated in independent studies. Furthermore, circum-
venting known pitfalls of analyzing PBMC in a clinical setting (Debey et al., 2006,
2004) by using stabilized RNA derived from whole blood would further strengthen
the validity of blood-based surrogate biomarkers for early diagnosis of lung cancer
and other malignant diseases. We therefore investigated the validity of whole blood-
based gene expression profiling for the detection of NSCLC patients among hospital
based controls as well as healthy individuals.
4.2. Results
4.2.1. Establishment of a gene expression profiling-based
classifier for blood-based diagnosis of NSCLC
The classifier was build based on an initial TS containing 35 NSCLC cases of dif-
ferent stages (stage I: n=5, stage II: n=5, stage III: n=17, stage IV: n=8) and 42
hospital based controls suffering in part from severe comorbidities such as COPD,
hypertension, cardiac diseases as well as malignancies other than lung cancer (see
Tab. 4.1).
We first evaluated three different approaches, namely SVM, LDA and PAM to iden-
tify the best algorithm to build a classifier for the diagnosis of NSCLC in a 10-fold
CV design (see Fig. 4.2.1A). To this end we used 36 different feature lists extracted
from the list of differentially expressed genes according to 36 different cut-off p-values
of the T-statistics. In this setting the SVM algorithm performed best by reaching
the highest AUC (mean AUC = 0.754) at a cut-off p-value of the T-statistics of
0.003 (Fig. 4.2.1B). Thus for subsequent classification we applied SVM by using the
484 feature list obtained at a cut-off p-value of the T-statistics of p-value<0.003 for
differential expressed genes between cases and controls based on the entire TS.
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Training set (TS) Validation set (VS1) Validation set (VS2)
NSCLC controls* NSCLC controls* NSCLC controls**
total number 35 42 28 26 32 70
female 10 14 9 10 16 35
male 25 28 19 16 16 35
median age 61 61 62 65 67 44
NSCLC stage 1 5 NA 6 NA 32 NA
NSCLC stage 2 5 2 0
NSCLC stage 3 17 12 0
NSCLC stage 4 8 8 0
Table 4.1.: Clinical and epidemiological characteristics of cases with lung cancer
and respective controls
Clinical and epidemiological characteristics of cases and controls in the training
set as well as the two independent validation sets are given. *Hospital based **
healthy blood donors; median age is given in years, NA: not applicable
Figure 4.2.1.: Experimental design and parameter optimization
A: In the training set (TS) the optimal classifier was established, and then ap-
plied to two validation sets VS1 and VS2. To test the specificity of this optimized
classifier additional 1,000 classifiers using random feature lists of equal size were
permuted and applied to VS1 and VS2. The workflow layout was originally de-
signed by Dr. T. Zander. B: Identification of the optimal algorithm for classi-
fication based on the TS. The AUC is plotted against the cut-off p-value of the
T-statistics for feature selection for all three algorithms (SVM, LDA, PAM) in the
10-fold cross-validation of the TS. SVM leads to the highest mean AUC (mean
AUC = 0.754) at a cut-off p-value of 0.003 which is highlighted by a dotted line.
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4.2.2. The diagnostic NSCLC classifier can be used to detect
NSCLC cases in two independent validation sets
First, we validated whether the classifier can be used to discriminate NSCLC cases
of early and advanced stages among hospital based controls. Therefore in the first
independent VS, cases and controls were chosen in a similar setting as in the TS,
this is, patients with NSCLC stage I to IV and clinical symptoms associated with
lung cancer and hospital based controls with relevant comorbidities (n=26). The
AUC for the diagnostic test of NSCLC in this first VS (VS1) was calculated to be
0.824 (p-value<0.001, Fig. 4.2.2A). In addition, we observed a significant difference
between the SVM based probability scores to be a NSCLC case for actual NSCLC
cases and controls in VS1 (p-value<0.001, T-test).
After demonstrating that the classifier can be used to detect NSCLC cases among
individuals with comorbidities we also investigated whether this test can be used
to distinguish NSCLC cases presenting at stage I with no or only minor symptoms
from healthy individuals. Therefore we recruited a second independent VS consist-
ing of 32 NSCLC cases at stage I and 70 healthy blood donors (VS2). By applying
the identical classifier to VS2 the AUC was determined to be 0.977 (p-value<0.001,
Fig. 4.2.2B). We also observed a highly significant difference in the probability val-
ues to be a NSCLC patient for cases in contrast to controls (p-value<0.001, T-test).
Healthy controls without significant comorbidity (VS2) tend to have lower probabil-
ity scores compared with hospitalbased controls (VS1 and TS) although this finding
was not statistically significant (Fig. 4.2.2D).
4.2.3. Permutation test to analyse the specificity of the classifier
To further underline the specificity of this classifier, we used 1000 random feature
lists each comprising 484 features to likewise build a SVM-based classifier in the
TS which then were applied to VS1 and VS2, respectively (Fig. 4.2.2C). For VS1
the mean AUC obtained by using these random feature lists was 0.6839 with 31
AUCs being ≤ 0.824, the AUC obtained using the NSCLC specific classifier. This
corresponds to a p-value of 0.031 for the permutation test further confirming the
specificity of the NSCLC classifier. Similar by applying the permuted classifiers to
VS2 only 11 of random feature lists lead to an AUC of≤ 0.977, the AUC obtained us-
ing the NSCLC-specific classifier (p-value=0.011). In conclusion, a NSCLC-specific
blood-based classifier was build that was successfully used to identify NSCLC cases
among hospital based controls as well as NSCLC cases of early stage among healthy
individuals.
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Figure 4.2.2.: Performance of optimized classifier in VS1 and VS2
(A) Receiver operating characteristic (ROC) curve for the optimized classifier
established in the training set applied to validation set 1 (VS1: all stage NSCLC
patients and hospital based controls), AUC = 0.824. (B) ROC curve for the
optimized classifier applied to validation set 2 (VS2: stage I NSCLC patients,
healthy controls), AUC = 0.977. Shown is the true positive rate (Sensitivity) on
the y-axis against the false positive rate (1-Specificity) on the x-axis. (C) Box
plots comprising 1,000 AUCs obtained by using a random list of 484 features to
build the classifier in TS and then apply it to VS1 (left) and VS2 (right). The real
AUC using the specific classifier is depicted with grey circles. (D) Test scores to be
a case of all samples from VS1 and VS2 were ranked. NSCLC cases are marked
in red and controls in blue. Membership in a specific cohort is indicated by a
vertical line underneath the graph. For visualization of the test score obtained by
the SVM algorithm we used the following transformation: log2(score + 1) + 0.1.
The layout was adapted from a graphic originally designed by Dr. T. Zander.
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4.3. Summary and Discussion
Using RNA-stabilized whole blood from smokers in three independent sets of NSCLC
patients and controls we present a gene expression based classifier that can be used
as a biomarker to discriminate between NSCLC cases and controls. The optimal
parameters of this classifier were first determined by applying a classical 10-fold CV
approach to a TS consisting of NSCLC patients (stage I-IV) and hospital based
controls (TS). Subsequently this optimized classifier was successfully applied to two
independent VSs, namely VS1 comprising NSCLC patients of stage I-IV and hospital
based controls (VS1) and VS2 containing patients with stage I NSCLC and healthy
blood donors. This successful application of the classifier in both VSs underlines
the validity and robustness of the classifier. Extensive permutation analysis using
random feature lists and the possibility of building specific classifiers independently
of the composition of the initial TS further support the specificity of the classifier.
We found no associations between stage of disease and the probability score assigned
to each sample. In addition we observed no association between other cancers and
the probability score of the controls (data not shown). But controls without doc-
umented morbidity (controls in VS2) tend to have lower probability scores to be
a case as compared to controls with documented morbidity, although this was not
statistically significant.
Recently, Showe et al. (Showe et al., 2009) reported a NSCLC associated gene
expression signature derived from PBMC of predominantly early stage NSCLC pa-
tients. Since we used RNA-stabilized whole blood and not PBMC for analysis, we
were not surprised that the signature identified by Showe et al. could not be used
in our dataset to distinguish between cases and controls. The same holds true when
applying our classifier to the published data set (data not shown). Findings de-
rived from several of our own studies further underline that signatures derived from
PBMC and RNA-stabilized whole blood samples cannot be directly compared (De-
bey et al., 2006, 2004). However, as previously shown by us and others, for clinical
applicability and robustness we would favor RNA-stabilized approaches since these
methods reveal more reliable results in a multi-center setting (Debey-Pascher et al.,
2011).
Overall, our data demonstrate the feasibility of a diagnostic test for NSCLC based
on RNA-stabilized whole blood. Our findings form the basis for validation studies
in a multi-center setting in prevalent NSCLC patient cohorts enriched for early
stage disease. At the end, this endeavor might open the avenue to test the blood-
based NSCLC classifier in prospective trials to evaluate the predictive potential of
diagnostic classifiers for NSCLC in high-risk individuals.
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4.4. Further analysis of MAQC-II data
To evaluate whether our approach is comparable to standards defined in the MAQC-
II study (Shi et al., 2010), we applied our preferred method established before for
data processing, feature selection and classifier development to one of the 6 GEX
data sets provided by the MAQC consortium. This multiple myeloma data set (Zhan
et al., 2006; Shaughnessy et al., 2007) comprised a total of 340 samples in the TS
plus 214 samples in the VS and defined four different endpoints, namely event free
survival (EFS) meaning a lack of malignancy or disease recurrence, overall survival
(OS) after 730 days, gender (representing the sex of patients, which is highly pre-
dictable by the microarray data; positive control), and random (randomly assigned
sample class labels that are not predictable by microarray data; negative control)
measured on the Affymetrix HG-U133A microarray. We defined a model (FC/p-
value filter for feature selection, linear SVM classifier) without further optimization
by internal 10-fold CV which was repeated 10-times in the TS (internal validation)
and applied this model to the independent VS (external validation). These results
were compared to classification performance of best-performing models defined by
MAQC-II data analysis teams for all 4 endpoints.
Figure 4.4.1.: Distribution of AUC performance of our classifiers (LIMES) defined
by internal 10-fold CV repeated 10-times (int, grey), external validation (ext, blue)
as well as the best-performing models of MAQC-II (n = 17, white). Endpoints
event free survival (EFS), overall survival (OS), gender (positive control), and
random (randomly assigned sample class labels, negative control) of the multiple
myeloma dataset provided by MAQC-II were assessed. Boxes indicate the 25% and
75% percentiles, and whiskers indicate the 5% and 95% percentiles. The layout
was adapted from a graphic originally designed by Prof. Dr. J. L. Schultze.
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As demonstrated by Fig. 4.4.1, both internal and external classification performance
results for AUC across all 4 endpoints are similarly well to best-performing models
obtained by data analysis teams included in the MAQC-II. Similar results were
obtained for MCC, sens and spec (data not shown). Overall, our analysis approach
to make clinical predictions is up to the MAQC-II standards and good modeling
practice is provided.
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approaches enhance classification
This chapter introduces methods to enhance molecular diagnostics including novel
strategies to predict the outcome of a large biomarker study from a small pilot
study and to estimate approximate sample size of future validation cohorts. These
concepts are developed on a large acute myeloid leukemia (AML) gene expression
data set and then applied to predict the diagnosis of NSCLC, active tuberculosis
(ATB) and human immunodeficiency virus (HIV) from microarray data.
5.1. Motivation
Irrespective of widespread establishment of transcriptional-based biomarkers, the
number of gene signatures that have entered clinical practice is alarmingly small and
the translation of basic findings to clinical utility such as diagnosis and prognosis
has been slow. As already pointed out in the introduction, the MAQC-I study (Shi
et al., 2006) has successfully demonstrated that the microarray technology itself is
reliable and reproducible. As questions remained regarding the reliability of the
technology in clinical applications such as disease diagnostics or prognostics, the
MAQC-II project (Shi et al., 2010) was launched to investigate the capabilities and
limitations of microarray technology. Various data analysis methods in developing
and validating of predictive signatures were assessed and classifier models and a
consensus on the “best practices” for these models was reached. Important results
from this large consortium effort include an outcome dependent model prediction
performance and a high degree of concordance between well-implemented internal
and external validation. As many classifiers with similar statistical performance
can be identified for a studied endpoint, a great uncertainty about selecting the
“optimized” model remains.
In this project we sought to address several unresolved issues. First, to better judge
the validity of small pilot trials we developed a two-step validation approach com-
bined with randomized permutation (“clinical trial simulation”). Second, to predict
the minimum size of a consecutive pivotal validation trial we describe an algorithm
combining sample simulation and adaptive learning approaches (“on the fly opti-
mization strategy”). This approach can also estimate overall best test performance.
Utilizing these approaches we introduce a high-performance test for primary molec-
ular diagnosis of leukemia, we estimate the trial size and test performance for pivotal
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trials using peripheral blood to develop three independent biomarker tests to detect
patients with ATB, NSCLC and HIV.
5.2. Results
5.2.1. Establishment of AML GEX data as a reference set
The evaluation of simulation and adaptive learning approaches to accelerate clinical
biomarker development first required the establishment of a sufficiently large set of
high-throughput data suitable for assessing a clinically relevant endpoint. Ideally,
the data set should be derived from a common data space based on a single technol-
ogy. This feature would be particularly beneficial for normalization issues of data
derived from multiple locations and/or studies. Therefore, we searched for a diag-
nostic setting that would fulfill the following criteria: 1) sufficient data on a single
technical platform, even if from different sources, 2) ability to integrate such data
with high enough quality, 3) prior knowledge about the performance of such tech-
nology in a diagnostic setting, 4) a disease setting with a high enough prevalence,
and 5) the need to further improve molecular diagnostics to improved therapy and
disease outcome. High dimensionality of GEX data and recently suggested guide-
lines by the MAQC consortium made this technology a prime source to test our
overall approach.
We chose primary molecular diagnosis for AML as the first model endpoint. Sev-
eral studies already reported the successful establishment of transcriptional-based
classifier for disease subclassification, outcome prediction and differential diagnosis
(Bacher et al., 2009a,b). Surprisingly, primary molecular diagnosis was not an end-
point in these studies. AML is a malignant disease of the myeloid white blood cell
line characterized by a rapid growth of abnormal white blood cells. Malignant cells
interfere with normal blood cell production and initially accumulate in bone marrow
and peripheral blood with further suppression of its normal counterparts and later
infiltrate solid organs and tissues. Patients with AML typically have a poor progno-
sis. Importantly, current diagnostic strategies involve bone marrow examination by
an experienced hematologist, flow cytometry, PCR as well as cytogenetic analysis
(Cheson et al., 2003). This rather time-consuming procedure does not allow for
designing novel induction therapies according to risk factors. Thus, there is obvious
need for diagnostic tools to rapidly confirm primary diagnosis by light microscopy
while at the same time ascertain prognostic and predictive factors. We therefore
investigated the use of RNA microarray analysis of peripheral blood or bone mar-
row as a tool for primary diagnosis that might substitute currently used diagnostic
technologies. As AML has a low prevalence but is a deadly disease if not diagnosed
in time, a test used for screening or primary diagnosis of AML would have to achieve
sensitivity and specificity > 97% preferably >99% to minimize false-negative results
while avoiding unacceptable levels of false-positive results.
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Positives Negatives Further sample description Reference
43 AML Gutiérrez et al. (2005)
50 AML
Haferlach et al. (2005)50 ALL
98 CML and CLL
163 AML Metzeler et al. (2008)
150 AML Ross et al. (2004)5 ALL
26 AML Stirewalt et al. (2008)38 Healthy controls
285 AML Valk et al. (2004)5 Healthy controls
175 ALL Mullighan et al. (2009)
108 Healthy controls Baty et al. (2006)
14 Healthy controls Borovecki et al. (2005)17 Huntington’s disease
42 Healthy controls Burczynski and Dorner (2006)85 UC/ Crohn’s disease
8 Healthy controls Ramilo et al. (2007)262 Infectious diseases
14 Healthy controls Connolly et al. (2004)
26 Healthy controls Debey-Pascher
7 Healthy controls Gow et al. (2009)8 CFS
121 Healthy controls Sinnaeve et al. (2009)101 Coronary artery disease
20 Healthy controls Scherzer et al. (2007)85 Parkinson disease
7 Healthy controls Watford et al. (2008)
717 1296 ∑
Table 5.1.: HG-U133A AML data set
Summary of GEX studies included in the HG-U133A AML data set. Numbers
shown are the actual number of samples used in the final data set. In total, this
data set includes 2013 samples from 17 different studies.
In an initial screen we identified 113 studies addressing diagnostics issues in leukemia
and for only 45 studies transcriptome data were available. Seven of these studies were
performed on a single microarray platform using the Human Genome model HG-
U133A microarray from Affymetrix. Only one of these studies addressed molecular
primary diagnosis of AML as the major endpoint; however, this study was extremely
small with only 26 AML patients and 38 healthy controls (Stirewalt et al., 2008). All
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other studies focused on differential diagnosis respectively subclassification or disease
and treatment outcome (Valk et al., 2004; Ross et al., 2004; Haferlach et al., 2005;
Gutiérrez et al., 2005; Metzeler et al., 2008). We therefore integrated additional data
sets to be able to address the important question of AML primary diagnosis with
sufficiently high statistical power. In total, 2013 samples from 17 different studies
passing defined quality control criteria (see chapter 3) were compiled to form a
new data set (Tab. 5.1). These studies included samples from AML (n=717) and
healthy controls (n=410) as well as samples comprising other diseases not related
to leukemia (n=558) and other leukemia samples including acute lymphoblastic
leukemia (n=230) and chronic leukemia (n=98).
5.2.2. Trial simulation approach
5.2.2.1. Performance of a small pilot trial
To simulate a typical pilot trial study (PTS) setting as a first step of test develop-
ment, 150 samples were drawn randomly from the complete data set and distributed
into the three sets TS, VS1 and VS2, each containing 25 AML cases and 25 controls
(Fig. 5.2.1A). This initial setting allowed the development of a classifier within TS
and two independent validations (in VS1 resp. VS2). Since classifier performance in
subsequent validation cohorts might be strongly influenced by the characteristics of
the patient population within TS, it was already suggested in MAQC-II to perform
swap analysis of training and validation cohorts (Shi et al., 2010). In principle,
swapping independent patient cohorts is just a special case of random permuta-
tion of samples. We therefore extended this approach from a single swap to 10,000
permutations (termed ‘10,000 trial simulation approach’; TSA) containing for each
simulation random drawing of one TS and two independent VSs (Fig. 5.2.1A). Using
our conventional linear SVM-based classification with a FC/p-value filter (FC 10,
p-value 0.0001) for feature selection, a relatively high mean AUC of 0.9688 in both
VSs was achieved by TSA for this AML pilot trial (Fig. 5.2.1B). Taken together,
TSA allows quantification of the influence of sample distribution (into the respec-
tive cohorts) on the statistical performance of the classifier and average metrics gives
an early estimate for overall classifier performance to be expected for the endpoint
under study.
Next classification algorithms, feature selection, or size and sample distribution
within TS were varied to elucidate their influence on prediction performance. Again,
AUC, MCC, sensitivity and specificity were evaluated by TSA generating a total of
210,000 classifier. We first used a different SVM kernel and further compared SVM
to LDA and PAM algorithms (n= 8×10,000 classifier, Fig. 5.2.1C). SVM and PAM
performed similarly well while LDA did not reach comparable high mean AUC. The
non-parametric wilcoxon test resulted in more features not passing the filter cut-offs.
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Figure 5.2.1.: Classification performance of AML pilot trial
(A) The pilot trial study simulation for AML is shown as a schematic view. First,
a small pilot trial study (PTS) is drawn from the complete cohort. This PTS
is divided in a training set (TS) and two validation sets (VS1, VS2) without
replacement. Feature selection and classifier construction is based on the TS. The
TS classifier is applied to the 2 VSs. The entire process is repeated 10,000 times.
The workflow layout was adapted from a graphic originally designed by Prof. Dr.
J. L. Schultze. (B) AUC values for 10,000 iterations of classification, displayed
are individual classification results (left panel) for VS1 (grey) and VS2 (blue) and
the summarizing boxplots (right panel). Boxes indicate 25th and 75th percentiles,
the line within the box marks the median, whiskers above and below the box
indicate 90th and 10th percentiles, outliers are plotted as dots. Distribution of AUC
performance of (C) different classifier and feature selection algorithms (SVM with
linear and radial kernel, PAM and LDA) in combination with a t-test or Wilcoxon
test and (D) different feature size cut-offs for fold-change (FC)/p-value (pV) filter
(D) are displayed as boxplots. NA values indicate the number of tests without
features passing the filter cut-offs.
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Since TSA clearly established the framework for classifier performance (range, me-
dian, 75% percentile) we next addressed dependency of classifier performance on
feature size and feature selection cut-off (n= 5×10,000 classifier, Fig. 5.2.1D). Unex-
pectedly, reducing feature size resulted in inferior classifier performance suggesting
that due to the overall small sample size, more features are required to correctly clas-
sify in independent validation cohorts (Fig. 5.2.1D). This was similarly true when
reading out MCC, sensitivity and specificity (Fig. B.0.1).
For completion, TSA also clearly established that further reduction of sample size or
unequal distribution of samples in TS results in reduced overall classifier performance
(Tab. 5.2).
%AML %Control Min. 1st Qu. Median Mean 3rd Qu. Max.
VS1
25 25 0.728 0.9568 0.9712 0.9683 0.9856 1
20 25 0.7248 0.952 0.968 0.9644 0.984 1
15 25 0.632 0.9424 0.9632 0.958 0.9808 1
10 25 0.6752 0.9344 0.9584 0.9515 0.9776 1
5 25 0.1008 0.9184 0.9504 0.9383 0.9728 1
VS2
25 25 0.7648 0.9568 0.9712 0.9686 0.9856 1
20 25 0.7696 0.952 0.968 0.9645 0.984 1
15 25 0.6672 0.944 0.9632 0.9582 0.9808 1
10 25 0.6448 0.9344 0.9584 0.9514 0.9776 1
5 25 0.0928 0.9184 0.9504 0.9387 0.9728 1
VS1
20 20 0.648 0.9504 0.968 0.9634 0.9824 1
15 15 0.6992 0.9376 0.96 0.9541 0.9776 1
10 10 0.6128 0.92 0.9488 0.9392 0.9696 1
5 5 0.3648 0.8832 0.9312 0.9118 0.96 1
VS2
20 20 0.692 0.9504 0.9664 0.9635 0.9824 1
15 15 0.6448 0.9376 0.96 0.9543 0.9776 1
10 10 0.5936 0.92 0.948 0.9391 0.9696 1
5 5 0.408 0.8824 0.9312 0.9114 0.9616 1
Table 5.2.: AUC performances for different case:control proportions
Shown are the summary statistics of AUC performance for different proportions
of AML to control samples in 10,000 permutations of TSA.
Overall, TSA seems to be well-suited to establish overall classifier performance that
can be expected independent of the actual clinical situation with subsequent patient
recruitment into TS and validation cohorts for the endpoint under study. Moreover,
dependencies of classifier performance and the influence of sample distribution, clas-
sification algorithms and feature selection are easily uncovered.
Depending on the sample distribution to the three independent cohorts (TS, VS1,
VS2), performance of a significant number of classifiers would not have supported
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further classifier development. Moreover, many classifier did not reach the set target
of performance (e.g. AUC> 0.99). To further elucidate whether one single drawing
of samples into the three cohorts predicts the outcome in a large validation cohort, we
reanalyzed all classifiers developed during feature cut-off filter variation (n=60,000).
First, we estimated the number of classifiers who would have been candidates to be
further used in clinical practice by the proportion of classifiers in TSA with mean
AUC in VS1 and VS2 >0.99. In total, 1451 out of 60,000 classifiers (2.4183%)
fulfilled this criterion. We next applied those classifiers to the remaining samples
from the large AML cohort (n=1863). Only 572 classifiers (39.4211%) from the
candidate classifiers resulted in a AUC value >0.99 for this larger validation cohort
and vice versa, 60,5789% would result in inferior prediction performance. AUC
distributions of these classifiers are visualized in the density plot of Fig. 5.2.2 and
correlation between internal and external validation in this setting are shown in
Fig. B.0.2. These results further demonstrate that the classical design of fixed sample
drawing into the different cohorts is an inadequate approach to establish a final
classifier.
Figure 5.2.2.: Distribution of AUC values of external validation for classifiers re-
sulting in AUC values >0.99 in internal validation, displayed as a density plot. A
dashed horizontal line indicate AUCs >0.99.
5.2.2.2. Selection of a good classifier from the pilot study
There are several ways to select a good classifier from a pilot trial. Usually, this
classifier will then be fixed and validated in a big VS. Conservative approaches split
the PTS into a pilot TS and a pilot VS, A single classifier is trained on the pilot
TS and evaluated on the pilot VS. A major drawback of this approach is that only
50% of the data is used for classifier training. As already shown in Fig. 5.2.2, a high
proportion of classifiers would result in overoptimistic performance results.
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Our approach is building from the whole PTS using features identified in the TSA
and in this way, expecting to get a robust feature ranking from different sample sub-
sets. We choose four different approaches to identify and rank informative features
in TSA (see chapter 3). First, we counted the number of times a feature is identi-
fied as differentially expressed in each TSA iteration and each feature can then be
ranked according to this criteria (“DE selection”). By using subsets of the original
data set, stable markers would be expected to appear more often than uninformative
features in the signatures. Second, we assessed features together with classification
performance using the score assigned to each feature. In linear SVM classification,
the absolute values of the weights of each feature can be regarded as the contri-
bution of each feature and a ranking can be obtained according to the weighted
ranksum (“weights SVM”). Both methods focuses on DE features. As other fea-
tures not chosen by this strict filter might be informative as well, we also calculated
the ranksum of all features according to both the calculated p-values (“pV rank-
ing”) and FCs (“FC ranking”). A comparison of feature ranking revealed that DE
ranking and weighted SVM resulted in comparable rankings, with similar features
identified as best performing features. In comparison, pV and FC rankings let to
a higher variance in ranking comparison and pV ranking was the least comparable
method regarded to specific feature ranks. All rankings are visualized in Fig. B.0.4.
All features identified during 10,000 TSA iterations are saved and summarized. Then
a classifier is build in the PTS AML cohort of 150 samples using the top 10, 20,
50, 100 and 200 features identified in all four approaches, namely DE selection,
weights SVM, pV and FC ranking. These 20 classifiers are then applied to the
remaining samples from the large AML cohort (n=1863). As shown in Fig. 5.2.3A
and Fig. 5.2.3B, all rankings let to stable classification results with nearly similar
performance (mean AUC = 0.9765). Feature ranking using the weights of a linear
SVM resulted in slightly higher AUC values for 3 out of 5 classifiers and in higher
MCC values for 4 out of 5 classifiers. Minimal performance was obtained when
using features ranked according to a p-value obtained by statistical testing (“pV
ranking”). For completion, we also calculated the 10, 20, 50, 100 and 200 best
performing features from all 150 samples in the PTS without any subsampling. As
demonstrated by the grey barplots of Fig. 5.2.3A and Fig. 5.2.3B, feature ranking by
weighted SVMs also outperformed the performance obtained without subsampling.
All five classifiers using the weights SVM method were also significantly superior
to random classifiers of equal size as tested in permutation analysis (Fig. 5.2.3C).
Hence, the weights SVM feature ranking method was further used to build final
diagnostic signatures in the other data sets.
5.2.2.3. Comparison of trial simulation approach to bootstrap design
Additionally, we compared our TSA (sample-split without replacement) approach
to a classical bootstrap design where samples are drawn into TS and the two VSs
with replacement. When analyzing the prediction performance of the resampling
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Figure 5.2.3.: Selection of a good classifier in pilot AML cohort
A-B: Shown are AUC (upper panel) and MCC (lower panel) prediction results for
both all four different feature ranking methods obtained in 10,000 iterations of
TSA for the small pilot AML trial and a classical approach without subsampling
using the best ranked 10, 20, 50, 100 and 200 features applied as a classifier to
the remaining samples of the large AML cohort. C: Box plots comprising 1000
AUCs obtained by using random feature lists of equal size. The real AUC using
the specific weights SVM classifier is depicted with red circles.
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designs for different FC/p-value filter cut-offs, the classical bootstrap design leads
to significantly higher AUC values in comparison to our approach (p-value < 10−16
for all FC/p-value filter, see density plots (sec. 2.3.1) in Fig. 5.2.4 and Fig. B.0.3) as
expected due to the overlap of samples between TS and VS. The same results are
obtained for other performance measurements (data not shown).
Figure 5.2.4.: Sample-split versus bootstrap predictions for small AML cohort
Shown are AUC distributions for 10,000 iterations of TSA for different FC/p-
value filter for sample split (sample drawing without replacement, black lines) and
classical bootstrap (sample drawing with replacement, dashed lines), displayed as
density plots.
5.2.2.4. Variation of trial simulation iterations
Overall, there are
(
150
50
)
> 1040 ways to choose 50 elements (TS) from a set of 150
elements (AML PTS). As TSA is a rather computational intensive procedure, we
compared results from 10,000 iterations to those obtained in 1000 and 100 per-
mutations. When comparing the prediction performance, no significant differences
were found between AUC distributions of different numbers of TSA permutations
(Fig. 5.2.5A), the same is true for the other performance measurements (data not
shown). Regarding feature rankings, 100 permutations resulted in higher variance,
whereas the ranking obtained in 1000 permutations are highly comparable to the
feature ranking from 10,000 iterations. Thus, in the following sections, 1000 itera-
tions of TSA were used. In this way, TSA results for 150 samples can be obtained
on a 64-bit Windows system with 8GB of RAM within few hours.
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Figure 5.2.5.: Comparison of different TSA iterations
(A) Shown are AUC distributions of 10,000 (black), 1000 (blue) and 100 (red)
permutations of TSA in the small AML cohort. (B) Feature ranking comparison:
Shown is the feature ranking in 10,000 permutations from the 1000 highest ranked
features obtained in 100 (red) and 1000 (black) permutations of TSA in the small
AML cohort.
5.2.2.5. Comparison to the large data set
In clinical biomarker development results from small pilot trials are supposed to form
the basis for larger validation trials, however, prediction of classifier performance in
the larger cohorts is still an unsolved issue. Furthermore, classifier performance in
larger cohorts is expected to improve (Simon et al., 2003; Ein-Dor et al., 2006). To
capture the overall improvement by enlarging the cohorts (TS, V1, V2), we repeated
the trial simulation approach on the complete AML data set (n=2013, Tab. 5.1).
Again, linear SVM classification outperformed SVM performance with a radial ker-
nel, LDA and PAM algorithms (Fig. 5.2.6A) as also observed in the small AML
cohort. Although there was still a slight improvement of the spectrum of classifiers
when increasing the feature size by changing feature selection cut-offs (Fig. 5.2.6B),
all 6000 tests performed at least with an AUC of 0.977. Similar improvements were
observed when reading out MCC, specificity or sensitivity performance (data not
shown). In comparison to the small cohort, no NAs, indicating that no features
passed the respective test cut-offs, were observed.
When directly comparing the initial PTS of the small AML data set with the com-
plete AML data set it became clear that only the larger data set results in a suffi-
ciently high AUC in the majority of classifiers developed. As shown in Fig. 5.2.7A,
in the large AML cohort with 63.1% of all tests reached an AUC>0.99, 99.3% >0.98
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Figure 5.2.6.: Classification performance of large AML data set
AUC distributions shown as boxplots summarizing 1000 iterations of classification
for (A) different classifier and feature selection algorithms (SVM with linear and
radial kernel, PAM and LDA) in combination with a t-test or Wilcoxon test and
(B) different feature size cut-offs for fold-change (FC)/p-value (pV) filter. The
boundary of the box closest to zero indicates the 25th percentile, the line within
the box marks the median and the boundary of the box farthest from zero indicates
the 75th percentile. Whiskers above and below the box indicate the 90th and 10th
percentiles. Outliers are plotted as dots.
and all classifiers resulted in an AUC>0.977. In fact, 81.2% of all classifiers generated
in the small PTS showed an AUC>0.95 and 50% reached AUCs>0.967. Only 2.4%
reached an AUC>0.99. Assessing the MCC showed similar results, while basically
all classifiers generated in the large dataset reached an MCC >0.9, not even 60% of
all classifiers within the small AML dataset reached an MCC>0.9 (Fig. 5.2.7B).
To elucidate whether the improvement in the larger dataset is associated with differ-
ences in feature distribution all transcripts (n=22,283) measured on the Affymetrix
HG-U133A were evaluated for being part of at least one of 6000 classifiers (Fig. 5.2.7C).
While a total of 2503 transcripts were part of at least one classifier in the PTS, only
606 transcripts were identified in the large data set. Even more striking, while no
transcript was identified to be present in all classifiers in the small AML data set, 8
transcripts were present in all 6000 classifier in the large data set. When assessing
feature size, an enormous variance became apparent in the small AML data set,
while there was clearly less variance in the larger data set (Fig. 5.2.7D). Interest-
ingly, reduced variance in feature size in the large data set was seen irrespective of
filter criteria settings that determine the potential feature size. Together, these re-
sults support a robust gene expression profiling-based classifier as a test for primary
diagnosis of AML with a sensitivity and specificity of greater 99.5%. At the same
time these results also indicate that even initial PTS would require larger patient
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cohorts for robust classifier development, a requirement that can rarely be met.
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Figure 5.2.7.: Classifier performance and feature comparison between small and
large AML cohort
(A+B) Shown is the percentage of all 6000 classifiers established in TSA reaching
specific AUC (A) and MCC (B) thresholds in the small (red) and large (blue)
AML cohort. (C) Shown is the percentage of feature participation in all 6000
classifier established in TSA. (D) Variance of feature size identified in 1000 TSA
iterations summarized in boxplots. Both plots visualize the small AML chohort
in red and the large AML cohort in blue.
5.2.2.6. Interpretation and validation of the final AML signature
We applied the feature ranking by ranks of the SVM weights to obtain a final
AML signature from the large AML cohort (n=2013) as described in sec. 5.2.2.2. A
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complete annotation of the 50 highest ranked features from the large AML cohort
is provided in Tab.A.6.
In order to validate this AML signature, we established another AML data set per-
formed on the Affymetrix HG-U133 2.0 microarray. This study included a total of
2088 samples from 15 different studies not used in the previous analysis (Tab. 5.3).
1093 AML and 995 control samples were analyzed. Most control samples were
healthy controls or unrelated diseases. As this data set was performed on a dif-
ferent platform, we only used transcripts also present on the HG-U133A platform
(n=22,283 transcripts) and normalized both HG-U11A and HG-U133 2.0 arrays to-
gether using quantile normalization for batch-effect removal. A classifier was build
on the HG-U133A data of 2013 samples using the weighted SVM AML signature
and then the classifier was applied applied to the HG-U133 2.0 data set of 2088
samples.
Positives Negatives Further sample description Reference
404 AML Mills et al. (2009)302 Myelodysplastic syndrome
96 AML Miesner et al. (2010)
460 AML de Jonge et al. (2010)98 pediatric AML
35 AML Silva et al. (2009)
9 liver transplant Martinez-Llordella et al.
(2007)8 healthy controls
6 Alzheimer/ Dementia GSE183093 healthy controls
39 Malaria vaccine trial Vahey et al. (2010)
240 Multiple sclerosis De Jager et al. (2009)
136 Juvenile idiopathic arthritis Barnes et al. (2009)59 healthy controls
40 healthy controls Radom-Aizik et al. (2009)
27 Juvenile idiopathic arthritis Frank et al. (2009)15 healthy controls
5 Steven-Johnson syndrome Chung et al. (2008)
59 Peridontitis Papapanou et al. (2007)
17 Juventile idiopathic arthritis Fall et al. (2007)30 healthy controls
1093 995 ∑
Table 5.3.: HG-U133 2.0 AML data set
Summary of GEX studies included in the HG-U133 2.0 AML data set. Numbers
shown are the actual number of samples used in the final data set. In total, this
data set includes 2088 samples from 15 different studies.
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For the 10, 20, 30, 50, 75, 100, 150 and 200 highest ranked features, a mean AUC
performance of 0.9845 was reached (Tab.A.4), with a minimum AUC of 0.9671
from the 10 highest ranked features and a maximum AUC of 0,9972 from the 200
highest ranked features. Sensitivity ranged between 0.9469 and 0.9927 while speci-
ficity reached values between 0.8995 and 0.9899 at the threshold from the maximum
Youden Index. Results were significantly higher in comparison to performance ob-
tained when using the small AML cohort (Tab.A.5).
Furthermore, the best-performing 10, 20, 30 and 50 features performed also sig-
nificantly better compared to 1000 random feature lists of equal size (Fig. 5.2.8),
whereas for 75 and more features, results were not significant in comparison to 1000
random feature lists. This indicates that a smaller feature set is more informative
and specified for AML prediction than a larger number of features, although all sets
performed similarly well on the independent HG-U133 2.0 AML data set.
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Figure 5.2.8.: Classifier performance on HG-U133 2.0 AML data set
Shown are box plots comprising 1000 AUCs obtained by using random feature lists
of equal size for 10, 20, 30, 50, 75, 100, 150 and 200 features to build a classifier
using the HG-U133A data applied to the HG-U133 2.0 data set. The real AUC
using the specific SVM classifier from the weighted SVM ranking is depicted with
red circles. The corresponding p-values are displayed below.
Next, the functional relevance of the obtained signature was analyzed. Gene On-
tology (Ashburner et al., 2000) pathway analysis by GOrilla (Eden et al., 2009)
revealed a significant enrichment for immune system processes as well as related
pathways such as T-cell, lymphocyte and leukocyte activation (see Tab. 5.4). Fur-
thermore, when performing enrichment analysis of Disease Ontology annotation
(Osborne et al., 2009) associated with the 200 highest ranked AML features using
the FunDO tool (Du et al., 2009), leukemia was the most relevant significantly
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GO term Description P-value
GO:0002376 immune system process 6.52E-21
GO:0006955 immune response 1.46E-12
GO:0002682 regulation of immune system process 9.7E-12
GO:0051249 regulation of lymphocyte activation 2.45E-10
GO:0050863 regulation of T cell activation 2.79E-10
GO:0050870 positive regulation of T cell activation 9.1E-10
GO:0002696 positive regulation of leukocyte activation 9.19E-10
GO:0050867 positive regulation of cell activation 1.66E-9
GO:0051251 positive regulation of lymphocyte
activation
2.01E-9
GO:0050896 response to stimulus 2.09E-9
Table 5.4.: GO enrichment analysis of 200 top ranked AML features. Shown are
the 10 most significantly enriched GO terms.
Figure 5.2.9.: Disease Ontology enrichment analysis of AML signature
Disease Ontology enrichment analysis for the 200 highest ranked AML features.
Shown are the top five diseases and the genes in the list which map to them. The
sizes of the disease nodes are proportional to the number of edges.
enriched disease term (Bonferroni corrected p-value < 10−18), followed by cancer
(Bonferroni corrected p-value < 10−8) as visualized in Fig. 5.2.9. These results
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indicate a functional relevance of the obtained AML signature and a phenotype-
related feature ranking.
5.2.2.7. Implementation of a web-based tool for AML classification
To make the established AML data set and the validated signature available for
scientists who are not familiar with a command line based environment like the
R language, I implemented a web-based AML diagnostic system prototype using
RWui (Newton et al., 2011). Within this application AML primary diagnosis is
available and classification prediction probabilities for a new sample are reported
(Fig. 5.2.10). An Affymetrix microarray HG-U133A cel-file has to be uploaded and
is normalized within the system. Then classification analysis starts using a linear
SVM established in the total AML HG-U133A data set (n=2013 samples) with the
highest 200 features from sec. 5.2.2.6. During the workflow the diagnostic software
provides the user process information and the results can be displayed directly or
downloaded. In a clinical application, the diagnostic software would ask the user to
fill in detailed sample information and clinical covariables e.g. molecular character-
istics and FAB status. The system could also offer AML subclassification or chronic
leukemia differential diagnosis if sample size and therefore statistical power will be
sufficient.
Figure 5.2.10.: AML diagnosis tool
5.2.2.8. Further research on AML subclassification
In principle, genomic profiling using microarray technology could be used for pri-
mary diagnosis, differentially diagnosis, subclassification of diseases, therapy out-
come, prognosis and prediction of disease. In the previous section, we proved that
66
5.2 Results
primary AML diagnosis is possible with high accuracy. Currently subclassifica-
tion of patients with AML is done using a range of molecular markers. Hence the
presence or absence of recurrent cytogenetic aberrations is used to identify the ap-
propriate therapy. Several studies already reported the successful establishment of
transcriptional-based classifier for disease subclassification (Valk et al., 2004; Ross
et al., 2004; Bacher et al., 2009a,b). We assessed subclassification based on cyto-
genetic aberrations (a summary of subgroups analyzed is provided in Tab.A.1) by
TSA. Due to small sample sizes, we only draw one TS and one VS from the entire
data in the ratio 1:1. As shown in Fig. 5.2.11, prediction performance depends on
the subtype analyzed in this meta-analysis. While favorable risk groups such as
t(15;17), t(8;21) and inv(16) result in mean AUC values > 0.8 the chromosomal
abnormality 11q23 assigned as an unfavorable risk group is more difficult to predict
indicating that either the current classification system does not entirely reflect the
molecular heterogeneity of the disease or sample sizes are too small.
Figure 5.2.11.: TSA for AML subclassification
Shown are the AUC values of 1000 TSA permutations for 8 different subgroups
defined by cytogenetic aberrations. Due to small sample sizes, only one training
and one validation set were drawn from the entire data at a ratio 1:1.
5.2.3. Adaptive learning approach allows classifier optimization
and further sample size estimation
The MAQC-II study and others (Ein-Dor et al., 2005; Shi et al., 2010) have clearly
established that many classifiers with similar performance can be developed from a
given data set. Therefore, static use of the initial best-performing signatures might
not be the best choice in the end, once clinical application is considered. Especially
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when using high-throughput gene expression profiling, completely specified and ana-
lytically validated biomarker candidates may not be feasible before its use in pivotal
clinical trials. Adaptive trial designs for phase III trials when no classifier is avail-
able at the start of the trial have been proposed (Freidlin and Simon, 2005; Jiang
et al., 2007; Simon, 2008). Consequently, approaches that lead to continuous opti-
mization of existing classifiers should be evaluated irrespective of current regulatory
issues concerning such strategies (FDA, 2005). In essence, continuous classifier opti-
mization can be achieved by adaptive learning techniques opening completely novel
opportunities when integrating large parallel biological data for medical diagnostics.
We modeled and tested our data-driven adaptive learning approach for diagnostic
classifier development as follows (see Fig. 5.2.12): First, we divided our compiled
large AML data set (n=2013) into one set for adaptive learning (ALS) and two
external independent VSs, each cohort equally comprising n=671 samples. The
ALS was used for adaptive learning assessment. An initial TS of 50 samples (25
AML, 25 controls) was randomly drawn from the ALS. Internal classifier validation
was performed in this set by TSA (100 iterations) as described in sec. 5.2.2. The
mean AUC for 100 TSA permutations was saved. A classifier build in the entire
initial TS was applied to the two external VSs (external validation). In the next
step, further 20 samples randomly taken from the remaining samples in the ALS
were added to the initial TS and internal as well as external validation was performed
using this set of 70 samples, resulting in a mean AUC for internal and two AUCs for
external validation. Next, 20 new samples were included into a 90-sample comprising
set, internal and external validation was applied and this procedure was repeated
for sequentially adding multiple of 20 samples until all ALS samples were used
(32 sequential draws). To ensure results were not depending upon a specific sample
sequential arrangement, adaptive learning with the fixed ALS and VSs was repeated
100 times for bias reduction. Thus in summary, 100 mean AUCs for internal and 2
AUCs for external validation were saved for each sample size.
As expected, for smaller numbers of samples the AUC was lowest, but increased
steadily with increasing numbers of samples (visualized by the boxplots of Fig. 5.2.13).
As underscored by higher AUC values in the two external VSs for each given sam-
ple size, TSA underestimated the statistical performance of the developed classifiers
(brown and orange lines in Fig. 5.2.13).
Another aspect in gene signature development that is still controversial is the sample
size of initial pilot studies (Ein-Dor et al., 2006). While prediction performance of
the clinical dataset within MAQC-II were judged to be more difficult endpoints, it
was not formally addressed whether the sample size of the data sets was too small
to reach higher statistical power given the underlying biological difference between
the classes within the data sets. Adaptive learning can be used for curve sketching
allowing the calculation of the number of patients required to reach a certain level
of statistical performance.
Hence next, we evaluated the adaptive learning results to determine minimal sample
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Figure 5.2.12.: Schematic view of the adaptive learning design
The large AML data set is divided into one set for adaptive learning (ALS) and
two external independent VSs, each cohort equally comprising n=671 samples.
An initial TS of 50 samples (25 AML, 25 controls) is randomly drawn from the
ALS. Internal classifier validation is performed in this set by TSA (100 iterations).
A classifier build in the entire initial TS is applied to the two external VSs (ex-
ternal validation). Next, further 20 samples randomly taken from the remaining
samples in the ALS are added to the initial TS and internal as well as external
validation was performed using this set of 70 samples. This procedure is repeated
by sequentially adding multiple of 20 samples until all ALS samples are used.
Adaptive learning with the fixed ALS and VSs was repeated 100 times for bias
reduction. Thus in summary, 100 x100 AUCs for internal and 2 AUCs for external
validation are read out for each sample size.
size required for validation cohorts. Therefore, we fitted a cubic smooth spline curve
to the summarized mean-of-the-mean AUCs (see sec. 3.2.7), indicated by the blue
line of Fig. 5.2.13. The smoothing spline estimate fˆ is used to predict the maximum
value xmax to calculate the maximum performance of a classification model for a
specific endpoint. Sample sizes for pivotal validation cohorts were estimated at
90% and 95% of this maximum by calculating fˆ(0.9 ∗ xmax) and fˆ(0.95 ∗ xmax),
respectively (red lines in Fig. 5.2.13). In this AML model, a trial with 290 patients
would have been estimated by adaptive learning to reach 90% of maximum statistical
performance, while 390 new patients would have been required to reach 95%.
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Figure 5.2.13.: Adaptive learning for continuous classifier optimization and sam-
ple size estimation
Prediction performance obtained during adaptive learning is summarized for inter-
nal and external validation. Shown are boxplots from 100 TSA for each adaptive
learning set (internal validation) and external validation estimates for external
VS1 (brown) and VS2 (orange). A blue line displays the smooth cubic spline
fit to the internal validation AUCs. 90% and 95% sample size estimations are
marked with red lines.
5.2.4. Adaptive learning and trial simulation of extrapolated
data
In initial pilot trials, sample sizes are usually too small to establish completely spec-
ified and analytically validated biomarker candidates (Ein-Dor et al., 2006). The
generation of more samples often is not possible or expensive and time-consuming.
With this practical limitation in mind, an alternative might be the inclusion of ar-
tificial samples, referred to as data oversampling or extrapolation. The idea is to
simulate new samples according to the distribution of given samples. We choose a
rather simple feature-by-feature approach using metric relationships from two ran-
domly chosen samples to generate new samples (see sec. 3.2.6 for details). Here, this
oversampling was used for sample size estimation of larger pivotal validation studies
based on an initial small data cohort, which would be beneficial to accelerate clinical
translation of diagnostic GEX studies and parameters were chosen to increase the
variance within the data set, this is to increase the range of expression values for
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expressed transcripts and to decrease homogeneity in the simulated data set.
Based on the PTS of AML data (n=150), we generated a total of 370 AML and 370
controls, resulting in a new data set with a total of 890 samples including the original
150 real samples. When applying adaptive learning to the extrapolated data set, we
observed a higher variance of AUC, particularly at lower sample size. Moreover, the
means of mean AUCs was lower when compared to the real data set. In addition,
patient estimation for 90% respectively 95% statistical performance revealed higher
numbers (450 and 630 patients) than observed within the real data set (290 and 390
patients, Fig. 5.2.14).
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Figure 5.2.14.: Adaptive learning of extrapolated AML data set
Shown are boxplots from 100 TSA for each adaptive learning set. A blue line
displays the smooth cubic spline fit to the mean-of-the-mean AUCs. 90% and
95% sample size estimations are marked with red lines.
For completion, we also applied a more sophisticated approach for microarray data
extrapolation proposed by Parrish et al. (2009). This method is based mathemati-
cal transformations of the underlying expression measures such that the transformed
variables follow approximately a Gaussian distribution to estimate associated pa-
rameters. Using this model, we generated 717 AML and 1296 control samples and
applied our adaptive learning approach. As visualized in Fig. B.0.5, increasing sam-
ple sizes did not lead to higher AUC values. Remarkable, the prediction performance
remains similar independent of an underlying cohort size. Apparently, extrapolated
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samples were already more similar than the real underlying data set making this
approach not applicable for sample simulation in adaptive learning based on a small
pilot trial.
Overall, although our data extrapolation approach overrates the sample sizes for
larger pivotal validation cohorts, it is well suitable to estimate patient numbers
based on the distribution of a given initial data set required for biomarker approval.
Furthermore, while we have identified more than 4,000 publically available sample
data suitable to develop a very reliable biomarker for primary molecular diagnosis
of AML, this analysis clearly demonstrated that less than 80% of patient samples
already would have been sufficient to present this test to the drug authorities.
We also performed TSA on the extrapolated AML data set to compare these results
to the small and large AML prediction performance. Applying 1000 iterations of
TSA to the extrapolated data set revealed a substantially higher prediction perfor-
mance compared to the small data set (Fig. 5.2.1D), however, performance of the
large data set (Fig. 5.2.6B) was not reached, as shown by the percentage of clas-
sifiers with high AUCs (Fig. 5.2.15A). The number of features being part of up to
6000 classifiers increased similarly to the large data set (Fig. 5.2.15B). More impor-
tantly, when comparing the weights SVM ranking of the features obtained in TSA,
a higher concordance between the large and extrapolated cohort could be shown
(Fig. 5.2.15C). In this regard the extrapolated and the large data set were more sim-
ilar than the large and the small data set. Next, we investigated the classification
ability of these features and data set. Therefore, we established classifiers using the
highest ranked features (best ranked 10, 20, 30, 50, 75, 100, 150 and 200 features;
n=8 cut-offs in total) derived from extrapolation with both the original small PTS
and the new extrapolated data set and applied the classifier to the remaining sam-
ples of the large AML data. Compared to the AUCs obtained by the original PTS,
neither highest ranked extrapolated features on the original PTS nor highest ranked
extrapolated features with the extrapolated data set reached comparable prediction
performance.
Thus, despite higher similarity between extrapolated and large cohort in terms of
feature stability, feature ranking and prediction performance within each data set,
this concordance did not enhance prediction performance on a data set not used in
the analysis.
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Figure 5.2.15.: Performance of extrapolated data set
(A) Percentage of all 6000 classifier established in TSA reaching specific AUC
thresholds in the small (red), extrapolated (grey) and large (blue) data. (B)
Percentage of feature participation in all 6000 classifier established in TSA in the
small (red), extrapolated (grey) and large (blue) data. (C) Feature ranking of
large data versus feature ranking in the small data (red) and extrapolated data
(black) showing the top 500 ranked features. (D) AUC prediction results using
the best ranked 10, 20, 30, 50, 75, 100, 150 and 200 features (n=8) from the small
and extrapolated data as a classifier build in the small and extrapolated (sim)
data set applied to the remaining samples of the large AML cohort. All 8 AUC
values are summarized in box plots for 3 different combinations of data used to
build the classifier and data used to get the feature ranking.
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5.2.5. Performance and predictions of other disease data sets
We next extended our findings by applying the established methods TSA and adap-
tive learning to three additional data sets of blood-based gene expression profiling.
All sets were generated on a different platform, the Illumina bead-based array sys-
tem. Identification of patients with early stage lung cancer (NSCLC), active TB,
or HIV infection were chosen as endpoints. A summary of all sets used is given in
Tab. 5.5. For each setting feature selection was varied by different FC/p-value filter
cut-offs (n=6) and TSA applied thereby receiving a total of 6.000 different cohort
simulations per data set.
Data
set
Platform Number of
samples
Positives Negatives Reference
complete
AML
Affymetrix
HG-
U133A
2013 717 1296a Tab. 5.1
PTS
AML
Affymetrix
HG-
U133A
150 75 75 random samples
from complete
AML data
val.
AML
Affymetrix
HG-
U1332.0
2088 1083 9956a Tab. 5.3
NSCLC Illumina
WG6 V2
233 95 138b Zander et al.
(2011)
HIV Illumina
WG6 V2
257 106c 151d Debey-Pascher,
Tab.A.2
TB Illumina
HT12 V3
147 54 93e Berry et al. (2010)
Table 5.5.: Microarray data sets used for model development and validation
Summary of GEX data sets are given. aOther leukemia, other diseases, healthy
controls, bHospital-based controls, healthy controls, cHIV, LTNP, dOther diseases,
healthy controls, eLatent TB, healthy controls.
5.2.5.1. NSCLC
First, we used the NSCLC data set used to establish our preferred classification work-
flow in chapter 4. Similar to AML, TSA revealed a decrease in performance with
more stringent FC/p-value filter criteria, still overall mean AUC values of 0.8776
were reached (Fig. 5.2.16A), comparable to the AUCs of 0.824 and 0.977 obtained
in chapter 4 for VS1 and VS2. Few features passed the FC≥ 3/p-value<0.0001
filter cut-off (21%). Mean sensitivity ≥ 0.84 and mean specificity ≥ 0.77 could be
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obtained at the maximum Youden Index (YI). Next, we extrapolated the original
NSCLC data set to 1160 samples and applied our data-driven adaptive learning ap-
proach by applying TSA as internal validation to each of a total of 30 steps. Sample
size estimations by cubic spline fitting for a pivotal validation cohort were 610 in-
dividuals to reach 90% of highest performance and further 730 samples would be
required to get 95% performance (Fig. 5.2.16B).
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mean MCC: 0.68 0.67 0.65 0.63 0.610.69
mean sens: 0.85 0.86 0.85 0.86 0.840.86
mean spec: 0.83 0.82 0.80 0.78 0.770.83
Figure 5.2.16.: TSA and adaptive learning of NSCLC data set
A: 1000 TSA permutations for 6 different FC/p-value feature selection cut-off
combinations. Shown are the boxplots summarizing AUC prediction performance.
NA values indicate the number of tests without features passing the filter cut-offs.
Mean MCC, sens and spec for both cohorts are given below. B: Adaptive learning
using simulated data based on the original NSCLC cohort. Boxplot comprise
100 mean-of-the-mean AUCs of 100 TSA for each adaptive learning set. A blue
line mark the fitted cubic spline curve, while red lines indicate 90% and 95%
estimations.
Among the 200 highest ranked features derived from weighted SVM ranking in TSA
(see sec. 5.2.2.2), 66 were enriched for disease-terms. GO pathway analysis reveals
on one side an association with stimulus response but also an enrichment of immune
and immune system processes, as shown in Tab. 5.6. Tab.A.7 provides a detailed
annotation of the 50 highest ranked features. When comparing the top ranked
features obtained by TSA to the 484-signature from chapter 4, there was only a 9%
overlap to the top 500 ranked features.
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GO term Description P-value
GO:0009607 response to biotic stimulus 6.3E-12
GO:0051707 response to other organism 7.59E-12
GO:0035821 modification of morphology or physiology
of other organism
2.75E-11
GO:0031640 killing of cells of other organism 1.16E-10
GO:0006955 immune response 2.08E-10
GO:0002376 immune system process 2.64E-10
GO:0006952 defense response 2.86E-10
GO:0001906 cell killing 2.25E-9
GO:0009620 response to fungus 2.25E-9
GO:0050832 multi-organism process 3.43E-9
Table 5.6.: GO enrichment analysis of 200 top ranked NSCLC features. Shown are
the 10 most significantly enriched GO terms.
5.2.5.2. HIV
Another GEX data set was established in our group to identify a cohort including
both HIV+ and LTNP patients in comparison to control samples (see Tab.A.2).
After HIV infection, the individual genetic background plays a central role for the
variable disease progression towards Acquired Immune Deficiency Syndrome (AIDS).
LTNPs are rare represented individuals in the HIV infected patient population (1−
2%) having AIDS-free survival without antiretroviral therapy for more than 10-15
years (Sheppard et al., 1993). In this project, we assessed primary HIV diagnosis and
included the LTNP samples (n=27) in the HIV cohort (n=79) in order to improve
HIV diagnosis in the clinic. Our control cohort comprises healthy controls (n=88)
as well as patients with other inflammatory diseases (34 patients with sepsis, 29
patients with scleroderma).
Again, prediction performance was increased when increasing the feature size for
classifier generation (Fig. 5.2.17A). Stringent filter selection cut-offs of FC≥ 2.5/p-
value<0.001 and above resulted in few features passing those filters (20.6%) and
hence, less classifiers could be build. For the filters FC≥ 2.75/p-value<0.005 and
FC≥ 3/p-value<0.0001 only 8.1% and 1.9% of all sample subsets could be used to
build classifiers for the chosen filter criteria. For the feature filters FC≥ 1.75/p-
value<0.05 a mean sensitivity ≥ 0.90 and mean specificity ≥ 0.92 at the maximum
YI were observed. As a next step we applied our adaptive learning approach to the
simulated HIV data sets of 1280 samples to estimate the number of samples required
for a validation and approval trial. We generated 300,000 classifier applying TSA
in 30 steps. Based on curve sketching of adaptive learning prediction results we
expect the development of a test to detect HIV with an AUC exceeding 0.95. To
reach this goal, adaptive learning predicts the requirement for a validation trial
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with 490 individuals to obtain 90% of the maximum statistical performance and 670
individuals for 95% (Fig. 5.2.17B).
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Figure 5.2.17.: TSA and adaptive learning of HIV data set
A: 1000 TSA permutations for 6 different FC/p-value feature selection cut-off
combinations. Shown are the boxplots summarizing AUC prediction performance.
NA values indicate the number of tests without features passing the filter cut-
offs. Mean MCC, sens and spec for both cohorts are given below. B: Adaptive
learning using simulated data based on the original HIV cohort. Boxplot comprise
100 mean-of-the-mean AUCs of 100 TSA for each adaptive learning set. A blue
line mark the fitted cubic spline curve, while red lines indicate 90% and 95%
estimations.
When assessing the 200 highest ranked features in the HIV data set (see Tab.A.8 for
detailed annotation of 50 top features) identified by using the weights of SVMs in
TSA, 55 were found to be associated with diseases. Interestingly, enriched GO terms
comprised multi-organism processes such as morphology or physiology modification
of other organism, killing cells of other organism as well as response to biotic stimulus
and bacterium. Furthermore, viral transcription and viral infectious cycle were
included into significantly enriched GO terms of the HIV signature, thus supporting
a biological meaningful function of the derived HIV signature as well (Tab. 5.7).
5.2.5.3. TB
We further analyzed a recently published data set that was used to establish a
diagnostic signature for ATB in whole-blood (Berry et al., 2010). TB is an infec-
77
5.2 Results
GO term Description P-value
GO:0035821 modification of morphology or physiology
of other organism
5.24E-8
GO:0031640 killing of cells of other organism 9.87E-8
GO:0009607 response to biotic stimulus 6.91E-7
GO:0001906 cell killing 7.26E-7
GO:0019083 viral transcription 8.97E-7
GO:0006415 translational termination 1.16E-6
GO:0019058 viral infectious cycle 1.61E-6
GO:0009617 response to bacterium 2.18E-6
GO:0043624 cellular protein complex disassembly 2.56E-6
GO:0043241 protein complex disassembly 2.75E-6
Table 5.7.: GO enrichment analysis of 200 top ranked HIV features. Shown are
the 10 most significantly enriched GO terms.
tious disease caused by Mycobacterium tuberculosis strains. Most infections remain
asymptomatic, termed latent TB, and about 5 − 10% progress to active disease,
which can be fetal if left untreated (Lawn and Zumla, 2011). TB diagnosis is made
by finding M. tuberculosis bacteria in a clinical sample and current tests cannot
identify individuals with ATB (Barry et al., 2009). We assessed primary ATB diag-
nosis by comparing ATB against latent TB (LTB) and control samples in order to
establish whole-blood based transcriptional biomarkers to identify individuals who
will develop the active disease (Tab.A.3).
In comparison to the TSA results from AML, NSCLC and HIV data, TB prediction
performance was not dependent on feature selection cut-off. More features passed
the stringend feature selection cut-offs of FC≥ 3/p-value<0.0001 (71.8%). The sta-
tistical performance was nearly similar for all 6 cut-offs (Fig. 5.2.18A) with a mean
AUC of 0.8974. In the original paper, a sensitivity of 61.67% and a specificity of
93.75% were reported (Berry et al., 2010). In our setting, mean sensitivities ≥ 0.82
and mean specificities ≥ 0.90 were obtained at the maximum YI, showing a high
increase in case detection rates by TSA. For application of our data-driven adaptive
learning approach we extrapolated the original TB data set to a set of 879 samples
to estimate the number of samples required for a validation and approval trial. In
total, 290,000 classifier were build applying 100 TSA permutations in 29 steps. Sam-
ple size estimations were 410 individuals to reach 90% of the maximum statistical
performance and 510 individuals for 95%. Maximum performance exceeded for a
TB blood test was 0.97 (Fig. 5.2.17B).
Pathway analysis of the 200 most informative TB features revealed that 45 features
were disease related genes. Functional GO analysis found an enrichment of GO terms
related to immune system processes such as different immune responses, response
to cytokine stimulus and B cell receptor signaling pathway (Tab. 5.8). A complete
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Figure 5.2.18.: TSA and adaptive learning of TB data set
A: 1000 TSA permutations for 6 different FC/p-value feature selection cut-off
combinations. Shown are the boxplots summarizing AUC prediction performance.
NA values indicate the number of tests without features passing the filter cut-
offs. Mean MCC, sens and spec for both cohorts are given below. B: Adaptive
learning using simulated data based on the original TB cohort. Boxplot comprise
100 mean-of-the-mean AUCs of 100 TSA for each adaptive learning set. A blue
line mark the fitted cubic spline curve, while red lines indicate 90% and 95%
estimations.
annotation of the 50 highest ranked features is given in Tab.A.9. In contrast to
NSCLC, there was an overlap of 42% of the top 400 ranked TSA features with the
recently published biology-driven 393-feature list (Berry et al., 2010) strongly sug-
gesting that the biology-driven approach to obtain a classifier revealed high accuracy
for the most important features for classifier generation.
5.3. Summary and Discussion
In summary, we established a comprehensive workflow to accelerate the clinical
translation of gene expression based biomarker. Overall, 1,800,000 models were
evaluated (Tab.A.10). First, we developed a randomized clinical trial simulation
approach (TSA) to better judge the variation of classification performance one can
obtain from a small pilot trial. Most informative features for classifier generation can
be identified using ranksums of all signatures of TSA further weighted by underlying
SVMs. This approach was developed based on a small AML pilot trial randomly
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GO term Description P-value
GO:0002376 immune system process 4.68E-9
GO:0006955 immune response 2.96E-8
GO:0050778 positive regulation of immune response 2.55E-6
GO:0045087 innate immune response 5.36E-6
GO:0002253 activation of immune response 6.33E-6
GO:0050776 regulation of immune response 2.01E-5
GO:0002684 positive regulation of immune system
process
2.11E-5
GO:0034097 response to cytokine stimulus 3.12E-5
GO:0050853 B cell receptor signaling pathway 4.54E-5
GO:0006952 defense response 1.05E-4
Table 5.8.: GO enrichment analysis of 200 top ranked TB features. Shown are the
10 most significantly enriched GO terms.
drawn from a large AML data set comprising over 2000 samples from 17 different
studies. Comparison with the prediction performance of the entire cohort reveals
that initial pilot trials would require larger patient cohorts. To predict the minimum
size of such a consecutive pivotal validation trial we established a method combining
sample extrapolation and adaptive learning approaches. This strategy also estimates
the overall best statistical performance to be expected from additional larger vali-
dation trials. Utilizing a combination of TSA and adaptive learning, we estimated
trial size and test performance for pivotal trials using peripheral blood to develop
three independent biomarker tests to detect patients with ATB, NSCLC and HIV.
All approaches are predestined to significantly shorten the time from explorative
pilot studies of signature-based biomarkers to their clinical routine use.
Conventional procedures often involve CV procedures to estimate the predictive
performance of microarray classifiers. Early studies have already shown that for
selecting a good classifier, 10-fold CV model selection gives more accurate results
than the more expensive leave-one-out CV (Simon et al., 2003). Although CV
has been shown to give an unbiased estimate of prediction performance, the best
model to estimate model’s error rate is still controversial (Molinaro et al., 2005;
Berrar et al., 2006; Varma and Simon, 2006). For small sample sizes it was shown
that CV results in high variability of the error estimation and bootstrap methods
provide improved performance, but often at the cost of increased bias (Braga-Neto
and Dougherty, 2004). Bootstrap corrections with the .632+ bootstrap method are
biased in small sample sizes with strong signal-to-noise ratios (Molinaro et al., 2005).
However, our intention in this study is not to compare several methods for estimating
the ‘true’ prediction error of a prediction model but rather to mimic a typical clinical
situation and to estimate the variance one obtains by subsequent patient recruitment
into the different training and validation cohorts. TSA shows that for the small AML
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pilot trial, prediction performance is largely dependent on the TS composition and
results based on the classical design of TS and VS should be interpreted carefully
to avoid overoptimistic results. The overall development process may be inefficient
if claims are based on initial, unreliable results (Ransohoff , 2007).
Ein-Dor et al. (Ein-Dor et al., 2005) noticed by reanalyzing breast cancer prognostic
data sets that many signatures with similar prediction accuracy can be developed
from one data set. Although selecting a single optimized model is the most common
approach for biomarker development, we and others (Chen et al., 2011) analyzed
whether the combination of different models could be preferable. Hence, we propose
a feature selection method based on ranksum derived from different subsets of the
original data set weighted by the contribution of each feature in the SVM. In this
way, stable signatures with features present in different subsets of the original data
sets are combined with classification performance. A similar approach was developed
in (Davis et al., 2006; Abeel et al., 2010).
The number of features included in a final classifier is still controversial. Many au-
thors argue that more features lead to overfitted results while other claim that mod-
ern classification techniques overcome these concerns (Hua et al., 2005; Dougherty
and Brun, 2006; Sima and Dougherty, 2006; Simon, 2008). We observe that less
stringent features selection cut-offs lead to higher performance in TSA. On the
other hand, classifiers with more features were not superior to random classifiers
when applying classifiers from the large AML cohort to an independent validation
set measured on a different platform (HG-U133 2.0), supporting the specificity of
the classifiers with a smaller feature set.
ROC curves must be used with caution unless one has a very large sample (Hanczar
et al., 2010; Berrar and Flach, 2012). Although the AUC is the most frequently
used method for performance assessment of a microarray classifier, one has to keep
in mind that ROC analysis measures a model’s ability to rank positive and negative
cases relative to each other and that the AUC cannot directly measure clinical benefit
or loss (Hilden, 2005). The partial AUC was proposed as an alternative measure
for the full AUC (Walter , 2005). For completion, we included MCC, sensitivity and
specificity as performance measurements with a threshold at the maximum Youden
Index (Youden, 1950). Overall, lower prediction rates were obtained by the MCC
may be due to a nonoptimal threshold. The choice of the decision threshold is
not straightforward and depends on the particular clinical application, for example
a screening diagnostic test might be optimized for high sensitivity (Metz , 1978;
Obuchowski, 2005). Bootstrap validation by different subsets of the final validation
set can present a range of possible performance independent of sample composition
in a validation set as well.
Sample size estimation is an important aspect of microarray data analysis in order
to achieve sufficient power with minimal sample size to reduce cost and time. Many
methods are developed to determine the number of replicates required to have ade-
quate power to identify differentially expressed genes (Yang et al., 2003; Wang and
81
5.3 Summary and Discussion
Chen, 2004; van Iterson et al., 2009; Lin et al., 2010), either based on theoretical
considerations of the underlying distribution or based on pilot data. As differential
expression was not the key objective of our project, we developed an approach ap-
plicable for classification analysis in a clinical setting. Our sample size estimation is
intended to give clinicians guidance on patient numbers recruited for pivotal valida-
tion trials to obtain a specific prediction performance and therefore, we employed a
data-driven approach based on simulated data. This simulated data is derived from
a heuristic approach as we observed that a more sophisticated model based on the
method of Parrish et al. (2009) resulted in overoptimistic prediction performance.
A similar extrapolation approach was performed in the publication from Ein-Dor et
al. modeling Gaussians distributions to generate simulated samples concluding that
at least thousands of samples are needed to achieve stable feature selection (Ein-Dor
et al., 2006). Oversampling is also a common approach for learning from imbalanced
data (He, 2009). We further observed that sample size estimation can slightly vary
when re-analyzing existing data sets, indicating that information obtained from 100
different patient drawings together with 100 repetitions of TSA in each step may not
be complete. I would envise enhancing this to 1000 different patient drawings. Still
one should mention that for 100 permutations a 64-bit Windows system with 8GB
of RAM needed approximatly 1 week for computation. Therefore, improving the
existing scripts with for example using the multicore package in R (Urbanke, 2012)
for running parallel computations should be considered to obtain computationally
more efficient algorithms.
Finally, one should keep in mind that methods are developed based on a data set
with good predictive performance, the AML data set. For a final proof of method,
completely synthetic data should be generated, for example as described byMolinaro
et al. (2005).
For the efficient translation of cancer genome information into the clinic, studies
must go beyond statistical analyses of large genomic data sets. This process will
require the inclusion of expertise and insights from molecular biology, genetics and
systems biology, as well as clinical experiences. We performed functional analyses
of resulting gene sets and observed disease-related enrichment of the obtained sig-
natures and phenotype-related feature ranking. For example, the HIV signature
is enriched for GO terms of viral infection which is in accordance with biological
common sense and supports their functional relevance.
Taken together, the here proposed methods can further optimize the translation
of the cancer genomic applications into effective diagnostic biomarkers. For AML
diagnostics, a web-based prototype was already implemented with the intention of
making the data and signature available for scientists not familiar with a command
line based environment like the R language.
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6. Critical consideration of a novel
high-throughput technology
As shown in the preceding chapters, blood-based mRNA GEX profiling has become
an important issue in medical applications and useful clinical predictions can be
made from this high-throughput technology. In this section I would like to focus on
the challenges when a novel high-throughput technology is applied to the develop-
ment of blood-based diagnostic biomarkers. Reasonable concerns would arise from
the reproducibility of expression profiles and the impact of RNA isolation meth-
ods. The following study interrogates the latter concern using a recently introduced
bead-array based microRNA (miRNA) expression technology.
6.1. Motivation
In addition to blood-based GEX profiling, the characterization of the small RNA
transcriptome including miRNAs has opened additional avenues for diagnostic ap-
proaches. MiRNAs are short (~22 nucleotides) non-coding RNAs and play a regula-
tory role by translational repression or degradation of specific target mRNAs at the
post-transcriptional level (Bartel, 2004). MiRNA expression profiles have already
been proposed as useful biomarkers in cancer and other diseases(Calin et al., 2004,
2005; Calin and Croce, 2006; Iorio et al., 2005; Mattie et al., 2006; Lawrie et al.,
2007). One important result of these efforts is that expression profiling derived from
miRNAs can be used for cancer classification with more accuracy than mRNA ex-
pression profiles Lu et al. (2005). Since miRNAs can be detected in blood and body
fluids (Skog et al., 2008), peripheral blood might be a perfect source to monitor
tumor-associated miRNA expression signatures. Most recently, blood-based disease
specific miRNA signatures were identified in lung cancer patients (Keller et al.,
2009a), patients suffering from multiple sclerosis (Keller et al., 2009b) as well as in
young stroke patients (Tan et al., 2009). However, when applying miRNA expression
profiling in routine clinical settings, the method of RNA preservation, the manner
of RNA extraction as well as the reliability of the miRNA profiling procedure have
to be carefully considered. Technical issues regarding high-throughput miRNA ex-
pression profiling are discussed by various authors (Wang et al., 2008; Nelson et al.,
2008). More recently, a bead array based assay was introduced comprising of 735
human miRNAs allowing high-throughput expression profiling in a large number of
samples (Chen et al., 2008). In this project this newly introduced array platform is
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evaluated for miRNA expression profiling of peripheral blood. Our comprehensive
miRNA screen is intended to serve as a reference for future studies assessing periph-
eral blood in the context of diagnosis and monitoring of certain diseases in clinical
studies.
6.2. Results
First, the technical reproducibility of miRNA profiles was evaluated within and be-
tween different Sentrix Array Matrix (SAM) devices, which allow the assessment
of 735 miRNA profiles of 96 samples in parallel. First, RNA samples derived from
peripheral blood mononuclear cells (PBMC) of 11 different healthy donors (biologi-
cal replicates) were analyzed in triplicates on one SAM (intra-SAM reproducibility)
and in the next step the same 11 RNA samples used for the intra-SAM evalua-
tion were analyzed on two additional SAMs (inter-SAM reproducibility). Before
analyzing the data, quality assessment was performed and outliers were removed
(see sec. C.2). Different normalization procedures were compared between replicate
samples and as highest overall correlation between samples and the lowest variance
was observed after quantile normalization (data not shown), this method was used
in all following analyses. The intra- and inter-SAM reproducibility of the replicates
was estimated by calculating the Pearson correlations (r2) for all pair-wise com-
binations of individual miRNA profiles within a given sample. The overall mean
correlation coefficient in intra-reproducibility was 0.9933 ± 0.0066. For inter-SAM
analysis the overall mean correlation coefficient was 0.9880 ± 0.0069. Taken to-
gether, intra- and inter-SAM reproducibility of the miRNA microarray assay was
very high (Fig. 6.2.1A).
To test the lowest amount of total RNA derived from peripheral blood mononuclear
cells, that still yields reliable results in the miRNA assay, a titration experiment was
performed using a broad range of input amounts of total RNA (2, 12.5, 25, 50, 100,
200, 500 ng) from three healthy individuals which were tested in triplicates. Analysis
of variance was performed to assess the reproducibility of miRNA microarray data in
the titration experiments by comparing all RNA input amounts below 500 ng against
the 500 ng RNA reference and the correlation within each biological replicate were
calculated. As demonstrated in Fig. 6.2.1B, correlations remained relative constant
when using 100 to 500 ng total RNA and even 2 ng total RNA leads to reproducible
(r2 > 0.9) results. When comparing all input amounts of 2, 12.5, 25, 50, 100 and
200 ng to the reference of 500 ng there was a statistically significant difference (t-
test p-value <0.05) for the samples with 50 ng or less input amount indicating that
less than 100 ng total RNA is not sufficient to produce reliable results in peripheral
blood derived samples.
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Figure 6.2.1.: Analysis of peripheral blood samples with miRNA microarrays
A: The intra- and inter-array data reproducibility was estimated by calculating
the Pearson correlation coefficients (r2) for all pair-wise combinations of technical
triplicates derived from 11 different blood donors analyzed on the same and on
different arrays and displayed in boxplots. B: Performance of total RNA input
was estimated by calculating r2values between different input amount versus the
500 ng group. The boundary of the box closest to zero indicates the 25th per-
centile, the line within the box marks the median, and the boundary of the box
farthest from zero indicates the 75th percentile. Whiskers above and below the
box indicate the 90th and 10th percentiles. Outliers are plotted as dots. In B, *
mark p-values < 0.01 (unpaired t-test) in comparison to the 500 ng group.
Next, we were interested if the presence of other RNA molecules such as mRNA
including miRNA precursor RNA or ribosomal RNA had any influence on the blood
expression profiling of miRNAs. To address this question, we compared PBMC de-
rived miRNA profiles of total RNA to enriched low molecular weight (LMW) RNA
profiles from six healthy individuals. Therefore, fractions of total RNA as well as
of less abundant LMW enriched RNA below 200 bp were extracted. In contrast
to the total RNA fraction, pri-miRNA sequences as well as mRNAs and ribosomal
RNAs should be depleted in the LMW RNA fraction. By statistical testing for dif-
ferentially expressed miRNAs between total and enriched LMW-RNA, 134 miRNAs
out of 735 (18%) were identified to be significantly changed in the process of LMW
RNA enrichment (FC > +/- 2, total difference in mean signal intensity between
both groups > 100 and Benjamini-Hochberg adjusted p-value < 0.05). Unsuper-
vised hierarchical clustering based on the most variable transcripts in this dataset
demonstrate a clear separation of the expression profile between total and enriched
small RNA (Fig. 6.2.2A). Taken together, there is a significant difference in the ex-
pression profiles between total and enriched LMW RNA indicating that the miRNA
assay is sensitive to size fractionation.
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Figure 6.2.2.: Impact of RNA isolation and sampling handling on miRNA expres-
sion profile
Unsupervised hierarchical cluster analysis of (A) total and enriched LMW RNA
and (B) freshly isolated or cryopreserved PBMC samples performed on quantile
normalized data using the most variable miRNAs in the dataset (SD/mean 0.5
to 10). Only the cluster dendrogram is shown. C: Overall variance in PAXgene
(dark gray) and PBMC (light gray) samples was ranked and plotted. Variance
was calculated in quantile normalized data for each miRNA transcript that was
called present (detection p-value <0.05) in at least one-third of the 12 samples.
Statistical difference between corresponding whole blood and PBMC variance was
calculated using paired t test and resulted in a p-value <0.05.
Since many tissues and cells from clinical samples are often stored for long time
periods in liquid nitrogen, i.e. to allow retrospective gene or miRNA expression
analysis, it is important to know if expression profiles remain stable or undergo in
vitro changes. We therefore assessed whether the storage of viable cells in liquid
nitrogen has any impact on the stability of miRNA transcripts. For this purpose,
miRNA expression profiles derived from total RNA obtained from fresh or frozen
PBMC of 29 healthy individuals were compared. Hierarchical cluster analysis clearly
demonstrated an incisive effect on miRNA expression profiles, resulting in a clear
separation of fresh PBMC from frozen specimens (Fig. 6.2.2B). None of the related
sample pairs clustered together or were grouped together, indicating that fresh and
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frozen cells cannot be compared directly.
To determine the effect of different blood cell populations and their influence on
miRNA expression profiling, we compared RNA derived from PBMC to RNA from
whole blood samples. Therefore, blood samples from six donors were collected into
either CPT tubes followed by PBMC separation and total RNA isolation using
TRIZOL or were collected into PAXgene Blood RNA Tubes followed by direct RNA
extraction using the newly introduced PreAnalytiX’s PAXgene Blood miRNA Beta
Version kit. There was no relevant difference in the amount and quality of the ob-
tained RNA. When assessing miRNA microarray quality both RNA isolation tech-
niques revealed comparable results. We observed increased variance in the whole
blood samples (t-test p-value<0.05) in comparison to PBMC samples probably due
to the increased heterogeneity of cell types in whole blood compared to the PBMC
fraction (Fig. 6.2.2C). The clear differences between whole blood versus PBMC de-
rived profiles lead to a total of 158 miRNAs (21.55%) differentially expressed miR-
NAs (p-value < 0.05, fold-change > +/- 2) and a mean r2 between sources of 0.7889
± 0.180.
To verify the accuracy of this bead-based technology and to validate miRNA expres-
sion, qPCR data was explored for 12 miRNAs for blood samples derived from the
six aforementioned healthy donors. Three RNA isolation approaches were chosen:
total RNA, enriched small RNA and PAXgene RNA. In all three comparisons abso-
lute normalized expression values from the miRNA array were highly correlated to
qPCR negative Ct values with Spearman’s correlation r2-values of 0.9597 for total
RNA samples, 0.8346 for enriched small RNA samples and 0.8873 for PAXgene RNA
samples (Fig. 6.2.3).
6.3. Summary and Discussion
To study the reproducibility of data generated on this new miRNA array platform
we evaluated several technical replicates derived from peripheral blood samples of
healthy subjects. A high reproducibility of miRNA expression data was estimated
by calculating correlation coefficients of technical replicates on the same as well
as on different SAM devices. All technical replicates analyzed revealed correlation
coefficients > 0.98 indicating high reproducibility and reliability of this miRNA
microarray assay. A high sensitivity of the miRNA assay method was shown for
tissue samples and cell lines by Chen et al. (Chen et al., 2008) and we extend
these findings demonstrating that highly reproducible miRNA expression profiles
are generated with 100 – 200 ng total RNA input from PBMC and stabilized whole
blood.
In contrast to mRNA profiling technologies, miRNA profiling must take into ac-
count the difference between mature miRNAs and their precursors. The data of
our study clearly indicate that assay results are different if using total RNA or
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Figure 6.2.3.: Correlation of miRNA array and qPCR expression
Correlation between array and qPCR results are displayed in a scatterplot illus-
trating the association of normalized miRNA array expression (log10) versus the
Ct value for six total RNA (A), enriched small RNA (B), and PAXgene samples
(C) together with a linear regression fit line. Spearman’s correlation coefficients
were calculated as well for each RNA isolation technique.
enriched LMW-RNA derived from peripheral blood. However, reproducibility and
correlation were very high if results were compared between assays using the same
preprocessing procedures (r2>0.99) showing that the enrichment procedure itself did
not add variation to the measurement. Thus, enrichment of LMW-RNA can on one
hand lower cross hybridization through inactive precursors of the miRNAs present
in total RNA or through additional mRNA interference. On the other hand this
procedure might also lead to a biased composition of mature miRNAs lacking for
example less abundant active miRNA sequences. Both phenomena could account
for the variations we observed when using RNA enrichment. However since total
RNA as well as enriched LMW-RNA thereof give reliable and reproducible results
both methods should be valid for diagnostic purposes when taken into account its
specific limitations.
Cryopreservation of clinical specimens, including PBMC, is a commonly used tech-
nique in many clinical trials. In particular for multicenter studies, the performance
of batch testing of harvested frozen samples in a central diagnostic unit is often
preferred upon the independent analysis of fresh samples at different study sites.
However, cryopreservation is associated with adverse effects on subsequent func-
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tional studies in comparison to those performed with freshly isolated cells. Here we
estimated the influence of cryopreservation of isolated PBMC on miRNA expression
profiles by comparing cryopreserved PBMC to their matched counterparts directly
lysed after isolation. We clearly demonstrated that the miRNA profiles of cryop-
reserved PBMC samples were not comparable to freshly isolated PBMC similar to
findings obtained in mRNA expression studies (Debey et al., 2004; Debey-Pascher
et al., 2011). A careful and uniform selection of sample material therefore needs to
be assured within a study and attention needs to be paid to those transcripts that
are affected by sample handling procedures.
In a clinical setting peripheral blood is the most widely used tissue for disease
monitoring. If miRNA expression profiling will become a routine tool for diagnostic
and prognostic clinical studies it is crucial to understand the differences by using
either whole blood samples or isolated PBMC. We compared miRNA expression
profiles derived from PBMC using TRIZOL isolation and from whole blood using
a PAXgene Blood miRNA Kit Beta Version extraction kit. Most importantly, we
assessed the newly introduced PAXgene isolation method as a robust technique for
total RNA including miRNA extraction of blood samples whose RNA quality is
comparable to RNA obtained from PBMC using TRIZOL. Analysis of amount of
present miRNAs, overall signal intensity and intra-group correlation gave similar
results. Akin to mRNA expression profiling, whole blood derived miRNA profiles
exhibit higher variance and results in miRNAs significantly differentially expressed
in comparison to the PBMC derived profile.
Finally the expression of 12 miRNAs was determined by qPCR as another estab-
lished expression technology. Good correlation coefficients between miRNA array
expression levels and qPCR values were assessed for total RNA, enriched small RNA
as previously reported (Chen et al., 2008). PAXgene samples performed similarly
well. We therefore conclude that the bead array platform revealed reliable results
compared to the hitherto used qPCR method as golden standard for miRNA profil-
ing.
Taken together, we present clear evidence that highly reproducible and reliable
miRNA profiles of primary human peripheral mononuclear cells as well as of whole
blood samples are obtained by the miRNA bead array technology. We clearly demon-
strate that sample handling and the choice of either PBMC or whole blood is a rather
critical issue when assessing miRNA profiles. Furthermore, we evaluated that the as-
say monitors different expression profiles when RNA size fractionation is performed.
This comprehensive dataset of miRNA profiles derived from peripheral blood of
healthy individuals might serve as a valuable resource for future steps towards the
establishment of a comprehensive global miRNA profile of human peripheral blood
for diagnostic as well as prognostic purposes.
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7.1. Discussion
More than 10 years after Golub et al. proposed for the first time that transcriptional-
based classification can be used for the differential diagnosis of AML and ALL (Golub
et al., 1999), the number of tests applied to clinical practice is alarmingly small and
to date no single test has been approved using gene expression profiling of peripheral
blood (Staratschek-Jox et al., 2009). Fundamental concerns regarding the microarray
technology itself as well as the reliability of the technology in clinical applications
such as disease diagnosis and prognosis were eased by results derived during the first
and second phase of the MAQC project (Shi et al., 2006; Guo et al., 2006; Kuo et al.,
2006; Canales et al., 2006; Shippy et al., 2006; Shi et al., 2010; Luo et al., 2010;
Oberthuer et al., 2010; Parry et al., 2010; Huang et al., 2010; Fan et al., 2010b).
Hence, this thesis aims to accelerate the translation of basic findings to clinical
utility. Several aspects in the process of diagnostic biomarker development are
evaluated by analyzing genome-wide expression data derived from 4738 individuals
in 37 studies addressing four clinical endpoints to assess over 1,800,000 different
classifiers.
The initial hype of genome-wide technology has been replaced by realism, and it
has become clear that many of the hopes based on early studies did not manifest
due to underpowered studies, non-standardized sample procedures and insufficient
bioinformatics analysis. However, blood-based transcriptional biomarkers have the
potential to be used in routine clinical applications (Baird, 2006; Staratschek-Jox
et al., 2009). A good starting point will be diseases for which there is a lack of
acceptable diagnostic tools and which would greatly benefit from an improvement.
Hence, in this thesis, we focused on settings with (1) high enough prevalence and
(2) a clinically relevant endpoint with a need for more relevant and reliable diagnos-
tic tests. In our opinion, it is necessary to ensure that blood transcriptomics will
not be purely seen as another add-on diagnostic method further increasing costs
within our healthcare systems with its limited financial resources but rather that it
will serve as a substitution technology for older, less reliable, and less informative
technologies. In principle, genomic profiling could be used for primary diagnosis,
differential diagnosis, subclassification of diseases, therapy outcome, prognosis, and
prediction of diseases with one single technology. However, for example in leukemia
diagnosis, transcriptional profiling has mostly been applied to optimize disease sub-
classification and prognostic as well as predictive purposes. We addressed this issue
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by re-evaluating the use of GEX for the primary diagnosis of AML. To answer this
important question, we integrated data sets from 17 different studies to form a new
data set comprising a total of 2013 samples. By comparing AML samples to a co-
hort of healthy controls as well as samples comprising other diseases not related
to leukemia and other leukemia samples including ALL and chronic leukemia we
addressed primary as well as differential diagnosis of acute leukemia. Furthermore,
we also assessed AML subclassification based on cytogenetic aberrations in a first
step towards a combined AML diagnostic tool.
While blood-based profiling is the obvious application for hematologic malignancies
such as leukemia, an increasing number of studies assessed the use of blood tran-
scriptomics for the diagnosis of other diseases as well (Twine et al., 2003; Burczynski
et al., 2005; Sharma et al., 2005; Osman et al., 2006; Critchley-Thorne et al., 2007;
Showe et al., 2009; Staratschek-Jox et al., 2009; Chaussabel et al., 2010). For many
of these other disease states, the primary affected tissues are not readily available
or can only be obtained through invasive intervention. Peripheral blood as a very
promising alternative is an easily accessible and practical surrogate source (Baird,
2006; Burczynski and Dorner , 2006) based on the assumption that it reflects patho-
logical changes because circulating blood is in contact with almost every organ and
tissue in the body. In this thesis, we applied high-throughput microarray technology
to answer the important clinical question of NSCLC, ATB, and HIV diagnosis. In
all studies, the control cohort comprised healthy controls as well as closely related
diseases. This study design ensures a higher potential of discovering the disease in
a heterogeneous setting since variations in the selection of study populations will
have a great impact on experimental results.
For all genomic studies to make an impact on medicine, a strict standardization
of all procedures from sample handling to study design and bioinformatics analy-
sis is crucial. Regarding sample handling, important protocols were established by
the MAQC-I consortium providing quality control tools to avoid procedural failures
(Shi et al., 2006; Guo et al., 2006; Kuo et al., 2006; Canales et al., 2006; Shippy
et al., 2006). Stabilization of RNA is one prerequisite for large multicenter studies,
and RNA analysis of peripheral blood in particular relies on very careful sample
procurement and processing (Debey et al., 2004, 2006; Debey-Pascher et al., 2011;
Elashoff et al., 2012). Furthermore, compatibility and therefore comparability be-
tween different microarray platforms (Kuo et al., 2006; Canales et al., 2006) as
well as between older and new versions of microarrays (Eggle et al., 2009; Barbosa-
Morais et al., 2010) is not straightforward and make the long-term development of
biomarker diagnostics on this technology rather difficult. Hence, an important issue
for the industry is to produce devices available over longer periods of time.
In addition to blood-based GEX profiling, the characterization of the small RNA
transcriptome including miRNAs has opened additional avenues for diagnostic ap-
proaches (Calin and Croce, 2006). MiRNAs are small non-coding RNAs that play
a role in transcriptional or post-transcriptional regulation of genes involved in nu-
merous biological processes, including differentiation and proliferation. Profiling of
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miRNA expression levels has indicated that, similar to mRNA profiling, distinct
miRNA signatures can be obtained. In further research, the platform requirements
for blood-based biomarker development were exemplarily examined for miRNA ex-
pression profiling. Here, we could show that both intra- and inter-array reproducibil-
ity are key aspects when applying a novel high-throughput platform in a clinical set-
ting. We have studied the performance of a miRNA expression profiling microarray
platform when assessing samples derived from peripheral blood in healthy subjects.
More importantly, we addressed reproducibility and sample handling issues as well
as the influence of different blood-based RNA extraction methods.
Despite the MIAME standards defined in 2001 (Brazma et al., 2001), data storage
in databases such as GEO (Edgar et al., 2002; Barrett et al., 2011) and more impor-
tantly, comprehensive experimental annotation indicating clinical and epidemiologi-
cal characteristics of data is still insufficient (Kostka and Spang, 2008; Quackenbush,
2009). We observed that when building the AML data set, downloading a data set
from GEO is simple, but assigning respective class labels often has to be done man-
ually by browsing through the related article and its given supplement. Often, the
annotation of samples is incomplete, and detailed clinical documentation that allows
a comparison to be made for the different studies was not given, rendering large-
scale meta-analysis and integration of GEX data a challenging task. To make data
available beyond their initial publication, effective data-reporting standards should
be enforced.
Another major requirement in order to determine early study limitations is the stan-
dardization of bioinformatics data analysis. As suggested by the MAQC-II study,
we first established our preferred standard classification process comprising feature
selection, algorithm and parameter optimization in internal 10-fold CV repeated 10
times and performance assessment through ROC analysis as discussed in chapter 4.
All bioinformatics approaches are documented in supplemental R scripts making
analysis procedures available to and reproducible by others (Appendix D). Us-
ing this standard approach, a RNA-stabilized whole blood diagnostic classifier for
NSCLC consisting of 484 transcripts could be established in a TS that can be used
as a biomarker to discriminate between NSCLC patients and control samples. Sub-
sequently, this optimized classifier was successfully applied to two independent and
blinded VSs resulting in AUC values of 0.824 (VS1) and 0.977 (VS2). This successful
application of the classifier in both VSs underlines the validity and robustness of the
NSCLC classifier. Extensive permutation analysis using random feature lists sup-
ports the specificity of the established transcriptional classifier. We further showed
that the use of this approach to make clinical predictions performs similarly well
to best-performing models obtained in the MAQC-II Multiple Myeloma data set
analyzing 4 different endpoints.
The complexity and volume of transcriptional profiling requires heightened attention
to robust design, methodological details and avoidance of bias to making genomic-
based biomarker useful for the clinic (Ioannidis, 2007). Insufficient sample size
resulting in lower power of GEX studies is a major drawback in the process of trans-
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lating blood transcriptomics into clinical routine practice. To analyze the validation
of claims derived from initial pilot studies, we developed TSA as a method to in-
vestigate the overall classifier performance that can be expected independent of the
actual clinical situation with subsequent patient recruitment into training and vali-
dation cohorts. We used a small pilot trial of 150 samples randomly drawn from the
large AML data set to mimic a typical clinical trial. Using this PTS, the variance
obtained by random assignments into the cohorts was estimated for different fea-
ture selection and classification algorithms as well as for different feature selection
cut-offs. Linear SVM classification in combination with a t-test outperformed other
methods and was subsequently used for all upstream analyses. We could show that
prediction performance is largely dependend on sample cohort inclusion. Further-
more, we demonstrated that many models showing good performance in classifying
the two VSs when using the conservative workflow of one single division into data
sets did not reach sufficient statistical performance when applied to the remaining
samples of the large AML cohort. Hence, we propose a larger sample-split approach
to investigate the overall variance of prediction performance and to predict the out-
come of a large biomarker validation study from the PTS.
Next, we assessed the predictive performance obtained when using the large AML
cohort of 2013 samples. We proved that in this data set, a robust GEX-based
classifier as a test for the primary diagnosis of AML can be developed with a high
sensitivity and specificity. In comparison to the small PTS, all random drawings of
cohorts reached AUC values >0.977 and 63% came to an AUC>0.99 whereas in the
small PTS, only 2.4% resulted in such a high AUC. Feature lists were rather stable in
terms of feature sizes derived from different cut-offs and the individual transcripts
included in signatures. These results also indicate that even initial PTS would
require larger patient cohorts for a robust classifier development, a requirement that
can rarely be met. The overall development process may be inefficient if claims are
based on initial, unreliable results (Ransohoff , 2007).
Methods to select a good classifier from the PTS were compared by different ways to
agglomerate feature lists obtained during TSA. A method averaging feature weights
for SVM classification performed best in this setting in comparison to both meth-
ods simply using all DE signatures without summarized SVM weights and methods
ranking features according to FC and p-value. Hence, we propose a feature selec-
tion method based on ranksum derived from different subsets of the original data
set weighted by the contribution of each feature. In this way, stable signatures with
features present in different subsets of the original data sets are combined with classi-
fication performance. Ensemble feature selection with data perturbation of random
subsets has also been proposed by others (Abeel et al., 2010; Davis et al., 2006) and
are discussed in He and Yu (2010). The stability of feature selection can also be
analyzed as described by Boulesteix and Slawiski (Boulesteix and Slawski, 2009),
with the Davis index (Davis et al., 2006) or with the Kuncheva index (Kuncheva,
2007).
We then applied our approach in order to build a final biomarker for AML primary
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diagnosis using all samples in the large AML cohort (n=2013). This classifier was
applied to an independent and blinded AML data set of additional 2088 samples not
used in any previous analysis, analyzed on a newer array version than the original
AML data set (HG-U133 2.0). High predictive performance was derived in this VS
(AUC>0.97). Classifiers with few features (50 features or less) were also significantly
superior to 1000 random classifiers supporting the specificity of the established sig-
natures. More sophisticated methods for batch effect removal when comparing two
data sets performed on a different platform such as the ComBat algorithm (Johnson
et al., 2007) might even lead to a higher validation performance. I also developed
a web-based AML diagnostic system prototype for scientists not familiar with a
command line environment like the R language.
Completely specified and analytically validated biomarker candidates may not be
feasible before its use in pivotal clinical trials and adaptive trial designs have been
proposed for phase III trials (Freidlin and Simon, 2005; Jiang et al., 2007; Simon,
2008). Consequently, we developed an adaptive learning approach in contrast to
a static use of initial best-performing classifiers for (a) a continuous classifier op-
timization and (b) an estimation of the sample size required for a larger pivotal
validation cohort. In essence, continuous classifier optimization can be achieved
by adaptive learning techniques opening completely novel opportunities when inte-
grating large parallel biological data for medical diagnostics and curve sketching of
adaptive learning results allowed the calculation of the number of patients required
to reach a certain level of statistical performance in such a pivotal clinical trial.
Sample generation is often not possible or time-consuming due to high costs and
low prevalence of certain diseases. This practical limitation may be solved by the
inclusion of artificial samples that can be simulated according to the distribution of
given samples. Hence, we investigated the use of oversampling methods to improve
classifier development from a small PTS. Sample simulation based on a given data set
could in principle be used for three approaches: to improve classification performance
when using more samples, to obtain more stabilized feature ranking, or to make
predictions on a test set. By comparing sample size estimations from the large
and extrapolated AML data set, we could show that an estimate of the sample size
from the extrapolated data can be obtained, although these estimates are higher
than those from the original cohort. We could further demonstrate that although
the large and extrapolated AML data set showed a high concordance in terms of
feature stability, feature ranking and prediction performance within each data set,
the signatures stabilized by extrapolation did not result in enhanced prediction
performance.
Utilizing the established approaches TSA and adaptive learning, we estimated the
trial size and test performance for pivotal trials using peripheral blood to develop
three independent tests to detect patients with NSCLC, HIV-positive patients, and
patients with ATB. All signatures obtained by weighted SVM feature ranking showed
a disease-related pathophysiology and phenotype-related feature ranking. The AML
signature comprised a significant Gene Ontology enrichment for immune system pro-
94
7.2 Perspectives for future research
cesses as well as related pathways such as T-cell, lymphocyte and leukocyte acti-
vation. Furthermore, leukemia was the most relevant significantly enriched Disease
Ontology term. The NSCLC signature revealed an association with immune and im-
mune system processes while the TB signature was enriched for immune response,
cytokine stimulus, and B cell receptor signaling pathway. Interestingly, enriched
GO terms of the blood-based HIV signature included viral transcription and vi-
ral infectious cycle supporting the functional relevance of the obtained signatures.
Therefore, signatures also fulfilled the desirable biomarker characteristic of accuracy,
stability, and mechanism (Shi et al., 2010; Fan et al., 2010b).
Thus in summary, using several simple clinical questions as models novel strategies
that are aimed at closing the gap from initial promising pilot studies to clinical
application of novel biomarkers were developed. I envision the following strategy for
GEX classifier development:
1. TSA with 1000 permutations or more to estimate variance of prediction per-
formance from a pilot study
2. Agglomeration of features by weighted SVM ranking
3. Random classifiers as controls to analyze specificity of established signature
4. Adaptive learning of extrapolated data to estimate sample size required for a
larger pivotal validation cohort
7.2. Perspectives for future research
The here presented methods and results open several perspectives for future research.
First, more samples should be recruited to improve the proposed signatures for
NSCLC, HIV-positive patients, and patients with ATB according to sample sizes
estimated by adaptive learning. Control cohorts should include healthy controls
as well as closely related diseases to improve the study design. Heighted attention
should be paid to covariates such as age and gender. For example, a larger control
cohort for NSCLC should also comprise SCLC to ensure differential diagnosis of lung
cancer and smoking levels should be comparable in cases and respective controls.
Next, the decision threshold currently taken at the maximum YI should also be
optimized. This decision rule for classifying the test results as either positive or
negative should be set according to the specific clinical application, for example a
screening diagnostic test can be optimized for high sensitivity (Metz , 1978; Obu-
chowski, 2005). The threshold selection should be analyzed in the given data set
and can then be used to predict new samples. A proper screening program im-
proves patients’ outcome by early detection and minimizes possible burdens from
false-positive results.
Another perspective for future research would be the evaluation the number of fea-
tures included in a final biomarker set, as the feature size is still controversial (Hua
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et al., 2005; Dougherty and Brun, 2006; Sima and Dougherty, 2006; Simon, 2008;
Chang et al., 2011). Random signatures should be generated to verify the specificity
of the established classifier. Recursive feature elimination as proposed by (Guyon
et al., 2002; Duan et al., 2005; Zhang et al., 2006; Mundra and Rajapakse, 2010; Li
et al., 2012) can be applied to identify the best-performing set of features.
One limitation of the current setting is that all classification models were applied to
two-class diagnostic problems. Hence, the next steps would be expanding to multi-
class classification tasks, for example separating HIV+, LTNP, and control samples
or separating ATB, LTB, and controls. Multiclass classification algorithms include
fuzzy SVMs and decision tree approaches (Lee and Lee, 2003; Nguyen and Rocke,
2002; Tsujinishi and Abe, 2003; Mao et al., 2005) and a comprehensive evaluation of
these multicategory classification methods have been performed by Statnikov et al.
(2005) and Li et al. (2004). As a first step, we already compared different mul-
ticlassification algorithms for blood-based prediction analysis of different diseases
(Henseler , 2009). The assessment of the prediction performance for such a case
needs to be defined. Multi-class ROC graphs and AUCs are more complex since the
entire space needs to be managed. With n classes the confusion matrix becomes an
n×n matrix with n correct classifications on the diagonal and n2−n possible errors
on the off-diagonal (Hand and Till, 2001).
Additionally, one should keep in mind that methods are developed based on a data
set with good predictive performance, the AML data set. For a final proof of method,
completely synthetic data should be generated, for example as described in Molinaro
et al. (2005) or Van den Bulcke et al. (2006) and TSA as well as adaptive learning
should be repeated using this data as well. This data also opens the possibility to
confirm claims of prediction performance by TSA.
Over the last years, an increasing number of other high-throughput technologies
apart from GEX were established, and the generation of so called ’omics’ data is
commonplace in various biomedical research fields. Interesting novel options for
clinical applications offer the profiling of miRNA levels, chromosomal copy num-
ber changes, epigenetic modifications, DNA sequencing and protein levels. Meta-
analysis by combining multiple studies for a conclusive finding has become popular
(Tseng et al., 2012) and the inclusion of other data such as pathway information
(Ramilo et al., 2007; Chang and Ramoni, 2009; Li et al., 2009; Ma and Kosorok,
2010) or protein-protein interaction networks (Chuang et al., 2007; Taylor et al.,
2009; Cun and Frohlich, 2012) might enhance its predictive power.
Recently, declining costs for novel high-throughput sequencing platforms (“next-
generation” sequencing) made this technology available for the application to larger
clinical studies (Shendure and Ji, 2008; Ding et al., 2010; Cronin and Ross, 2011; Su
et al., 2011). High-throughput sequencing is in particular attractive for clinical util-
ity as the genome coverage is less biased and the dynamic range is larger (Schuster ,
2008). Still, standards already available for sample processing, data storage, and
especially data analysis need to be met for clinical translation. Similar to MAQC-
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I and MAQC-II, the third phase of the MAQC project (MAQC-III), also called
Sequencing Quality Control (SEQC), aims at assessing the technical performance
of next-generation sequencing platforms and will evaluate various bioinformatics
strategies as well.
Complementary technologies may be successful for endpoints not predictable by gene
expression profiling alone and the most effective technology may also vary by study
endpoint (Tillinghast, 2010). All approaches presented in this thesis can be applied
to other technologies and help in bringing these technologies toward the clinic as
well. There is a need for bioinformatics to handle the massive amount of data
produced and to develop novel methods allowing the integration of various kinds of
data, thus providing challenging opportunities for future research. Careful planning
and robust study design is required to incorporate molecular profiling into clinical
practice and we propose our strategy to be extended to other high-throughput data.
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Cytogenetic subgroup Number of samples Risk group assignment
normal karyotype 336 favourable or intermediate
t(15;17) 43 favourable
t(8;21) 41 favourable
inv(16) 41 favourable
t(11q23) 44 unfavourable or intermediate
complex other 25
single aberrations 54
other 63
NA 114
Table A.1.: AML subclassification based on cytogenetic aberrations. Risk group
assignment is taken from Chen et al. (2010).
subgroup total number female male n.d. mean age
HIV HIV 79 13 50 16 40
LTNP 27 10 16 1 41
controls healthy controls 88 44 38 6 43
sepsis 34 16 18 0 56
sclerodemia 29 23 6 0 62
Table A.2.: Clinical and epidemiological characteristics of cases with HIV and re-
spective controls; mean age is given in years. n.d. not defined.
group total number female male mean age
ATB 54 19 35 37
LTB 69 40 29 29
controls 24 15 9 30
Table A.3.: Clinical and epidemiological characteristics of cases with TB and re-
spective controls; mean age is given in years.
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AUC MCC Sensitivity Specificity
10 highest ranked features 0.9671 0.8587 0.9561 0.8995
20 highest ranked features 0.9785 0.8733 0.9469 0.9256
30 highest ranked features 0.9762 0.8536 0.8902 0.96382
50 highest ranked features 0.9964 0.9540 0.9716 0.9829
75 highest ranked features 0.9853 0.9322 0.9433 0.9899
100 highest ranked features 0.9818 0.9193 0.9323 0.9879
150 highest ranked features 0.9932 0.9636 0.9762 0.9879
200 highest ranked features 0.9972 0.9684 0.9927 0.9749
Table A.4.: Large AML classifier performance on HG-U133 2.0 AML data set
Shown are AUC, MCC, sensitivity and specificity for the 10, 20, 30, 50, 75, 100,
150 and 200 highest ranked features from feature ranking in the large cohort to
build a classifier using the large HG-U133A data applied to the HG-U133 2.0
data set. MCC, sensitivity and specificity were assessed at the maximum Youden
Index.
AUC MCC Sensitivity Specificity
10 highest ranked features 0.9050 0.6893 0.9378 0.7327
20 highest ranked features 0.9181 0.6927 0.9341 0.7417
30 highest ranked features 0.9270 0.7036 0.9360 0.7518
50 highest ranked features 0.9542 0.7494 0.8317 0.9176
75 highest ranked features 0.9486 0.7244 0.8417 0.8834
100 highest ranked features 0.9513 0.7537 0.8070 0.9437
150 highest ranked features 0.9727 0.8363 0.8756 0.9608
200 highest ranked features 0.9750 0.8425 0.8820 0.9608
Table A.5.: Small AML classifier performance on HG-U133 2.0 AML data set
Shown are AUC, MCC, sensitivity and specificity for the 10, 20, 30, 50, 75, 100,
150 and 200 highest ranked features from feature ranking in the small cohort to
build a classifier using the small HG-U133A data applied to the HG-U133 2.0
data set. MCC, sensitivity and specificity were assessed at the maximum Youden
Index.
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Table A.6.: Annotation of AML signature
Rank Probe ID Gene Symbol Entrez ID RefSeq ID
1 207094_at CXCR1 3577 NM_000634
2 203435_s_at MME 4311 NM_000902
3 217023_x_at TPSAB1 64499 NM_003294
4 204561_x_at APOC2 344 NM_000483
5 204007_at FCGR3B 2215 NM_000570
6 209995_s_at TCL1A 8115 NM_001098725
7 210549_s_at CCL23 6368 NM_005064
8 201427_s_at SEPP1 6414 NM_001085486
9 206622_at TRH 7200 NM_007117
10 216474_x_at TPSAB1 64499 NM_003294
11 205051_s_at KIT 3815 NM_000222
12 210084_x_at TPSAB1 7177 NM_003294
13 209905_at HOXA9 3205 NM_152739
14 210321_at GZMH 2999 NM_033423
15 39318_at TCL1A 8115 NM_001098725
16 203948_s_at MPO 4353 NM_000250
17 203434_s_at MME 4311 NM_000902
18 215382_x_at TPSAB1 7177 NM_003294
19 204006_s_at FCGR3A 2214 NM_000569
20 214651_s_at HOXA9 3205 NM_152739
21 210119_at KCNJ15 3772 NM_002243
22 205683_x_at TPSAB1 7177 NM_003294
23 216782_at — — —
24 211163_s_at TNFRSF10C 8794 NM_003841
25 204885_s_at MSLN 10232 NM_001177355
26 203828_s_at IL32 9235 NM_001012631
27 221345_at FFAR2 2867 NM_005306
28 207907_at TNFSF14 8740 NM_003807
29 220068_at VPREB3 29802 NM_013378
30 203691_at PI3 5266 NM_002638
31 207826_s_at ID3 3399 NM_002167
32 207741_x_at TPSAB1 7177 NM_003294
33 221558_s_at LEF1 51176 NM_001130713
34 205366_s_at HOXB6 3216 NM_018952
35 207134_x_at TPSB2 64499 NM_024164
36 207008_at CXCR2 3579 NM_001168298
37 205568_at AQP9 366 NM_020980
38 203949_at MPO 4353 NM_000250
39 213110_s_at COL4A5 1287 NM_000495
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40 205131_x_at CLEC11A 6320 NM_002975
41 210998_s_at HGF 3082 NM_000601
42 220010_at KCNE1L 23630 NM_012282
43 206135_at ST18 9705 NM_014682
44 205798_at IL7R 3575 NM_002185
45 214575_s_at AZU1 566 NM_001700
46 209670_at TRAC 28755 —
47 204891_s_at LCK 3932 NM_001042771
48 204115_at GNG11 2791 NM_004126
49 204698_at ISG20 3669 NM_002201
50 210997_at HGF 3082 NM_000601
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Table A.7.: Annotation of NSCLC signature
Rank Probe ID RefSeq ID Entrez ID Gene Symbol Illumina ID
1 10279 NM_005621 6283 S100A12 ILMN_1748915
2 2810040 NM_145699 200315 APOBEC3A ILMN_1680192
3 1580259 XM_497072 389787 LOC389787 ILMN_1665823
4 2370524 NM_007115 7130 TNFAIP6 ILMN_1785732
5 4390242 NM_004084 1667 DEFA1 ILMN_1679357
6 6980537 NA ILMN_1905548
7 3400551 NM_006138 932 MS4A3 ILMN_1726552
8 4060066 NM_000419 3674 ITGA2B ILMN_1747248
9 4560133 NM_005139 306 ANXA3 ILMN_1694548
10 360066 NM_013378 29802 VPREB3 ILMN_1700147
11 6960440 NM_001925 1669 DEFA4 ILMN_1753347
12 4050286 XM_928682 645671 LOC645671 ILMN_1710007
13 6860754 NM_000045 383 ARG1 ILMN_1812281
14 1190349 NM_002759 5610 EIF2AK2 ILMN_1706502
15 70338 NM_004510 3431 SP110 ILMN_1672661
16 6350364 NM_002704 5473 PPBP ILMN_1767281
17 5900072 XM_937928 347376 LOC347376 ILMN_1704385
18 1260228 NM_021105 5359 PLSCR1 ILMN_1752889
19 6180161 XM_371741 389293 LOC389293 ILMN_1675421
20 990097 NM_001816 1088 CEACAM8 ILMN_1806056
21 5080398 NM_003263 7096 TLR1 ILMN_1731048
22 520228 NM_182697 7328 UBE2H ILMN_1757644
23 6400736 NM_004345 820 CAMP ILMN_1688580
24 7570079 NM_002185 3575 IL7R ILMN_1675949
25 2340110 NM_032321 84281 MGC13057 ILMN_1809636
26 580307 NM_138444 115207 KCTD12 ILMN_1742332
27 1450309 NM_002934 6036 RNASE2 ILMN_1730628
28 520646 NM_000713 645 BLVRB ILMN_1797793
29 7400097 NM_001062 6947 TCN1 ILMN_1768469
30 6760255 NM_000104 1545 CYP1B1 ILMN_1693338
31 620324 XM_936731 647673 LOC647673 ILMN_1757702
32 7160608 NM_005067.5 6478 SIAH2 ILMN_1801313
33 430328 NM_016633 51327 ERAF ILMN_1696512
34 2680273 NM_004926 677 ZFP36L1 ILMN_1675448
35 1090427 XM_928349 653600 LOC653600 ILMN_1693262
36 7650678 NM_017709 54855 FAM46C ILMN_1713266
37 4210414 NR_002204 2503 FTHL11 ILMN_1706013
38 2760463 XM_931683 389293 LOC389293 ILMN_1672024
39 6960554 NM_005564 3934 LCN2 ILMN_1692223
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40 1240044 NM_002483 4680 CEACAM6 ILMN_1712522
41 5570484 NM_005143 3240 HP ILMN_1812433
42 3170241 NM_000140 2235 FECH ILMN_1774091
43 610148 NM_001725 671 BPI ILMN_1766736
44 160348 NM_002935 6037 RNASE3 ILMN_1802867
45 6200221 NM_021083 7504 XK ILMN_1759117
46 4120270 NM_018566 55432 YOD1 ILMN_1678919
47 7560072 NM_206962 3275 PRMT2 ILMN_1748922
48 2650440 NR_002200 2497 FTHL2 ILMN_1746525
49 3830138 NM_020841 114882 OSBPL8 ILMN_1782459
50 4180564 XM_371243 388621 LOC388621 ILMN_1677262
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Table A.8.: Annotation of HIV signature
Rank Probe ID RefSeq ID Entrez ID Gene Symbol Illumina ID
1 6510553 NM_001768 925 CD8A ILMN_1768482
2 4050703 NA ILMN_1881490
3 1850047 NM_206833 404217 CTXN1 ILMN_1759766
4 5550364 XR_000904 144581 RPL14L ILMN_1769937
5 1660021 XM_942993 647741 LOC647741 ILMN_1795159
6 940524 NM_005731 10109 ARPC2 ILMN_1810200
7 4390242 NM_004084 1667 DEFA1 ILMN_1679357
8 630022 NM_000683 152 ADRA2C ILMN_1733963
9 4850128 NM_033423 2999 GZMH ILMN_1731233
10 6560114 NM_001003 6176 RPLP1 ILMN_1689725
11 5270100 XM_943751 649516 LOC649516 ILMN_1661566
12 580131 NA ILMN_1862684
13 5700687 NM_016024 51634 RBMX2 ILMN_1678203
14 2340379 NM_006917 6258 RXRG ILMN_1750624
15 7610608 NM_020439 57172 CAMK1G ILMN_1804339
16 3360603 NM_015229 23277 KIAA0664 ILMN_1770719
17 3120020 NM_002286 3902 LAG3 ILMN_1813338
18 4150546 XM_931897 653210 LOC653210 ILMN_1651606
19 540470 NM_018090 55707 NECAP2 ILMN_1749011
20 3780114 NM_001004708 219983 OR4D6 ILMN_1813776
21 6520497 NM_001614 71 ACTG1 ILMN_1704961
22 2320504 NA ILMN_1915345
23 5050553 NM_014219 3803 KIR2DL2 ILMN_1678882
24 540731 NM_001768 925 CD8A ILMN_1760374
25 4070129 NM_005091 8993 PGLYRP1 ILMN_1704870
26 6200551 NA ILMN_1892403
27 5700541 NM_001013704 440313 LOC440313 ILMN_1749984
28 2100687 XM_928457 645416 LOC645416 ILMN_1700998
29 7550273 XM_931729 643665 LOC643665 ILMN_1664118
30 3840050 XM_495863 387751 GVIN1 ILMN_1668526
31 3310091 NM_005217 1668 DEFA3 ILMN_1725661
32 2630647 NM_207378 388007 SERPINA13 ILMN_1743046
33 3180075 NM_001008 6192 RPS4Y1 ILMN_1783142
34 1570491 XM_930555 653757 LOC653757 ILMN_1693207
35 2060706 NM_173574 257101 ZNF683 ILMN_1678238
36 2320400 XM_932788 645284 LOC645284 ILMN_1705982
37 3840524 NM_173566 253143 C22orf30 ILMN_1741295
38 4290692 NM_171825 815 CAMK2A ILMN_1666445
39 1940414 NM_018264 55253 TYW1 ILMN_1736135
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40 630274 NA ILMN_1823884
41 6130128 XM_943174 648003 LOC648003 ILMN_1725702
42 4200671 NM_017409 3226 HOXC10 ILMN_1725899
43 4010707 NM_001003945 210 ALAD ILMN_1679898
44 7550504 NM_033101 85329 LGALS12 ILMN_1776283
45 4200685 NM_003970 9172 MYOM2 ILMN_1716733
46 6980164 NM_000478 249 ALPL ILMN_1701603
47 2710674 NM_012418 25794 FSCN2 ILMN_1795472
48 4250037 NM_178865 347735 SERINC2 ILMN_1694509
49 1050475 NM_014513 3810 KIR2DS5 ILMN_1691803
50 4260386 NM_153231 162972 ZNF550 ILMN_1760102
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Table A.9.: Annotation of TB signature
Rank Illumina ID RefSeq ID Entrez ID Gene Symbol Probe ID
1 ILMN_2114568 NM_052942 115362 GBP5 1510364
2 ILMN_2261600 NM_001017986 2210 FCGR1B 2710709
3 ILMN_2391051 NM_001004340 2210 FCGR1B 6620209
4 ILMN_2302757 NM_003890 8857 FCGBP 130609
5 ILMN_1809467 NM_006634 10791 VAMP5 2630195
6 ILMN_2394210 NM_138718 116369 SLC26A8 5360626
7 ILMN_1776939 NM_152866 931 MS4A1 3190521
8 ILMN_1851599 NA 3930128
9 ILMN_1662731 NM_031365 1285 COL4A3 6380066
10 ILMN_2388547 NM_033255 94240 EPSTI1 5700725
11 ILMN_1805750 NM_021034 10410 IFITM3 6650242
12 ILMN_1740572 NM_000355 6948 TCN2 5670100
13 ILMN_1664330 NM_001712 634 CEACAM1 5340767
14 ILMN_1701114 NM_002053 2633 GBP1 6840035
15 ILMN_1670305 NM_001032295 710 SERPING1 2030309
16 ILMN_1727271 NM_173701 7453 WARS 3710068
17 ILMN_1690241 NM_138456 116071 BATF2 4730059
18 ILMN_1755843 NM_052961 116369 SLC26A8 270240
19 ILMN_2176063 NM_000566 2209 FCGR1A 520086
20 ILMN_1675756 NM_170736 3772 KCNJ15 1050215
21 ILMN_2408987 NM_001003802 6604 SMARCD3 460463
22 ILMN_1701621 NM_005138 9997 SCO2 7510537
23 ILMN_2374865 NM_001040619 467 ATF3 4780128
24 ILMN_1690105 NM_007315 6772 STAT1 1820750
25 ILMN_1671703 NM_001613 59 ACTA2 6480059
26 ILMN_1667114 NR_003662 388524 LOC388524 460050
27 ILMN_1654389 XM_001128342 728744 LOC728744 5570039
28 ILMN_1691071 NM_032738 84824 FCRLA 3780193
29 ILMN_1772466 NM_005490 10045 SH2D3A 5490452
30 ILMN_1810289 NM_133337 26509 FER1L3 3170273
31 ILMN_1759075 NM_012452 23495 TNFRSF13B 620484
32 ILMN_2049184 NM_004944 1776 DNASE1L3 290739
33 ILMN_1688631 NM_145343 8542 APOL1 6370470
34 ILMN_1887868 NA 5270403
35 ILMN_2148785 NM_002053 2633 GBP1 2190148
36 ILMN_1771385 NM_052941 115361 GBP4 1980524
37 ILMN_1701455 NM_018438 26270 FBXO6 3800398
38 ILMN_2390946 NM_145350 8578 SCARF1 5390204
39 ILMN_1673503 NM_001005747 785 CACNB4 2260446
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40 ILMN_1707979 NM_001007232 440068 INCA 3930368
41 ILMN_1780831 NM_003044 6539 SLC6A12 6220332
42 ILMN_2279844 NM_005356 3932 LCK 130274
43 ILMN_1733998 NM_005771 10170 DHRS9 630315
44 ILMN_1756953 NM_198460 163351 GBP6 3780047
45 ILMN_2337655 NM_004184 7453 WARS 4860224
46 ILMN_1747744 NM_005779 10184 LHFPL2 360132
47 ILMN_1683792 NM_015907 51056 LAP3 3290292
48 ILMN_1700671 NM_016135 51513 ETV7 6370768
49 ILMN_1701914 NM_014143 29126 CD274 4900239
50 ILMN_1669497 NM_017784 114884 OSBPL10 6760593
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Disease Cohort Condition n Summe
AML
small
Feature selection 6 60,000
Algorithm 1 80,000
TS size 80,000
large
Feature selection 6 6,000
Algorithm 1 8,000
ALA 32 320,000
simulated Feature selection 6 6,000ALA 32 320,000
TB
original Feature selection 5 5,000
simulated Feature selection 5 5,000ALA 29 290,000
NSCLC
original Feature selection 5 5,000
simulated Feature selection 5 5,000ALA 30 300,000
HIV
original Feature selection 5 5,000
simulated Feature selection 5 5,000ALA 30 300,000∑ 1,800,000
Table A.10.: Overview of the total number of classifiers established for trial simu-
lation and adaptive learning assessment.
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Figure B.0.2.: Model performance on internal validation compared with external
validation for AML data
Shown is the (A) AUC and (B) MCC performance of 60,000 models derived from
the small AML pilot trial in TSA (internal validation) plotted against the per-
formance of each model build in TSA applied to the remaining blinded samples
from the large cohort (external validation). Corresponding r2-Pearson Correlation
Coefficiants are 0.7976 (AUC) and 0.7294 (MCC).
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Figure B.0.3.: Sample-split versus bootstrap predictions for small AML cohort
Shown are AUC distributions for 10,000 iterations of TSA for different FC/p-
value filter for sample split (sample drawing without replacement, black lines) and
classical bootstrap (sample drawing with replacement, dashed lines), displayed as
density plots.
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Figure B.0.1.: Prediction performance of small AML
MCC (A), sensitivity (B) and specificity (C) values for 10,000 iterations of clas-
sification of the small AML cohort for VS1 (grey) and VS2 (blue) summarized in
boxplots for different feature size cutoffs (FC/p-value filter). Boxes indicate the
25th and 75th percentiles, the line within the box marks the median and whiskers
above and below the box indicate the 90th and 10th percentiles. Outliers are
plotted as dots.
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Figure B.0.4.: Comparison of AML feature ranking
All features are ranked using the four different methods described in chapter 3,
namely DE selection, weights SVM, p-value and FC ranking. Feature ranking
is performed using 10,000 iterations of TSA for the small AML PTS. Shown
are the top 500 ranked features for each individual method in comparison to
the ranking obtained in the three other methods to show similarity of obtained
feature rankings by the different methods. DE ranking and weights SVM ranking
are more similar than the other two methods and the p-value resulted in the least
similar feature ranking.
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Figure B.0.5.: Adaptive learning of simulated samples based on the method of
(Parrish et al., 2009).
Based on the proposed method, 717 AML and 1296 control samples were simulated
using information from the small AML PTS. Adaptive learning as described in
sec. 3.2.7 was performed using this data set, starting with 50 init TS samples and
then subsequentially adding 20 samples. Shown are the boxplots of 100 mean-of-
the-mean AUCs for TSA of different sample subsets, comparable to Fig. 5.2.13.
Cubic spline fitting for sample size estimation would not be informative in this
case.
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C.1. NSCLC GEX data set
Cases and controls
NSCLC cases and hospital based controls were recruited at the University Hospital
Cologne and the Lung Clinic Merheim, Cologne, Germany. Healthy blood donors
were recruited at the Institute for Transfusion Medicine, University of Cologne.
From all individuals PAXgene stabilized blood samples were taken for blood-based
gene expression profiling. For all NSCLC cases blood was taken prior chemotherapy.
To establish and validate a NSCLC specific classifier 3 independent sets of cases and
controls were assembled. The training set (TS) comprised 77 individuals, 35 of
those represent NSCLC cases of stage I-IV admitted to the hospital with symptoms
of non-small cell lung cancer (coughing, dyspnea, weight loss or reduction in general
health state) and 42 were hospital based controls with a comparable comorbidity but
no prior history of lung cancer. The validation set 1 (VS1, n=54) likewise contained
28 NSCLC cases of stage I-IV and 26 hospital based controls. Overall, the hospital
based controls in TS and VS1 enclosed individuals suffering from advanced chronic
obstructive pulmonary disease (COPD) as typically seen in a population of heavily
smoking adults (TS: n=7 VS1: n=5). Other diseases such as hypertension (TS:
n=17, VS: n=11) or other malignancies (TS: n=10; VS1: n=6) were also observed
in the group of hospital based controls. The validation set 2 (VS2, n=102) contained
32 NSCLC cases that had documented stage I NSCLC and were diagnosed mostly
during routine chest-rays or due to clinical workup of unspecific symptoms such as
reduced general health status. All individuals had an ECOG performance status of
0. In addition VS2 contains 70 healthy blood donors without prior history of lung
cancer. The analyses were approved by the local ethics committee and all probands
gave informed consent.
Blood collection, cRNA synthesis and array hybridization
Blood (2.5 ml) was drawn into PAXgene vials. After RNA isolation biotin la-
beled cRNA preparation was performed using the Ambion® Illumina RNA am-
plification kit (Ambion, UK) or Epicentre TargetAmpTM Kit (Epicentre Biotech-
nologies, USA) and Biotin-16-UTP (10 mM; Roche Molecular Biochemicals) or Il-
lumina® TotalPrep RNA Amplification Kit (Ambion, UK). Biotin labeled cRNA
(1.5 mg) was hybridized to Sentrix® whole genome bead chips WG6 version 2.1
(Illumina, USA) and scanned on the Illumina® BeadStation 500x. For data col-
lection, we used Illumina® BeadStudio 3.1.1.0 software. Data are available at
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http://www.ncbi.nlm.nih.gov/geo/GSE12771. For RNA quality control the ratio
of the OD at wavelengths of 260 nm and 280 nm was calculated for all samples and
was between 1.85 and 2. To determine the quality of cRNA, a semi-quantitative
RT-PCR amplifying a 5´prime and a 3´prime product of the ß-actin gene was used
and demonstrated no sign of degradation with the 5´prime and a 3´prime product
being present.
Classification algorithm
Expression values were independently quantile normalized. The classifier for NSCLC
was built and optimized based on the TS using a 10 fold CV design. Briefly, TS was
divided 10 times into an internal training and an internal validation set in a ratio
9:1. In the internal TS the differentially expressed genes between NSCLC cases and
controls were calculated using a T-test. Next 36 different feature lists were extracted
from this list of differential expressed genes by 36 times sequentially increasing the
cut-off of the p-value (p = 0.00001, p = 0.00002, p = 0.00003 . . . -. . . p = 0.08, p
= 0.09, p = 0.1). Subsequently, for each of the resulting 36 feature lists 3 different
learning algorithms (SVM, LDA, PAM) were trained on the internal training set
and used to calculate the probability score for each case of the respective internal
validation set. This approach was repeated 10 times according to the 10 dataset
splittings of this 10-fold CV. For each of the 10 CV steps the AUC was calculated
for the internal validation set. For each of the 36 cut-offs the mean of the 10 AUCs
was calculated. Each of the 10 split data sets was used once as internal validation
set. The optimal cut-off p value of the T-statistics and the optimal classification
algorithm were selected according to the maximum mean AUC ever reached in all
of the three algorithms. We subsequently built a classifier using the respective cut-
off p-value of the T-statistics and the selected algorithm in the TS. The classifier
was validated in 2 independent validation sets. The AUC was used to measure the
quality of the classifier. To test the specificity of the classifier the whole analysis was
repeated thousand times using random feature sets of equal size. For visualization of
the test score obtained by the SVM algorithm we used the following transformation
algorithm: log2(score+ 1) + 0.1.
C.2. microRNA profiling
Subject information and blood sample collection
Blood samples from 29 apparently healthy blood donors were collected in two Cell
Preparation Tubes with sodium citrate (CPT, Becton Dickinson, Heidelberg, Ger-
many) after written informed consent had been obtained and following approval by
the institutional review board. Peripheral blood mononuclear cells (PBMC) were
prepared following the manufacturer´s protocol. To evaluate the influence of freez-
ing cells in FCS with 10% (v/v) DMSO and storage in liquid nitrogen on miRNA
stability, one portion of the freshly isolated PBMC were lysed in TRIZOL® reagent
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(1 ml / 1 x 107 PBMC, Invitrogen, Karlsruhe, Germany) and stored at -80°C until
further processing. The other portion of isolated PBMC was resuspended in FCS
with 10% (v/v) DMSO (1 ml / 1 x 107 PBMC) and frozen at -80°C. The next
day frozen PBMC were cryopreserved in liquid nitrogen for several days to weeks
until further processing. In order to analyze the difference between total RNA and
less abundant low molecular weight (LMW) RNA we collected blood samples from
additional six healthy blood doners.
RNA isolation and miRNA microarray procedure
Total RNA from PBMC stored in TRIZOL® was isolated according to the manufac-
turer´s protocol. For RNA isolation from PBMC stored in liquid nitrogen, cells were
removed from liquid nitrogen and transferred to a 37°C water bath until thawing.
The thawed cell suspension was quickly transferred to 40 ml chilled RPMI medium
and centrifuged at room temperature at 400 x g for 10 min. Supernatant was re-
moved and PBMC were washed once with 50 ml of room temperature RPMI and
centrifuged at room temperature at 400 x g for 10 min. Supernatant was completely
removed and cells were subsequently lysed in TRIZOL® reagent. RNA isolation was
then performed according to the manufacturer´s protocol. Low molecular weight
(LMW) RNA molecules were enriched using Invitrogen’s PureLink miRNA Isolation
Kit (Invitrogen, Karlsruhe, Germany) according to manufacture’s protocol. 50 – 350
ng of LMW RNAs were enriched from 1 – 2 ug of total RNAs, and 10 – 70 ng of
the enriched RNAs were used for sample labeling and array hybridization. For the
comparison of isolation techniques blood samples from 6 apparently healthy blood
donors were collected either in Cell Preparation Tubes with sodium citrate (CPT) or
in PAXgene Blood RNA Tubes (PreAnalytiX, Hombrechtikon, Switzerland). PAX-
gene Blood RNA Tubes were stored at -20°C until further processing. PBMC were
prepared from CPT following the manufacturer´s protocol and stored in -80°C. To-
tal RNA from PBMC was isolated using TRIZOL® reagent (invitrogen) according
to the manufacturer´s protocol. RNA from PAXgene Blood RNA Tubes was iso-
lated using the PAXgene Blood miRNA Beta Version extraction kit. Total RNA was
quantified by UV-spectroscopy at 260 nm. The quality of the isolated RNA samples
were determined by measuring the A260 / A280 ratio and the integrity of the riboso-
mal 28s and 18s bands were determined by agarose-gel electrophoresis. MicroRNA
expression profiling was performed using the MicroRNA Profiling Beta-Test Assay
Kit for Sentrix Array Matrixes (Illumina, CA, USA). This system provides a highly
multiplexed assay and 96-sample Sentrix Array Matrix (SAM) readout. The miRNA
microarray assays were generally performed with 500 ng total RNA if not otherwise
stated. All steps were performed according to the manufacturer´s protocol. After
hybridization signal intensities at each address location were measured using Illu-
mina BeadArray Reader 500x (Illumina, CA, USA). The intensities of the signals
correspond to the quantity of the respective miRNA in the original sample.
Statistical and bioinformatics analysis
Raw data extraction of miRNA microarrays was performed with Illumina Beadstu-
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dio 3.1.1.0 software using the Beadstudio Gene Expression Analysis Module 3.1.8.
Prior analysis data quality assessment was performed and samples with lower over-
all intensity distributions and decreased number of miRNA transcripts detected as
present were excluded from further analysis. For further analysis we used quantile
normalization implemented in the Bioconductor affy package. Variable miRNAs
were defined by a coefficient of variation (SD/mean) between 0.5 - 10. Determi-
nation of present calls was based on the detection p-value assessed by Beadstudio
software; a miRNA transcript was called present if the detection p-value was <
0.05. Otherwise the miRNA transcript was called absent. Differentially expressed
miRNAs were selected using a fold-change/p-value filter. The Benjamini-Hochberg
method was used to adjust the raw p-values to control the false discovery rate.
Hierarchical cluster analysis was performed using the hcluster method in R. Before
clustering, the data were log2 transformed. Distances of the samples were calculated
using Pearson correlation and clusters were formed by taking the average of each
cluster.
Validation of miRNA expression results
Quantitative (q) PCR analysis of a selected number of miRNA targets was performed
on the six aforementioned blood samples from healthy donors. Three RNA isolation
approaches were compared: total RNA, enriched small RNA and PAXgene isolated
RNA. Twelve miRNAs were selected (hsa-miR-100, 125a, 125b, 135a, 146a, 150,17-
3p, 221, 26a, 31, 93 and 328) and data were produced using those RNA samples
that were also analysed in array based miRNA profiling. Absolute association of
normalized miRNA array expression intensities (log10) versus the negative cycle
treshhold (Ct) value was explored via Spearman’s correlation coefficient.
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Algorithmus D.1 Validation algorithm
# va l i d a t i o n func t i on
##################
# author Andrea Hofmann .
##################
# th i s func t i on
# 1 . bu i l d s a SMV c l a s s i f i e r on t r a i n i n g s e t o f ca s e s and c on t r o l s a l r eady f i l t e r e d
on DE genes
# 2 . app l i e s t h i s c l a s s i f i e r to a va l i d a t i o n s e t
# 3 . r e tu rn s AUC, MCC, Sens + Spec
##################
# input :
# data . case . t e s t + data . c on t r o l . t e s t = en t i r e t r a i n i n g data o f ca s e s + con t r o l s
# data . case . va l + data . c on t r o l . va l = en t i r e v a l i d a t i o n data o f ca s e s + con t r o l s
# output :
# AUC, MCC, Sens , Spec
l i b r a r y ( e1071 )
l i b r a r y ( mul t te s t )
l i b r a r y ( s t a t s )
l i b r a r y (ROCR)
ex t e rna l <− f unc t i on ( data . case . t e s t , data . con . t e s t , data . case . val , data . con . va l ) {
SVM <− svm( t ( cbind ( data . case . t e s t , data . con . t e s t ) ) , as . f a c t o r ( c ( rep ( " case " , nco l ( data .
case . t e s t ) ) , rep ( "Con " , nco l ( data . con . t e s t ) ) ) ) , p r obab i l i t y=TRUE)
svm . pred <− p r ed i c t (SVM, t ( cbind ( data . case . val , data . con . va l ) ) , p r obab i l i t y=T)
pred . d i s t <− a t t r (svm . pred , " p r o b a b i l i t i e s " ) [ , which ( colnames ( a t t r (svm . pred , "
p r o b a b i l i t i e s " ) )=="Con " ) ]
pred . r o c r <− p r ed i c t i o n ( pred . d i s t , as . f a c t o r ( c ( rep ( " case " , nco l ( data . case . va l ) ) , rep ( "
Con " , nco l ( data . con . va l ) ) ) ) )
p e r f . r o c r <− performance ( pred . rocr , measure="auc " )
AUC <− as . numeric ( p e r f . rocr@y . va lue s )
MCC <− performance ( pred . rocr , measure="phi " )@y . va lue s [ [ 1 ] ] [ [ which ( ( performance ( pred .
rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y .
va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) [ 1 ] ] ]
SENS <− performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] [ [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) [ 1 ] ] ]
SPEC <− performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] [ [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) [ 1 ] ] ]
r e turn ( cbind (AUC,MCC,SENS,SPEC) ) }
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Algorithmus D.2 Feature selection algorithms
# fea tu r e s e l e c t i o n func t i on
##################
# author Andrea Hofmann .
##################
# th i s func t i on
# 1 . c a l c u l a t e s DE genes based on given p−value , FC and t e s t s t a t i s t i c f o r 2 groups
# 2 . r e tu rn s l i s t o f DE genes
##################
# input :
# sample . 1 , sample . 2 = data f o r 2 groups
# f c =2, pval =0.05 , t e s t s t a t ="t " = va r i a b l e s with d e f au l t va lue s
# output :
# l i s t o f DE genes
l i b r a r y ( mul t te s t )
l i b r a r y ( s t a t s )
getDEgenes <− f unc t i on ( sample1 , sample2 , f c =2, pval =0.05) {
mean_s1 <− apply ( sample1 , 1 ,mean)
mean_s2 <− apply ( sample2 , 1 ,mean)
fc_s1_vs_s2 <− ge t f o ldchange (mean_s1 , mean_s2 , f c )
teststat_s1_vs_s2 <− mt . t e s t s t a t ( cbind ( sample1 , sample2 ) , c ( rep (0 , dim( sample1 ) [ 2 ] ) ,
rep (1 , dim( sample2 ) [ 2 ] ) ) , t e s t="t " )
pvals_s1_vs_s2 <− 2∗(1−pnorm( abs ( teststat_s1_vs_s2 ) ) )
pval_adjust <− p . ad jus t ( pvals_s1_vs_s2 , method = "BH" )
DEgenes_index <− i n t e r s e c t ( which ( fc_s1_vs_s2 [ ,2]==1) , which ( pval_adjust<pval ) )
re turn ( rownames ( sample1 [ DEgenes_index , ] ) ) }
ge t f o ldchange <− f unc t i on ( sample1 , sample2 , f c ) {
t ( apply ( as . matrix ( cbind ( sample1 , sample2 ) ) ,1 , i s f o l d change , f c ) ) }
i s f o l d chang e <− f unc t i on ( sample , f c ) {
change . f c <− f unc t i on ( va lue ) {
i f ( va lue < 1) { new_value <− −(1/ value ) }
e l s e { new_value <− value }
re turn ( new_value ) }
i s d i f f e r e n t <− 0
f o l d <− sample [ 1 ] / sample [ 2 ]
i f ( i s . na ( f o l d ) ) { fo ld <−1 }
i f ( f o l d > f c | | f o l d < (1/ f c ) ) {
i s d i f f e r e n t <− 1 }
r e s u l t <− c ( sapply ( fo ld , change . f c ) , i s d i f f e r e n t )
re turn ( r e s u l t ) }
Algorithmus D.3 Prediction algorithm
# gene ra l f unc t i on f o r p r ed i c t i o n
##################
# author Andrea Hofmann .
##################
# th i s func t i on
# 1 . r e qu i r e s a data s e t o f case and con t r o l samples and an ex t e rna l case / con t r o l
s e t
# 2 . d i v i d e s the data s e t i n to 1 t r a i n i n g and 2 va l i d a t i o n s e t s based on given
propor t i on s with or withour replacement
# 3 . c a l c u l a t e s d i f f e r e n t i a l l y expres sed genes in the t r a i n i n g s e t
# 3 . only goes on i f number d . e . genes >=2 ( r equ i r ed f o r c l a s s i f i e r )
# 4 . bu i l d s a c l a s s i f i e r in the t r a i n i n g s e t
# 5 . app l i e s c l a s s i f i e r to 2 va l i d a t i o n s e t s + ex t e rna l s e t
# 6 . r epo r t s DE genes + AUC.MCC. S e n s i t i v i t y . S p e c i f i c i t y o f p r ed i c t i o n o f 2
v a l i d a t i o n + ex t e rna l s e t s
##################
# input :
# data . case , data . c on t r o l = en t i r e datase t o f c a s e s + con t r o l s
# data . case , data . c on t r o l = en t i r e datase t o f c a s e s + con t r o l s
# s i z e . t s . case + s i z e . t s . con = number o f ca s e s in t r a i n i n g s e t f o r ca s e s and
c on t r o l s
# s i z e . vs . case + s i z e . vs . con = number o f ca s e s in v a l i d a t i o n s e t f o r ca s e s and
c on t r o l s
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# ext . vs , c l a s s e s . ext = ex t e rna l data + corre spond ing c l a s s e s
# c_fc + c_pval = f o l d change + p−value f o r gene s e l e c t i o n
# c_test = t e s t s t a t i s t i c f o r gene s e l e c t i o n . " t " f o r Welch t−t e s t ( unequal
va r i ance s ) . " wi lcoxon " f o r rank sum Wilcoxon t e s t
# c_ c l a s s i f i e r = c l a s s i f i c a t i o n a lgor i thm . "SVM" . "PAM" . "LDA"
# c_kernel = ke rne l f o r SVM c l a s s i f i c a t i o n . " l i n e a r " . " polynomial " . r a d i a l " . "
s igmoid "
# withoutReplacement = parameter T/F f o r sample s p l i t or boots t rap
##################
# output :
# DE. ts , l ength (DE. t s ) , pvals , FC, weights_SVM , AUC_VS1, AUC_VS2, MCC_VS1, MCC_VS2,
SENS_VS1, SENS_VS2, SPEC_VS1, SPEC_VS2,
# AUC_EXT, MCC_EXT, SENS_EXT, SPEC_EXT
##################
# c a l l :
# p r ed i c t i o n . func t i on ( parameters )
# permutation :
# permutation . r e s u l t s <− r e p l i c a t e (10000 . permutation . f unc t i on ( parameters ) . s imp l i f y=
FALSE)
l i b r a r y ( e1071 )
l i b r a r y ( mul t te s t )
l i b r a r y ( s t a t s )
l i b r a r y (ROCR)
permutation . func t i on <− f unc t i on ( data . case , data . cont ro l , s i z e . t s . case , s i z e . t s . con ,
s i z e . vs . case , s i z e . vs . con , c_fc=5,c_pval=0.001 , c_test="t " ,
c _ c l a s s i f i e r ="SVM" , c_kernel=" l i n e a r " , ext . vs ,
c l a s s e s . ext , withoutReplacement=TRUE)
{
i f ( withoutReplacement ) {
ds1 . case <− sample ( 1 : nco l ( data . case ) , s i z e . t s . case )
ds1 . con <− sample ( 1 : nco l ( data . c on t r o l ) , s i z e . t s . con )
ds2 . case <− sample ( ( 1 : nco l ( data . case ) ) [−ds1 . case ] , s i z e . vs . case )
ds2 . con <− sample ( ( 1 : nco l ( data . c on t r o l ) ) [−ds1 . con ] , s i z e . vs . con )
ds3 . case <− sample ( ( 1 : nco l ( data . case ) ) [−c ( ds1 . case , ds2 . case ) ] , s i z e . vs . case )
ds3 . con <− sample ( ( 1 : nco l ( data . c on t r o l ) ) [−c ( ds1 . con , ds2 . con ) ] , s i z e . vs . con ) }
e l s e { random . case <− sample ( 1 : nco l ( data . case ) , nco l ( data . case ) , r ep l a c e=TRUE)
random . con <− sample ( 1 : nco l ( data . c on t r o l ) , nco l ( data . c on t r o l ) , r ep l a c e=TRUE)
ds1 . case <− random . case [ 1 : s i z e . t s . case ]
ds1 . con <− random . con [ 1 : s i z e . t s . con ]
ds2 . case <− random . case [ ( s i z e . t s . case+1) : ( s i z e . t s . case+s i z e . vs . case ) ]
ds2 . con <− random . con [ ( s i z e . t s . con+1) : ( s i z e . t s . con+s i z e . vs . con ) ]
ds3 . case <− random . case [ ( s i z e . t s . case+s i z e . vs . case+1) : nco l ( data . case ) ]
ds3 . con <− random . con [ ( s i z e . t s . con+s i z e . vs . con+1) : nco l ( data . c on t r o l ) ]
}
t s <− cbind ( data . case [ , ds1 . case ] , data . c on t r o l [ , ds1 . con ] )
vs1 <− cbind ( data . case [ , ds2 . case ] , data . c on t r o l [ , ds2 . con ] )
vs2 <− cbind ( data . case [ , ds3 . case ] , data . c on t r o l [ , ds3 . con ] )
c l a s s e s . t s <− c ( rep ( " case " , l ength ( ds1 . case ) ) , rep ( "Con " , l ength ( ds1 . con ) ) )
c l a s s e s . vs1 <− c ( rep ( " case " , l ength ( ds2 . case ) ) , rep ( "Con " , l ength ( ds2 . con ) ) )
c l a s s e s . vs2 <− c ( rep ( " case " , l ength ( ds3 . case ) ) , rep ( "Con " , l ength ( ds3 . con ) ) )
DE. t s . a l l <− getDEgenes ( t s [ , which ( c l a s s e s . t s=="case " ) ] , t s [ , which ( c l a s s e s . t s=="Con " )
] , f c=c_fc , pval=c_pval , t e s t s t a t=c_test )
DE. t s <− DE. t s . a l l [ [ 1 ] ]
i f ( l ength (DE. t s )<2) {
auc . vs1 <− "NA"
mcc . vs1 <− "NA"
auc . vs2 <− "NA"
mcc . vs2 <− "NA"
sens . vs1 <− "NA"
spec . vs1 <− "NA"
sens . vs2 <− "NA"
spec . vs2 <− "NA"
w_SVM <− "NA"
auc . ext <− "NA"
mcc . ext <− "NA"
sens . ext <− "NA"
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spec . ext <− "NA" }
e l s e {
i f ( c _ c l a s s i f i e r=="SVM") {
SVM. t s = svm( t ( t s [DE. ts , ] ) , as . f a c t o r ( c l a s s e s . t s ) , k e rne l=c_kernel , c r o s s =10,
p r obab i l i t y = TRUE)
w_SVM <− t (SVM. t s $ c o e f s ) %∗% SVM. ts$SV
svm . pred <− p r ed i c t (SVM. ts , t ( vs1 [DE. ts , ] ) , p r obab i l i t y=T)
pred <− a t t r (svm . pred , " p r o b a b i l i t i e s " )
pred . d i s t <− pred [ , which ( colnames ( pred )=="Con " ) ]
pred . r o c r <− p r ed i c t i o n ( pred . d i s t , as . f a c t o r ( c l a s s e s . vs1 ) )
p e r f . r o c r <− performance ( pred . rocr , measure="auc " )
auc . vs1 <− as . numeric ( p e r f . rocr@y . va lue s )
mcc . vs1 <− performance ( pred . rocr , measure="phi " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
s ens . vs1 <− performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
spec . vs1 <− performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
svm . pred <− p r ed i c t (SVM. ts , t ( vs2 [DE. ts , ] ) , p r obab i l i t y=T)
pred <− a t t r (svm . pred , " p r o b a b i l i t i e s " )
pred . d i s t <− pred [ , which ( colnames ( pred )=="Con " ) ]
pred . r o c r <− p r ed i c t i o n ( pred . d i s t , as . f a c t o r ( c l a s s e s . vs2 ) )
p e r f . r o c r <− performance ( pred . rocr , measure="auc " )
auc . vs2 <− as . numeric ( p e r f . rocr@y . va lue s )
mcc . vs2 <− performance ( pred . rocr , measure="phi " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
s ens . vs2 <− performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
spec . vs2 <− performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
### independent v a l i d a t i o n s e t
svm . pred <− p r ed i c t (SVM. ts , t ( ext . vs [DE. ts , ] ) , p r obab i l i t y=T)
pred <− a t t r (svm . pred , " p r o b a b i l i t i e s " )
pred . d i s t <− pred [ , which ( colnames ( pred )=="Con " ) ]
pred . r o c r <− p r ed i c t i o n ( pred . d i s t , as . f a c t o r ( c l a s s e s . ext ) )
p e r f . r o c r <− performance ( pred . rocr , measure="auc " )
auc . ext <− as . numeric ( p e r f . rocr@y . va lue s )
mcc . ext <− performance ( pred . rocr , measure="phi " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
s ens . ext <− performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ]
spec . ext <− performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] [ which ( ( performance (
pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] + performance ( pred . rocr , measure="spec " )@y
. va lue s [ [ 1 ] ] − 1 )==max( performance ( pred . rocr , measure=" sens " )@y . va lue s [ [ 1 ] ] +
performance ( pred . rocr , measure="spec " )@y . va lue s [ [ 1 ] ] − 1 ) ) ] } }
re turn ( l i s t ( probes = DE. ts , number_probes = length (DE. t s ) , pva l s = DE. t s . a l l [ [ 2 ] ] , FC
= DE. t s . a l l [ [ 3 ] ] , weights_SVM = w_SVM, AUC_VS1 = auc . vs1 ,AUC_VS2 = auc . vs2 ,
MCC_VS1 = mcc . vs1 ,MCC_VS2 = mcc . vs2 ,SENS_VS1 = sens . vs1 , SENS_VS2 = sens . vs2 ,
SPEC_VS1 = spec . vs1 ,SPEC_VS2 = spec . vs2 , AUC_EXT = auc . ext ,MCC_EXT = mcc . ext ,
SENS_EXT = sens . ext , SPEC_EXT = spec . ext ) ) }
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